CADHERIN-LINKED MOLECULAR MECHANISMS GOVERNING THE TERMINAL DIFFERENTIATION OF HUMAN TROPHOBLASTIC CELLS IN VITRO

by

York Hunt Ng

B.S., Oklahoma City University, USA, 2001
M.Sc., The University of British Columbia, Canada, 2004

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY

in

THE FACULTY OF GRADUATE STUDIES

(Reproductive and Developmental Sciences)

THE UNIVERSITY OF BRITISH COLUMBIA

(Vancouver)

August 2010

© York Hunt Ng, 2010
Abstract

Background: The formation of the multinucleated syncytial trophoblast of the human placenta is a critical step in pregnancy, which is prone to failure. In these studies, I have examined the role of TWIST, a transcription factor identified as a key repressor of E-cad expression in normal and cancer cells of diverse origins, in the differentiation of human trophoblastic cells in vitro. The invasion of extravillous cytrophoblasts (EVTs) into the underlying maternal tissues and vasculature is a key step in human placentation. The molecular mechanisms underlying the development of the invasive phenotype of EVT include many of those first identified as having a role in cancer cell metastasis. In view of these observations, I have examined the expression, regulation, and function of Twist, Runx2 and N-cad in human trophoblastic cells in vitro.

Materials and Methods: Gain or loss-of-function studies were then performed to determine the role of Twist in terminal differentiation and fusion in these cells. The presence of multinucleated syncytiot was confirmed by indirect immunofluorescence. Concentration- and time-dependent studies were performed to determine whether interleukin (IL)-1β and transforming growth factor (TGF)-β1 regulate Twist and Runx2 mRNA and protein levels in EVT. Next, a siRNA strategy was employed to determine the role of Twist, Runx2 and N-cad in HTR-8/SVneo EVT cells.

Results: Exogenous expression of Twist resulted in a continuous and progressive decrease in E-cad expression and the subsequent formation of syncytiot in BeWo cells maintained under normal culture conditions. In contrast, siRNA specific for Twist inhibited the cAMP-mediated differentiation of these cells over time in culture. The cytokines, IL-1β and TGF-β1, respectively induced the differential up- and down-
regulation of Twist and Runx2 expression in primary cultures of EVTs in both a concentration and time-dependent manner. Use of a siRNA strategy demonstrated that a reduction in Twist, Runx2 or N-cad in HTR-8/SVneo cells concomitantly decreased the invasiveness of these cells.

**Conclusions:** Collectively, my findings demonstrate that TWIST is an upstream regulator of the E-CAD-mediated terminal differentiation and fusion of human trophoblastic cells *in vitro*. TWIST, RUNX2 and N-CAD are key molecules underlying the invasive capacity of EVTs.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>............................................................................................................... ii</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>............................................................................................................. iv</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>................................................................................................. ix</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>............................................................................................. xi</td>
</tr>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td>................................................................................... xv</td>
</tr>
<tr>
<td>CHAPTER 1: OVERVIEW</td>
<td>....................................................................................... 1</td>
</tr>
<tr>
<td>1.1</td>
<td>Introduction ................................................................................................. 1</td>
</tr>
<tr>
<td>1.2</td>
<td>Human implantation and placentation .............................................................. 3</td>
</tr>
<tr>
<td>1.2.1</td>
<td>Terminal differentiation of human cytotrophoblasts ........................................ 3</td>
</tr>
<tr>
<td>1.2.2</td>
<td>Models used in studying human placentation .................................................. 10</td>
</tr>
<tr>
<td>1.2.2.1</td>
<td>Rodent models ............................................................................................. 10</td>
</tr>
<tr>
<td>1.2.2.2</td>
<td>Non-human primate models ............................................................................. 11</td>
</tr>
<tr>
<td>1.2.2.3</td>
<td>In vitro models of trophoblast differentiation ............................................. 11</td>
</tr>
<tr>
<td>1.2.2.3.1</td>
<td>EVTs propagated from human first trimester placenta tissues ..................... 11</td>
</tr>
<tr>
<td>1.2.2.3.2</td>
<td>Villous cytotrophoblasts isolated from human term placentae .................... 12</td>
</tr>
<tr>
<td>1.2.2.3.3</td>
<td>Human trophoblastic cell lines .................................................................... 13</td>
</tr>
<tr>
<td>1.2.2.3.3.1</td>
<td>Choriocarcinoma cell lines .......................................................................... 13</td>
</tr>
<tr>
<td>1.2.2.3.3.2</td>
<td>HTR-8 cells ............................................................................................... 14</td>
</tr>
<tr>
<td>1.3</td>
<td>Cellular and molecular mechanisms involved in terminal differentiation of human trophoblasts .............................................................................................................. 15</td>
</tr>
<tr>
<td>1.3.1</td>
<td>Extracellular matrix degradation ................................................................... 15</td>
</tr>
<tr>
<td>1.3.1.1</td>
<td>Plasminogen activators and their inhibitors ............................................... 16</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>2.4</td>
<td>Generation of first-strand complementary DNA (cDNA)</td>
</tr>
<tr>
<td>2.5</td>
<td>Primer design</td>
</tr>
<tr>
<td>2.6</td>
<td>Semi-quantitative RT-PCR</td>
</tr>
<tr>
<td>2.7</td>
<td>Real-time-quantitative (q) RT-PCR</td>
</tr>
<tr>
<td>2.8</td>
<td>Western blot analysis</td>
</tr>
<tr>
<td>2.9</td>
<td>siRNA transfection</td>
</tr>
<tr>
<td>2.10</td>
<td>Expression vectors</td>
</tr>
<tr>
<td>2.11</td>
<td>Generation of stably transfected BeWo cell lines</td>
</tr>
<tr>
<td>2.12</td>
<td>Indirect immunofluorescence</td>
</tr>
<tr>
<td>2.13</td>
<td>Matrigel invasion assay</td>
</tr>
<tr>
<td>2.14</td>
<td>Statistical analysis</td>
</tr>
</tbody>
</table>

CHAPTER 3: TWIST REGULATES CADHERIN-MEDIATED DIFFERENTIATION AND FUSION OF HUMAN TROPHOBLASTIC CELLS IN VITRO ........................................ 61

3.1 Introduction and rationale ........................................ 61

3.2 Results ........................................................................ 64

3.2.1 8-bromo-cAMP promotes the terminal differentiation and fusion of BeWo cells in association with altered Twist and E-cad expression ........................................ 64

3.2.2 Twist siRNA inhibits the terminal differentiation and fusion of BeWo choriocarcinoma cells in the presence of 8-bromo-cAMP ........................................ 65

3.2.3 pEF1α-Twist promotes the terminal differentiation and
fusion of BeWo cells: correlation with E-cad mRNA and protein levels .................................................................67

3.3 Discussion and summary .................................................................87

CHAPTER 4: TWIST REGULATES CADHERIN-MEDIATED INVASION OF HUMAN TROPHOBLASTIC CELLS IN VITRO .........................93

4.1 Introduction and rationale .............................................................93

4.2 Results ..................................................................................................96

4.2.1 Determining the Twist and N-cad mRNA and protein levels in the human placenta, highly invasive EVTs, and poorly invasive trophoblastic cell lines ........................................96

4.2.2 IL-1β and TGF-β1 respectively promote and restrain the invasive ability of EVT primary cultures .........................96

4.2.3 Time-dependent effects of IL-1β and TGF-1 on Twist mRNA and protein levels in EVTs ........................................97

4.2.4 Concentration-dependent effects of IL-1β and TGF-β1 on Twist mRNA and protein levels in EVTs ........................................98

4.2.5 Decreased Twist down-regulates N-cad expression levels and reduces the invasive capacity of HTR-8/SVneo cells ...............98

4.2.6 Loss of N-cad reduces the invasive capacity of HTR-8/SVneo cells .................................................................99

4.3 Discussion and summary ........................................................................127
CHAPTER 5: A KEY ROLE FOR RUNX2 IN
HUMAN TROPHOBLAST INVASION ............................................... 131

5.1 Introduction and rationale ...................................................... 131

5.2 Results ................................................................................... 134

5.2.1 Runx2 is expressed in human placenta, highly invasive EVTs
and poorly invasive trophoblastic cell lines .............................................. 134

5.2.2 Time-dependent effects of IL-1β on Runx2
mRNA and protein levels in human EVTs ........................................ 134

5.2.3 Time-dependent effects of TGF-β1 on Runx2
mRNA and protein levels in human EVTs ........................................ 135

5.2.4 Concentration-dependent effects of IL-1β on Runx2
mRNA and protein levels in human EVTs ........................................ 135

5.2.5 Concentration-dependent effects of TGF-β1 on Runx2
mRNA and protein levels in human EVTs ........................................ 136

5.2.6 Attenuation of cytokine-modulated Runx2 mRNA
and protein levels in EVTs using neutralizing antibodies
directed against IL-1β or TGF-β1 .................................................. 136

5.2.7 Inhibition of Runx2 expression down-regulates N-cad mRNA and
protein levels and reduces the invasive capacity of
HTR-8/SVneo cells ............................................................................ 137

5.3 Discussion and summary .......................................................... 159

CHAPTER 6: GENERAL DISCUSSION ............................................... 163

6.1 Discussion ............................................................................... 163
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.2</td>
<td>Summary and conclusions</td>
<td>174</td>
</tr>
<tr>
<td>6.3</td>
<td>Future directions</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td>BIBLIOGRAPHY</td>
<td>178</td>
</tr>
<tr>
<td></td>
<td>APPENDIX</td>
<td>215</td>
</tr>
</tbody>
</table>
LIST OF TABLES

Table 2.1. Oligonucleotide primers for Twist, Runx2, N-cad, E-cad and GAPDH mRNA amplification (Semi-quantitative PCR) ......................................................53

Table 2.2. Real-time qPCR primers for Runx2, N-cad and GAPDH mRNA ........................................53
LIST OF FIGURES

Figure 1.1. A) Schematic diagram representing human trophoblastic cell differentiation.

B) Schematic diagram representing chorionic villi....................................................5

Figure 1.2. Schematic diagram representing of the basic structure of

type 1 classical cadherins in the plasma membrane.................................................27

Figure 1.3. Schematic diagram representing of the protein structure of the human Twist ....34

Figure 1.4. Schematic diagram representing of the protein structure of the human Runx2......38

Figure 3.1. Effects of cAMP on Twist mRNA and protein levels in BeWo cell cultures .........69

Figure 3.2. Effects of cAMP on E-cad mRNA and protein levels in BeWo cell cultures .........71

Figure 3.3. Immunolocalization of TWIST and E-CAD in BeWo cells cultured in the

presence or absence (control) of 1.5 mM 8-bromo-cAMP (cAMP).............................73

Figure 3.4. Effects of Twist siRNA on Twist mRNA and protein levels in BeWo cells
cultured in the presence of 1.5 mM 8-bromo-cAMP (cAMP).................................75

Figure 3.5. Effects of Twist siRNA on E-cad mRNA and protein levels in BeWo cells
cultured in the presence of 1.5 mM 8-bromo-cAMP (cAMP).................................77

Figure 3.6. Immunolocalization of TWIST, E-CAD and desmoplakin (DESMOPLAKIN)
in BeWo cells transfected with siRNA specific for Twist in the presence
of 1.5 mM 8-bromo-cAMP (cAMP).........................................................................79

Figure 3.7. Immunolocalization of TWIST, E-CAD and desmoplakin (DESMOPLAKIN)
in BeWo cells transfected with a scrambled control siRNA in the presence of
1.5 mM 8-bromo-cAMP (cAMP).............................................................................81

Figure 3.8. Twist and E-cad mRNA and protein levels in BeWo choriocarcinoma cells
stably transfected with pEF1α-Twist .......................................................................83
Figure 3.9. Immunolocalization TWIST, E-CAD and desmoplakin (DESMOPLAKIN) in mock transfected BeWo cells (Reagent) or BeWo cells stably transfected with pEF1α-Twist (pEF1α-Twist) .............................................................................. 85

Figure 3.10. A schematic diagram of a proposed role of Twist in regulating E-cad-mediated terminal differentiation and fusion of human trophoblastic cells .............................................................................................................. 92

Figure 4.1. Twist mRNA and protein levels in human placenta, highly invasive EVTs and poorly invasive trophoblastic cell lines ........................................................... 101

Figure 4.2. N-cad mRNA and protein levels in the human placenta, highly invasive EVTs, and poorly invasive trophoblastic cell lines ......................................................... 103

Figure 4.3. Regulatory effects of IL-1β and TGF-β1 on EVT invasion ................................. 105

Figure 4.4. Time-dependent effects of IL-1β on Twist mRNA and protein levels in EVTs ........................................................................................................................ 107

Figure 4.5. Time-dependent effects of TGF-β1 on Twist mRNA and protein levels in EVTs ........................................................................................................................ 109

Figure 4.6. Concentration-dependent effects of IL-1β on Twist mRNA and protein levels in EVTs ............................................................................................................... 111

Figure 4.7. Concentration-dependent effects of TGF-β1 on Twist mRNA and protein expression levels in EVTs ........................................................................................ 113

Figure 4.8. Effects of Twist siRNA on Twist mRNA and protein levels in HTR-8/SVneo cell cultures .............................................................................................................. 115

Figure 4.9. Effects of Twist siRNA on N-cad mRNA and protein levels in HTR-8/SVneo cell cultures .............................................................................................................. 117
Figure 4.10. Reduced Twist expression decrease the invasive capacity of HTR-8/SVneo cells ................................................................. 119

Figure 4.11. Effects of N-cad siRNA on N-cad mRNA and protein levels in HTR-8/SVneo cell cultures .................................................. 121

Figure 4.12. Reduced N-cad levels decrease the invasive capacity of HTR-8/SVneo cells ................................................................. 123

Figure 4.13. Disruption of N-CAD function decreases the invasive ability of HTR-8/SVneo cells ................................................................. 125

Figure 4.14. A schematic diagram of a proposed role of Twist in regulating N-cad-mediated differentiation of human trophoblastic cells ........... 130

Figure 5.1. Runx2 mRNA and protein expression levels in human placenta, highly invasive EVTs and poorly invasive trophoblastic cell lines ............. 139

Figure 5.2. Time-dependent effects of IL-1β on Runx2 mRNA and protein levels in EVTs ................................................................. 141

Figure 5.3. Time-dependent effects of transforming growth factor-β1 (TGF-β1) on Runx2 mRNA and protein levels in EVTs ......................... 143

Figure 5.4. Concentration-dependent effects of IL-1β on Runx2 mRNA and protein levels in EVTs ................................................................. 145

Figure 5.5. Concentration-dependent effects of TGF-β1 on Runx2 mRNA and protein levels in EVTs ................................................................. 147

Figure 5.6. Attenuation of IL-1β-mediated increase in Runx2 mRNA and protein levels EVTs ................................................................. 149

Figure 5.7. Attenuated of TGF-β1-mediated decrease in Runx2 mRNA and protein levels EVTs ................................................................. 149
protein levels in EVTs.................................................................151

Figure 5.8. Effects of Runx2 siRNA on Runx2 mRNA and protein levels
in HTR-8/SVneo cell cultures ...............................................................153

Figure 5.9. Effects of Runx2 siRNA on N-cad mRNA and protein levels in
HTR-8/SVneo cell cultures ...............................................................155

Figure 5.10. Reduced Runx2 levels decrease the invasive capacity of
HTR-8/SVneo cells ...........................................................................157

Figure 5.11. A schematic diagram of a proposed role of Runx2 in regulating
N-cad-mediated differentiation of human trophoblastic cells ............162

Figure 6.1. A schematic diagram of a proposed role of Twist in regulating
terminal differentiation and fusion of human trophoblastic cells ..........165

Figure 6.2. A schematic diagram of the proposed roles of Twist, Runx2 and N-cad
in regulating the invasive ability of human trophoblastic cells ............166
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>bHLH</td>
<td>Basic helix-loop-helix</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>BrdU</td>
<td>5-bromo-2’-deoxy-uridine</td>
</tr>
<tr>
<td>C</td>
<td>Carboxy</td>
</tr>
<tr>
<td>°C</td>
<td>Degrees centigrade</td>
</tr>
<tr>
<td>Ca²⁺</td>
<td>Calcium</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>Calcium chloride</td>
</tr>
<tr>
<td>CAM</td>
<td>Cell adhesion molecule</td>
</tr>
<tr>
<td>cAMP</td>
<td>Cyclic adenosine 3’,5’-monophosphate</td>
</tr>
<tr>
<td>cDNA</td>
<td>Complementary DNA</td>
</tr>
<tr>
<td>CP</td>
<td>Cytoplasmic domain</td>
</tr>
<tr>
<td>Cx</td>
<td>Connexin</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified eagle’s medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>dNTP</td>
<td>Deoxynucleoside triphosphate</td>
</tr>
<tr>
<td>E₂</td>
<td>Estradiol</td>
</tr>
<tr>
<td>EC</td>
<td>Extracellular subdomain</td>
</tr>
<tr>
<td>ECL</td>
<td>Enhanced chemiluminescence</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediamine tetra-acetate</td>
</tr>
<tr>
<td>EMT</td>
<td>Epithelial mesenchymal transition</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>EVT</td>
<td>Extravillous cytotrophoblast</td>
</tr>
<tr>
<td>FGF</td>
<td>Fibroblast growth factor</td>
</tr>
<tr>
<td>FGFR</td>
<td>FGF receptor</td>
</tr>
<tr>
<td>g</td>
<td>Grams</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
</tr>
<tr>
<td>h</td>
<td>Hours</td>
</tr>
<tr>
<td>HAV</td>
<td>Histidine-alanine-valine</td>
</tr>
<tr>
<td>hCG</td>
<td>Human chorionic gonadotropin</td>
</tr>
<tr>
<td>hPL</td>
<td>Human placental lactogen</td>
</tr>
<tr>
<td>Ig</td>
<td>Immunoglobulin</td>
</tr>
<tr>
<td>IGF</td>
<td>Insulin-like growth factor</td>
</tr>
<tr>
<td>IGFBP-1</td>
<td>IGF binding protein-1</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Interleukin-1β</td>
</tr>
<tr>
<td>IUGR</td>
<td>Intrauterine growth restriction</td>
</tr>
<tr>
<td>Kb</td>
<td>Kilo bases</td>
</tr>
<tr>
<td>kDA</td>
<td>Kilo daltons</td>
</tr>
<tr>
<td>LacZ</td>
<td>β-galactosidase</td>
</tr>
<tr>
<td>LH</td>
<td>Luteinizing hormone</td>
</tr>
<tr>
<td>Min</td>
<td>Minutes</td>
</tr>
<tr>
<td>ML</td>
<td>Milliliter</td>
</tr>
<tr>
<td>mM</td>
<td>Millimolar</td>
</tr>
<tr>
<td>MF</td>
<td>Microfilaments</td>
</tr>
<tr>
<td>MMP</td>
<td>Matrix metalloproteinase</td>
</tr>
<tr>
<td>MT-MMP</td>
<td>Membrane-type MMP</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>MW</td>
<td>Molecular weight</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger RNA</td>
</tr>
<tr>
<td>µl</td>
<td>Microliter</td>
</tr>
<tr>
<td>µM</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Nm</td>
<td>Nanomolar</td>
</tr>
<tr>
<td>NaCl</td>
<td>Sodium chloride</td>
</tr>
<tr>
<td>P</td>
<td>Probability</td>
</tr>
<tr>
<td>PA</td>
<td>Plasminogen activator</td>
</tr>
<tr>
<td>PAGE</td>
<td>Polyacrylimide gel electrophoresis</td>
</tr>
<tr>
<td>PAI</td>
<td>Plasminogen activator inhibitor</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PMSF</td>
<td>Phenylmethyl sulfonyl fluoride</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>RER</td>
<td>Rough endoplasmic reticulum</td>
</tr>
<tr>
<td>rRNA</td>
<td>Ribosomal RNA</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Reverse transcriptase-polymerase chain reaction</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>siRNA</td>
<td>Short interference RNA</td>
</tr>
<tr>
<td>SV40</td>
<td>Simian vacuolating virus-40</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>Transforming growth factor-β1</td>
</tr>
<tr>
<td>TIMP</td>
<td>Tissue inhibitor of MMP</td>
</tr>
<tr>
<td>TM</td>
<td>Transmembrane domain</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>TBS</td>
<td>Tris buffered saline</td>
</tr>
<tr>
<td>tPA</td>
<td>Tissue-type PA</td>
</tr>
<tr>
<td>Tris-HCL</td>
<td>Tris (hydroxymethyl)-aminomethane-hydrochloric acid</td>
</tr>
<tr>
<td>TSP</td>
<td>Thrombospondin type-1 repeat</td>
</tr>
<tr>
<td>uPA</td>
<td>Urokinase-type PA</td>
</tr>
<tr>
<td>VCAM</td>
<td>Vascular adhesion molecule</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>X-gal</td>
<td>5-bromo-4-chloro-3-indolyl-β-d-galactosidase</td>
</tr>
</tbody>
</table>
CHAPTER 1: OVERVIEW

1.1: Introduction

The human placenta plays a key role in regulating the growth, development, and survival of the fetus during pregnancy. It is the site of transfer of respiratory gasses, nutrients and waste products between the maternal and fetal systems; it serves as a barrier against blood-borne pathogens and the maternal immune system; and it fulfills an endocrine role by secreting hormones, growth factors and other bioactive substances required for the establishment and maintenance of pregnancy. The establishment and outcome of a pregnancy are highly dependent on the interactions and functional cooperation between the trophoblast and uterus (Pijnenborg et al., 1980; Aplin, 1991). Abnormal placental development is associated with clinical pathological conditions such as miscarriage, intrauterine growth restriction or preeclampsia (King and Loke, 1994; Benirschke and Kaufmann, 2000). Moreover, abnormal placental development associated with fetal aneuploidy contributes to early pregnancy loss (Salafia et al., 1993; van Lijnschoten et al., 1994). In a similar manner, abnormal placental structure has deleterious effects on the growth of the fetus (Krebs et al., 1996; Macara et al., 1996).

The trophoblast is an extraembryonic fetal tissue originating from the trophectoderm of the blastocyst. During placental development, three trophoblastic cell populations can be identified: cytotrophoblast stem cells and their derivative cell types: the syncytiotrophoblast and the extravillous cytotrophoblast (Hertig et al., 1956; Denker, 1993). The multinucleated syncytial trophoblast is formed from underlying mitotically
active, mononucleate cytotrophoblasts, and its formation is a cellular process dependent upon on a precise series of membrane-mediated events (Douglas and King, 1990). The cadherins are cell adhesion molecules capable of mediating the terminal differentiation and fusion of human cytotrophoblast (Getsios et al., 2000).

In order for a human placenta to develop and function properly, the embryonic trophoblastic cells must proliferate, differentiate and invade into the maternal endometrium (Aplin, 1991). Studies have shown the important roles played by members of the cadherin subtype in cell differentiation during cancer development and cancer cell invasion (Oka et al., 1993; Hazan et al., 2000). These findings allow us to identify the potential molecular mechanisms involved in trophoblast invasion, as the process of human trophoblast invasion utilizes similar molecular mechanisms as those of tumour cell invasion, albeit trophoblast invasion is a more tightly regulated, developmental process (Lala et al., 2002). The acquisition of the invasive and metastatic phenotype, and the transformation of a cell, result from complex cellular processes that will most likely regulate the levels and actions of transcription factors that control the genetic program. Very often, the regulatory factors associated with tumourigenesis are required for early development of tissues, including epithelial-mesenchymal transition genes (Twist, Snail, Slug, TGF-β) and phenotypic genes (Runx transcription factors) (Morrison and Kimble, 2006).

Careful control of gene expression by transcription factors is important in maintaining the physiological levels of proteins needed for normal cell function. However, expression of transcription factors can become aberrant in cancer cells due to epigenetic changes in chromatin, chromosome translocation or mutations (Yang et al., 2004; Blyth et al., 2005).
The main objective of my studies was to better understand the role(s) of cadherins in placental development. I have examined transcription factors, known as TWIST and RUNX2 during the terminal differentiation of human trophoblastic cells. In particular, TWIST is known to be a key regulator of cadherin-mediated interactions (Rosivatz et al., 2002; Vesuna et al., 2008). The ability of the cadherins to regulate the terminal differentiation of human trophoblastic cells was subsequently examined.

In this chapter, the development of the human placenta will be described with emphasis on the terminal differentiation of human cytotrophoblasts, particularly the molecular and cellular mechanisms involving the terminal differentiation of mononucleate cytotrophoblasts into either syncytiotrophoblasts or extravillous cytotrophoblasts. The cell biology of the cadherin gene superfamily and the transcription factors, TWIST and RUNX2, will also be reviewed.

1.2: Human implantation and placentation

1.2.1: Terminal differentiation of human cytotrophoblasts

The first step in human implantation involves apposition and attachment of trophodermal cells to the surface epithelium of the endometrium. After this initial contact, the trophodermal cells penetrate into the basement membrane of the maternal endometrium (Schlafke and Enders, 1975; Bentin-Ley et al., 2000). These stages of development are crucial in the process of establishing a successful pregnancy. Upon implantation, the embryonic trophoderm consists of two distinct but inter-related
epithelial cell layers: an inner layer of mitotically active cytotrophoblasts, and the outer syncytial trophoblast (Hertig et al., 1956) (Figure 1.1). Even though the trophoblastic cell subpopulation that is involved in the earlier stages of invasion of maternal tissue is still not clearly defined (Pijnenborg, 1990; Aplin, 2000), histological studies have shown that both the cytotrophoblasts and the syncytial trophoblast interact with the epithelial cells in the endometrium (Enders, 1976). During the third week after ovulation, these trophoblastic cells, after infiltration by a vascularized fetal mesenchyme, organize into mature chorionic villous structures. The chorionic villi are made up of a single layer of villous cytotrophoblast cells that rest on a basement membrane, a mesenchymal core containing fetal blood vessels, and an outer layer of syncytial trophoblasts that are in contact with the maternal endometrium and blood. The development and existence of the chorionic villi has been denoted as the hallmark of the human haemochorial placenta, whereby the fetal circulatory system is separated from the maternal blood cells throughout all stages of pregnancy by at least a single layer of trophoblastic cells, the syncytial trophoblast. This epithelial layer is the most important maternal-fetal barrier (Boyd and Hamilton, 1970, McGann et al., 1994).

The structural and functional properties of the villous cytotrophoblasts and the multinucleated syncytial trophoblast are different. For instance, the endoplasmic reticulum of villous cytotrophoblasts is poorly developed and non-vacuolated though it contains relatively large mitochondria and numerous free ribosomes (Boyd and Hamilton, 1970; Contractor et al., 1977).
Figure 1.1. A) Schematic diagram representing human trophoblastic cell differentiation. Mononucleate cytotrophoblasts will undergo differentiation and fusion to form syncytial trophoblast or will proliferate and differentiate to become highly invasive extravillous cytotrophoblasts (EVTs). B) Schematic diagram representing chorionic villi. Zone A represents a floating villous consisting of mononuclear villous cytotrophoblasts entering the non-invasive pathway. Zone B represents an EVT column. Zone C represents the extravillous pathway.
Villous cytotrophoblasts seem likely to be the primary site of synthesis of several peptide hormones, such as activin, inhibin and gonadotropin-releasing hormone (Khodr and Siler-Khodr, 1980; Miyake et al., 1982; Petraglia et al., 1991; 1996). In contrast, syncytial trophoblast contains larger nuclei and has more developed organelles such as a vacuolated rough endoplasmic reticulum (RER) associated with protein synthesis, numerous mitochondria for steroid hormone biosynthesis, and Golgi apparatus and secretory vesicles for secretion functions (Boyd and Hamilton, 1970). The syncytial trophoblast is initially formed during implantation and then maintained as a kind of steady-state structure at the maternal-fetal interface throughout pregnancy (Huppertz, 1999). The syncytial trophoblast is a dynamic structure that forms the continuous outer layer of the human placenta. The majority of the biological functions of the human placenta, such as transporting gasses and nutrients from the maternal to the fetal circulation throughout pregnancy, is performed by the multinucleated syncytial trophoblast layer (Richard, 1961; Kliman et al., 1986). Even though the mononucleate trophoblastic cells can produce human chorionic gonadotropin (hCG) at the earliest stages of pregnancy (Ohlsson et al., 1989), the syncytial trophoblast becomes the major source of this and most other peptide and steroid hormones produced by the human placenta throughout pregnancy for placental growth and for maternal adaptation to pregnancy (Hoshina et al 1982; Ringler and Strauss, 1990). Defects in the formation of the syncytial trophoblast are suspected to lead to several complications such as intrauterine growth restriction and pre-eclampsia (Lee et al., 2001, Ishihara et al., 2002).

In 1887, Langhans first suggested the cellular basis for the terminal differentiation in his morphological studies of the villous cytotrophoblasts in the human placenta (Boyd
and Hamilton, 1970). The human syncytial trophoblast is a terminally differentiated cell formed by post-mitotic fusion of the underlying villous cytotrophoblasts (Richard, 1961; Kliman et al., 1986). Other investigations have proposed that the development of the multinucleated syncytial trophoblast occurs from nuclear duplication in the absence of cytokinesis, a process in which the cytoplasm of a single eukaryotic cell is divided to form two daughter cells (Sarto et al, 1982). Functional studies using $^{3}$H-thymidine incorporation in human trophoblastic cells as well as succeeding studies have shown that the villous cytotrophoblasts are mitotically active and that nuclear division is completely absent in the multinucleated syncytial trophoblast in vivo (Richart, 1961; Galton, 1962; Gerbie et al, 1968). Ultrastructural analysis of the human term placenta demonstrated the presence of intercellular junctions within the syncytial trophoblast as well as within the boundary of direct contact between the villous cytotrophoblasts and the syncytial trophoblast. Furthermore, the junctional complexes within the syncytial trophoblast have been conceptualized as remnants of the cytotrophoblastic junctions that merged into the syncytial trophoblast cytoplasm following cellular fusion (Carter, 1964; Metz et al, 1979; Metz and Weihe, 1980).

Recent evidence has suggested that envelope-like human endogenous retrovirus (HERV) protein known as syncytin-2 is a crucial mediator of the fusion process involved in the syncytialisation of trophoblasts. For example, real-time reverse transcription PCR and Western blot analyses in differentiating primary trophoblast cells have shown a direct correlation between mRNA and protein levels of Syncytin-2 and cell fusion. Furthermore, experiments with siRNA (small interfering RNA) transfected BeWo and
primary human trophoblast cells demonstrated an important diminution in the number of
cell fusion processes upon repression of Syncytin-2 expression (Vargas et al., 2009).

To date, the molecular and cellular mechanisms that mediate the formation of the
syncytial trophoblast from the underlying villous cytotrophoblasts remain poorly
characterized. Detailed studies on the molecular and cellular biology in the formation of
the syncytial trophoblast are of critical importance for interpretation and treatment of
pregnancy complications.

A successful human pregnancy depends upon mononucleate cytotrophoblasts
entering one of the two distinct and mutually exclusive pathways. The villous
cytotrophoblastic cells will proliferate and differentiate by fusion to form the outer
syncytial trophoblast, as described above, or will enter the extravillous pathway to form
highly invasive extravillous cytotrophoblasts (EVTs) (Bischof and Campana, 2000)
(Figure 1.1).

In the extravillous pathway, cytotrophoblasts located within implanting chorionic villi
differentiate into EVT sulfs that invade deeply into the underlying maternal tissues and
uterine vasculature, thus allowing an increased and controlled supply of blood flow to the
placenta and ensuring an adequate supply of oxygen and nutrients to the developing fetus.
This is a critical step in human pregnancy (Pijnenborg et al., 1983 and 1994; Aplin,

Human EVT sls can be divided into three populations, depending upon their molecular
and morphological phenotypes and location within the extravillous compartment:
intermediate cytotrophoblasts that proliferate are located near the villous basement
membrane, interstitial cytotrophoblasts that will invade into the decidual stroma and
superficial myometrium, and endovascular cytотrophoblasts which will invade into the lumen of the spiral arteries (Pijnenborg et al., 1981, 1983; Roberston et al., 1986; Lala et al., 2002; Bischof and Irminger-Finger, 2005). EVTс will undergo cell proliferation and break through the outer layer of the syncytial trophoblast to develop large cellular columns that stretch out into the maternal decidua (Enders, 1968; Muhlhauser et al., 1993). Subpopulation(s) of EVTs will eventually detach from the tips of these cellular columns and invade into the decidual stroma and superficial myometrium as individual mononucleate cells and invade into the uterine arterial vasculature to replace the endothelial cells (Pijnenborg et al., 1980, 1983). This cellular event is believed to remodel the smooth muscle and elastin layers of the arteries and the underlying endothelial cells in these blood vessels that subsequently allow for increased maternal blood flow to the placenta later in pregnancy, and to thereby ensure an adequate supply of oxygen and nutrients to the developing fetus (Brosens et al., 1967; Pijnenborg et al, 1983).

The basic structure of the human placenta has become established at the end of the first trimester of pregnancy and all of the distinct trophoblastic cell subpopulations exist at the maternal-fetal interface (Boyd and Hamilton, 1970). Subsequently, trophoblastic cells continue to proliferate and differentiate, and promote placental growth until the end of pregnancy (Simpson et al, 1992). Therefore, it is important to acquire a detailed understanding of the molecular mechanisms that regulate human trophoblast terminal differentiation, both fusion and invasion, during formation and organization of the human placenta.
1.2.2: Models used in studying human placentation

1.2.2.1: Rodent models

Similarities have been noted between mouse and human in terms of placenta cell types (Carter, 2007) and genes controlling placental development (Rossant and Cross, 2001). The benefits of using the mouse as an experimental model include its short generation time. Other major benefits include the availability of embryonic stem cells, which help in gene targeting and the development of transgenic lines (Carter, 2007).

However, there are many differences between murine and human placentation; these include fewer placental hormones and a different mode of implantation in the mouse (Carter, 2007). More significantly, the transformation of uterine arteries in mice depends on maternal factors, such as the endothelium, rather than on trophoblasts and there is also limited trophoblast invasion in the mouse (Redline and Lu, 1989; Adamson et al., 2002; Pijnenborg, 2006). It is important to bear in mind that there are still other differences between mouse and human placenta that need to be addressed, such as the labyrinthine rather than villous structure of the exchange area in the mouse and the presence of three layers of trophoblast in the interhaemal membrane (Carter, 2007). Therefore, the mouse is considered to be a less than ideal experimental model for studies of trophoblast invasion and vascular remodelling, in relation to the situation in humans.
1.2.2.2: Non-human primate models

Studies have shown similarities among humans, baboons and macaques in terms of how the spiral arteries are invaded and transformed (Blankenship and Enders, 2003). Importantly, as in humans, the placenta of Old World monkeys (Cercopithecidae), e.g. baboon and macaque, are villous and haemochorial (Hill, 1932). Even though pre-eclampsia appears to be a uniquely human disease (Martin, 2003), there are findings where Old World monkeys (Palmer et al., 1979) and great apes (Stout and Lemmon, 1969) show symptoms that resemble pre-eclampsia. However, trophoblast invasion in non-human primates is more restricted than in the humans, and the absence of interstitial trophoblast cells in the monkey is a major difference in comparison to human placentation (Carter, 2007). Ethical issues and the high maintenance costs of primate colonies, as well as concerns for vulnerable or endangered species, limits the use of non-human primates as animal models (Caldecott and Miles, 2005).

1.2.2.3: In vitro models of trophoblast differentiation

1.2.2.3.1: EVTs propagated from human first trimester placenta tissues

Irving et al. (1995) reported a pure yield of EVT cultures by isolation (cutting the villi with a surgical scissor and mince finely with a razor blade) from first trimester placenta tissues (6-12 weeks gestation), as confirmed through morphological and phenotypical analysis. Indirect immunofluorescence showed that pure trophoblast outgrowths stain
100% positive for the epithelial cell markers cytokeratin 8 and 18, but do not stain for vimentin, a cell marker for mesenchymal cells (Irving et al., 1995). In addition, equal or more than 90% of mechanically isolated EVTs from placenta tissue immunostained positive for cytokeratin and insulin-like growth factor-II (Aplin et al., 1999). Therefore, the expression of these markers in isolated EVTs from placenta tissues allows the confirmation of a valid model for investigating EVT cell biology.

1.2.2.3.2: Villous cytotrophoblasts isolated from human term placentae

Villous cytotrophoblasts are isolated by a digestive enzyme from human term placental tissues followed by purifying the cells by using either immunoselection or density gradients. These cell isolating methods result in highly purified populations of mononucleate cytotrophoblasts (Kliman et al., 1987; Yui et al., 1994; Morrish et al., 1997). The cellular biology of mononucleate cytotrophoblasts mimics many of the cellular events associated with chorionic villous formation in vivo, for example, mononucleate cytotrophoblasts freshly isolated from human term placenta undergo aggregation, differentiation, and fusion to form a multinucleated syncytial trophoblast over time in culture. The level of β human chorionic gonadotropin increases during the formation of multinucleated syncytium in these primary cell cultures (Hoshina et al., 1982).
1.2.2.3.3: Human trophoblastic cell lines

1.2.2.3.3.1: Choriocarcinoma cell lines

Progress in understanding of human trophoblast differentiation has been restricted due to the cellular and morphological differences that exist between human placenta and animal models, as well as the fact that \textit{in vivo} human experimentation is difficult to justify. Trophoblastic cell lines derived from choriocarcinoma cells have provided a useful alternative for investigating human trophoblast differentiation \textit{in vitro} (King \textit{et al.}, 2000). Choriocarcinoma is a relatively uncommon malignant tumour of the human placenta that consists of mitotically active cytotrophoblasts (Benirschke and Kaufmann, 2000). The choriocarcinoma cell lines, known as BeWo, JEG-3 and JAR are the most commonly used cell lines.

BeWo choriocarcinoma cells undergo cellular differentiation in response to forskolin or cAMP (cyclic adenosine monophosphate) treatment (Seamon \textit{et al.}, 1981; Wice \textit{et al.}, 1990). In response to forskolin or 8-bromo-cAMP, BeWo cells show a marked reduction in DNA synthesis and within 48-96 hours of treatment these cells begin to fuse and form large syncytia (Coutifaris \textit{et al.}, 1991). This constitutes an \textit{in vitro} model to study the cellular and molecular processes involved in syncytial trophoblast formation.

JEG-3 choriocarcinoma cells are mononucleate trophoblastic cells that were established by Kohler \textit{et al.} (1971). When JEG-3 cells were treated with 8-bromo-cAMP, there was an increase in β human chorionic gonadotropin production; however these cells do not undergo differentiation to form a multinucleated syncytium under these culture conditions.
conditions (Chou et al., 1978; Burnside et al., 1985; Coutifaris et al., 1991). Instead, JEG-3 cells have been used as an in vitro model to study the cell biology of mononucleate trophoblasts.

JAR is a choriocarcinoma cell line originating from a human malignant cytotrophoblastic tumor. JAR cells have been used, for example, to study the molecular mechanisms involved in iodide transport from mother to fetus (Arturi et al., 2002). In preliminary gain-of-function studies using JAR cells transfected with an expression vector containing full-length Twist cDNA, I found significantly increased Twist mRNA expression, however the TWIST protein level remained unchanged (data not shown) and so these choriocarcinoma cells proved to be an unsuitable experimental system in which to study Twist-dependent effects.

1.2.2.3.3.2: HTR-8 cells

Studies of the trophoblast biology have been traditionally dependent on the use of primary trophoblast cultures from first trimester tissues (Kliman et al., 1986; Yagel et al., 1989). The drawback of using these primary cell cultures is their short life span, as the cells senesce after 5-6 passages. Furthermore, short-term cultures are not appropriate for certain experiments, such as those involving genetic manipulations, because these studies usually require long-term culture. Experiments using primary trophoblast cultures are also accompanied by high variability between samples due to heterogeneity in the cell population. HTR-8 cells, an EVT cell line, also known as parental HTR-8 cells or sometimes referred to as HTR-8/SVneo, when the parental HTR-8 cells are transfected
with Simian Virus 40 (SV 40) large T antigen (Tag). These transfected HTR-8/SVneo cells can normally be maintained in culture for more than 50 passages in comparison to their parental HTR-8 cells which senesced after 12-14 passages. Furthermore, these transfected cells retain most phenotypic features as compared to their non-transfected parental HTR-8 cells (Graham et al., 1993). HTR-8/SVneo cells also display a premalignant phenotype as indicated by hyperproliferative and hyperinvasive behaviour, and resistance to the anti-proliferation and anti-invasive effects of transforming growth factor β (TGF β) (Khoo et al., 1998). HTR-8/SVneo cells cultured in hypoxic conditions (2% oxygen concentration) exhibit reduced cell invasive properties. These cells also express cytokeratin and retain several important characteristics typical of primary cultures of first-trimester human cytotrophoblast cells, including altering their behaviour in response to a changing maternal environment (Kilburn et al., 2000).

1.3: Cellular and molecular mechanisms involved in terminal differentiation of human trophoblasts

1.3.1: Extracellular matrix degradation

In general, the extracellular matrix (ECM) that surrounds cells is comprised of proteins such as collagen, fibronectin, laminin and proteoglycans. Degradation of the ECM is required during biological processes such as tumour invasion and early placental development. Several key proteinases, such as those of the plasminogen activator (PA) family and the matrix metalloproteinase (MMP) family are activated to promote ECM degradation during these biological processes (MacDonald et al., 1998; Whiteside et al.,
2001, Denys et al., 2004). The roles of PA and MMP family members in human trophoblast differentiation are described in the following sections.

1.3.1.1: Plasminogen activators and their inhibitors

The plasminogen activators (PA) are substrate-specific proteinases that mediate cleavage of plasminogen to plasmin (Alfano et al., 2005). PA exhibits a wide range of serine protease activities that target extracellular matrix components such as laminin and fibrin, as well as assisting in the activation of zymogen forms of MMPs (Vaseelli et al., 1991; Andreasen et al., 2000; Durand et al., 2004). The PA system consists of the urokinase-type PA (uPA), the tissue-type PA (tPA), the PA inhibitors-1 and -2 (PAI-1 and PAI-2), and the uPA receptor (uPAR).

uPA is spatiotemporally expressed at the maternal-fetal interface during first trimester pregnancy in humans and higher primates (Hu et al., 1999; Feng et al., 2001). uPA has also been identified in subpopulations of extravillous cytotrophoblasts (EVTs) that invade into decidual tissue and spiral arteries to ensure a continuous supply of blood to the placenta (Fisher and Damsky, 1993). Neutralizing antibodies specific for uPA inhibit the invasive capacity of EVTs (Graham et al., 1994). Furthermore, IL-1β, which promotes trophoblast invasion, up-regulates uPA expression in EVTs (Karmakar and Das, 2002). This suggests that uPA may play a key role in regulating EVT invasion during pregnancy.

PAI inhibits the proteolytic activity of uPA by forming a complex with uPAR in a covalent manner that results in a conformational change (Andreasen et al., 1990). TGF-
β1, a growth factor that inhibits trophoblast invasion, can up-regulate PAI-1 and PAI-2 in EVTss (Graham, 1997; Karmakar and Das, 2002).

In addition, PAI-1 and PAI-2 are differentially expressed during the terminal differentiation and fusion of villous cytotrophoblasts isolated from human term placenta. PAI-1 is highly expressed in freshly isolated mononucleate cytotrophoblasts, while PAI-2 is highly expressed in the terminally differentiated syncytiotrophoblast (Feinberg et al., 1989).

1.3.1.2: Matrix metalloproteinases and their inhibitors

Matrix metalloproteinases (MMPs) are a homologous family of proteolytic enzymes. Based on their substrate specificity and structure, over 20 members of the MMP gene family are classified into four subgroups: the collagenases (MMP-1, MMP-8 and MMP-13) that digest type I, II, III, VII, and X collagens, which are major constituents of interstitial ECM; the gelatinases (MMP-2 and MMP-9) that digest type IV collagen, a basement membrane protein; membrane-type MMPs (MMP-14, MMP-15 and MMP-16) that are most commonly assigned a role in activating proMMP-2 by cleaving it at the cell surface; and the stromelysins (MMP-3, MMP-7, MMP-10, MMP-11, and MMP-12) that digest type IV, V and VII collagens, proteoglycans, laminin, fibronectin and elastin (Wang et al., 2000, Bischof et al., 2001; Cohen et al., 2006; Fingleton, 2006). These proteinases hold a zinc atom in a highly conserved active site and are responsible for ECM remodelling (Brown and Giavazzi, 1995). MMPs were initially thought to function mainly as enzymes that degrade the structural components of the ECM. However, these
proteinases have been found to regulate tissue architecture through their effects on the ECM and intercellular junctions, by producing substrate-cleavage fragments, creating spaces for cells to migrate, thereby activating or deactivating signalling molecules, either directly or indirectly (Sternlicht and Werb, 2001).

MMPs are tightly controlled, due to their degradative potential, and are secreted as latent proenzymes. The removal of an amino-terminal domain is required for the enzyme to be activated (Springman et al., 1990; Kleiner and Stetler-Stevenson, 1993). This tight regulation of enzyme activity is necessary in normal physiological situations, such as in wound healing or morphogenesis (Brenner et al., 1989; Bullen et al., 1995). However, there is excessive MMP expression in cancer progression (Brown et al., 1993; Davies et al., 1993). This enables the tumour cells to grow and then invade into the blood circulation and lymphatic system, thus leading to tumour spread.

Current studies show that the relationship between MMP expression and cancer is complex. For example, increased MMP activity may promote or inhibit tumour progression (Coussens et al., 2002) depending on factors such as the tumour site (primary or metastasis), the tumour stage and the MMP substrate profile and enzyme localization (tumor vs. stromal) (Fridman, 2006). MMP-2 and MMP-9 have been linked with the processes of cancer cell invasion and metastasis in humans, as these two proteinases have been associated in the progression of cervical uterine cancer (Libra et al., 2009). Furthermore, as the ECM may be the primary barrier to tumour growth and spread, MMPs may assist malignant tumour cells to overcome this barrier, and thus represent therapeutic targets in the treatment of cancer metastasis (Brown and Giavazzi, 1995).
The membrane-type MMPs (MT-MMPs), form a distinct membrane-type subclass in the MMP family since all the others members are secreted in the soluble forms. Instead, MT-MMPs induce the activation of pro-gelatinase A (68-kDa in gelatine zymography) on the cell surface into the activated form of 62-kDa fragments through a 64-kDa intermediate form (Sato et al., 1994; Takino et al., 1995). MT-MMPs have a major impact on cancer development due to their cellular localization at the tumour-matrix interface, for example, MT1-MMP promotes tumour invasion (Fridman, 2006). Furthermore, loss-of-function studies targeting MT1-MMP or MT2-MMP completely abolish the ability of SNAIL to induce carcinoma cell invasion through the underlying basement membrane (Ota et al., 2009).

Several studies have shown that MMP-2 and MMP-9 synthesis and activation are also necessary for trophoblast invasion (Librach et al., 1991, Shimonovitz et al., 1994; Bishop and Campana, 2000; Isaka et al., 2003). These two proteinases are differentially expressed in the first trimester (6-8 weeks) when trophoblast cells with MMP-2 being a key enzyme (gelatinase) are involved in trophoblast invasion through ECM degradation. In the late first trimester (9-12 weeks) trophoblasts, both of these gelatinases, MMP-2 and MMP-9 are involved in trophoblast invasion through degradation of collagen IV, the main component of the basement membrane (Librach et al., 1991; Xu et al., 2000; Staun-Ram et al., 2004). Besides regulating extravillous cytotrophoblast invasion, MMP-2 and MMP-9 are produced by the syncytial trophoblast and have a role in degradation and reformation of the placental basal lamina of chorionic villi (Sawicki et al., 2000).

The MMPs are inhibited by proteinase inhibitors known as tissue inhibitors of metalloproteinases (TIMPs). The TIMPs (TIMP-1, TIMP-2, TIMP-3 and TIMP-4) share
sequence identity with one another, and have similar activities towards the various members of the MMP gene family. However some specificity is evidenced by the finding that TIMP-1 preferentially binds to MMP-9, while TIMP-2 and TIMP-3, but not TIMP-1, are effective inhibitors of Membrane Type-MMPs (Strongin et al., 1995). Several MMPs and TIMPs are co-expressed in trophoblasts, suggesting that the invasive capacity of cytotrophoblastic cells could depend on the relative expression of various MMPs and TIMPs (Freitas et al., 1999; Terrade et al., 2002).

1.3.2: Extracellular matrix deposition

The ECM plays crucial roles in maintaining tissue integrity as well as modulating cellular differentiation during development (Lin and Bissell, 1991; Adams and Watt, 1993). The ECM also modulates the terminal differentiation and fusion of villous cytotrophoblasts isolated from term placenta (Kao et al., 1988). In humans, mononucleate cytotrophoblasts are separated from villous mesenchymal tissue by a basement membrane. Several ECM components including collagen type IV, laminin, heparan sulphate and proteoglycan are found within the basement membrane (Earl et al., 1990; Damsky et al., 1992; Onodera et al., 1997). The glycoprotein fibronectin is, however, expressed at different gestational periods in the basement membrane (Yamada et al., 1987; Virtanen et al., 1988; Earl et al., 1990), and addition of fibronectin to primary cultures of cytotrophoblasts promotes syncytial trophoblast formation in vitro (Kao et al., 1988). In addition, oncofetal fibronectin, an alternatively spliced variant of fibronectin, is synthesized and secreted by trophoblast cells in culture, and has been
identified at the contact sites between cytotrophoblast columns and the maternal decidua
(Matsuura and Hakomori, 1985; Matsuura et al., 1989; Feinberg et al., 1991), suggesting
that oncofetal fibronectin maintains placental-uterine interactions during pregnancy.

Another ECM component known as tenascin has anti-adhesive properties in vitro
(Aufderheide and Ekblom, 1988). This glycoprotein is expressed in areas beneath
degenerating syncytium, at locations where cytotrophoblast cells proliferate (Castelluci et
al., 1991; Damsky et al., 1992). This suggests that tenascin may play a direct or indirect
role in modulating villous cytotrophoblast differentiation.

1.3.3: ECM interactions: the integrin gene superfamily of cell adhesion molecules

One of the best characterized groups of ECM receptors that mediate cell-ECM
interactions are the integrins (Lochter, 1999). Integrins are glycoproteins and members
of a protein family that forms heterodimeric subunits that interact with various ECM
components (van der Flier and Sonnenberg, 2001). In mammals, 16 different integrin α
and 8 different integrin β subunits are currently known (Giancotti, 1997). The α and β
subunits interact with each other noncovalently. Each integrin has a specific set of
extracellular ligands, and the ligand specificity of the different integrin heterodimers is
determined by the specific combination of α and β subunits expressed on the cell surface
(Lafrenie and Yamada, 1996). Each subunit has a large extracellular domain, a single
transmembrane domain, and a short, noncatalytic cytoplasmic tail, apart from the β4
subunit that has a very large cytoplasmic domain (Colombatti et al., 1993). Integrins are
involved not only in adhesive functions between the cell and the ECM that provide
traction for movement and cell migration, but they can mediate cell-cell adhesion, and activate signal transduction pathways for anchorage-dependent survival and growth (Rosen et al., 1989).

Integrins are expressed in endometrial, decidual, and extravillous cytotrophoblasts (EVTs). During early pregnancy, different members of integrin subtypes (αVβ3, α4β1, α5β1, α6β1 and α7β1) are expressed in trophoblast-endometrium interfaces. During the differentiation of cytotrophoblasts along the extravillous pathway, expression of various integrins differs between proliferative and endovascular EVTs (Merviel et al., 2001). Function-perturbing antibodies to the α5β1 integrin subtype interrupt the organization of extravillous cytotrophoblast columns that form in chorionic villous explant cultures (Aplin et al., 1999). Aberrant expression of αvβ3 is associated with infertility, and women with recurrent miscarriages have a lower expression of α4β1 and α5β1 integrins in the stroma during the implantation window (Skrzypczak et al., 2001). Several other health issues such as preeclampsia and intrauterine growth restriction are believed to be caused by placental vascular problems that may explained by abnormalities in integrin patterns (Damsky et al., 1992; Aplin 1994, Merviel et al., 2001). In female mice, lack of a functional integrin β1 gene results in normal early embryonic development, but there is a failure to implant properly, with subsequent embryonic death (Stephens et al., 1995).

Other factors known to be involved in the implantation process may act through integrins. One example includes insulin-like growth factor-1 (IGF-1) mediated migration of EVTs that involves the αVβ3 integrin pathway (Kabir-Salmani et al., 2003 and 2004).
1.3.4: Cell-cell interactions

Many studies have focused on the expression of various members of the immunoglobulin (Ig) gene superfamily of Ca\(^{2+}\)-independent cell adhesion molecules (CAMs) in human trophoblastic cells (Buck, 1992; Burrows et al., 1996). For example, EVT\(s\) express vascular (V)-CAM-1, carcinoembryonic antigen (CEA)-CAM, melanoma (Mel)-CAM, platelet-endothelial (PE)-CAM-1, intercellular (I)-CAM, and neural (N)-CAM during the first trimester of pregnancy (Damsky et al., 1992; Burrows et al., 1994; Shih and Kurman, 1996; Coukos et al., 1998; Bamberger et al., 2000). A member of the selectin gene family of Ca\(^{2+}\)-dependent CAMs called E-selectin, that mediates leukocyte-endothelial cell interactions during inflammation, is also found in these EVT cells (Vestweber, 1992; Varki, 1994; Milstone et al., 2000). There is evidence that E-selectin influences how the blastocyst rolls along the inner uterine wall prior to implantation (Hoozemans et al., 2004). However, the biological function(s) of these CAMs at the maternal-fetal interface remains unclear and requires further investigation.

The regulated expression of gap junction components known as connexins (Cx), that help to establish cell-cell interactions, has been investigated during human trophoblast differentiation and invasion. A Cx subtype known as Cx43 is expressed in isolated human trophoblastic cells (Cronier et al., 1994). However, the role of gap junctions in the terminal differentiation and fusion of human villous cytotrophoblast remains to be elucidated. Although gap junctions between villous cytotrophoblasts and the syncytiotrophoblast in the first trimester placenta were detected in early ultrastructural
observations (De Viergilis et al., 1982), these junctions are not present in the trophoblastic cells from human term placenta (Metz et al., 1979 and 1980).

1.4: The cadherin superfamily

In view of the significant role of cell adhesion molecules involvement in regulating human trophoblast differentiation, we have focused our attention on the gene superfamily of cell adhesion molecules known as the cadherins. Cadherins are a gene superfamily of integral membrane glycoproteins that mediate calcium-dependent cell adhesion through homophilic interactions. The structural components of this gene family include an extracellular domain responsible for cell-cell interactions, a transmembrane domain, and a cytoplasmic domain that is linked to the cytoskeleton (Yagi and Takeichi, 2000). This gene superfamily of cell adhesion molecules consists of two evolutionarily distinct subfamilies: classical cadherins, which are homophilic Ca^{2+}-dependent cell-cell adhesion molecules; and non-classical cadherins (Yagi and Takeichi, 2000; Angst et al., 2001). Cadherins are widely known to regulate cell-cell adhesions, regulate cell shape, proliferation, migration, differentiation, and segregation, and are involved in intercellular signalling networks (Takeichi, 1991, 1995).

1.4.1: Classical cadherins

Over 15 members of the classical cadherin subfamily have been identified and are sub-classified into type I and type II cadherins. The most commonly known members of
The cadherin gene superfamily consist of a carboxy terminal cytoplasmic domain, a transmembrane domain, and an amino terminal extracellular domain, (Grunwald, 1993) (Figure 1.2). Some of the classical type I cadherins include E-cadherin (E-cad), N-cadherin (N-cad) and P-cadherin (P-cad). The names of these cell adhesion molecules originated from their tissue distribution during mouse embryonic development; with E-cad mainly expressed in epithelial cells, N-cad in neuronal cells and P-cad in the placenta (Nose and Takeichi 1986, Nagafuchi et al., 1987; Hatta et al., 1988; Suzuki et al., 1991). Type II classical cadherins include cadherin-6, -7, -8, -9, -10, -11, -12, -14, -19, and -20 (Takeichi, 1995).

The classical cadherin subfamily is defined by their highly conserved cytoplasmic domain, which connect with catenins (α-catenin, β-catenin, γ-catenin [also called plakoglobin], and p120ctn) to form the cytoplasmic cell adhesion complex that is necessary for extracellular cell-cell adhesion (Shibamoto et al., 1995; Cavallaro et al., 2002). For example, β-catenin and γ-catenin bind to the same conserved site at the C-terminal region of E-CAD in a mutually exclusive way (Ozawa et al., 1989; Nathke et al., 1994; Witcher et al., 1996), whereas p120ctn interacts with multiple sites in the cytoplasmic tail of E-CAD, including the juxtamembrane region (Ozawa, 1998; Yap et al., 1998). It is also known that α-catenin binds directly to β-catenin and γ-catenin, and thereby connects the cytoplasmic cell adhesion complex to the actin cytoskeleton (Cavallaro et al., 2002).

Studies using X-ray diffraction analysis suggest that the N-CAD extracellular domain forms a dimer, in which two monomers are arranged in parallel at the plasma membrane by forming an “adhesion dimer” at their N-terminus. An alternative model is that the two
monomers are arranged to form a rod- or cylinder-like oligomer rather than two monomers arranged in parallel (Takeichi, 1995). In addition, Ca\(^{2+}\) is essential for cadherin function by linking the five subdomains to form a rod-shape morphology on the cadherin molecules (Tong et al., 1994).

Type I and type II cadherins consist five extracellular repeats (EC1-5), and the main difference between them is the presence of a histidine, alanine, valine (HAV) tripeptide within the extracellular repeat (EC1) that is closest to the N-terminus. Cadherin molecules with a deletion of EC1 fail to mediate cell-cell interactions, suggesting that the HAV domain interactions between two CAMs may contribute to mediating homophilic protein-protein interaction (Takeichi, 1990; Knudsen et al., 1998). However, the HAV motif is not conserved in Type II cadherins, and the molecular basis of the specificity of cadherin interactions remains unclear. Furthermore, recent X-ray diffraction studies of
Figure 1.2. Schematic diagram representing the basic structure of type 1 classical cadherins in the plasma membrane. The cadherins are comprised of five extracellular subdomains (EC1-EC5). The EC1 subdomain contains the HAV, which is believed to play a role in cadherin-mediated adhesion. The cytoplasmic subdomains are highly conserved regions interact with a family of cytoplasmic proteins known as the catenins. CP1 interacts with p120\textsuperscript{ctn} and CP2 forms complexes with either β or γ-catenin and α-catenin. These interactions are believed to link the cadherins to the actin-based microfilaments (MF) of the cytoskeleton.
the extracellular domain of the *Xenopus* Type I cadherins suggest that other extracellular interfaces are involved in cadherin interactions, including the conserved tryptophan side chain at the membrane-distal end of a cadherin that intercalates into a conserved hydrophobic pocket in the corresponding partner (Boggon *et al.*, 2002).

Classical cadherins undergo calcium-dependent cell-cell adhesion in a homophilic manner, preferentially binding to like molecules, although in some cases a particular cadherin subtype may interact heterophilically with another cadherin subtype when two cell populations are mixed (Takeishi, 1995). Therefore, the interactions between two given cadherins can be classified into three categories: little or no heterophilic interactions; weak heterophilic interactions; and those in which homophilic and heterophilic interactions are not distinguishable (Nakagawa *et al.*, 1995; Takeichi, 1995).

Although the activity of Type I cadherins in tissue formation has been widely studied, with a focus on their cell adhesive properties, this is not the case for many Type II cadherins. However, some of the type II molecules are expressed in loosely associated cells, suggesting a weaker cell-cell interaction compared to type I molecules (Takeichi, 1995; Gumbiner, 1996).

1.4.2: Classical cadherins involvement in developmental processes

In addition to maintaining the structural integrity of cells and tissues, cadherins control a wide range of cellular behaviours (Huber *et al.*, 1996; Larue *et al.*, 1996). They regulate cell polarization (Larue *et al.*, 1994; Riethmacher *et al.*, 1995), and cell
movements including cell sorting and cell migration (Nose et al., 1988; Takeichi, 1988; Steinberg and Takeichi, 1994).

E-cad-deficient mouse embryos cannot normally develop into blastocysts, thus confirming the importance of E-cad in the organization of pre-implantation embryos (Larue et al., 1994; Riethmacher et al., 1995). N-cad, like E-cad, is critical during embryonic development. Indeed, the loss of either of these cadherin subtypes results in early embryonic death (Larue et al., 1994; Radice et al., 1997a). In addition, in mice without functional N-CAD, the myocardium is malformed, causing arrest of heart development, and the neural tube and somites are also not properly formed (Radice et al., 1997a). However, null mutant mice R-cadherin (R-cad) or P-cadherin (P-cad) are viable and fertile (Radice et al., 1997b; Dahl et al., 2002).

1.4.3: Classical cadherins and cancer

The majority of human cancers originate from epithelial cells. These epithelial cells are organized by a number of specific intercellular junctions, including adherens-type-junctions, tight junctions and desmosomes, which are interconnected with the actin and intermediate filament cytoskeleton (Cavallaro et al., 2002). Among the cell-cell adhesion molecules, cadherins appear to play a crucial role in establishing adherens-type-junctions (Takeichi, 1995; Huber et al., 1996; Yagi and Takeichi, 2000). It is well known that cell-cell adhesion is changed markedly during the development of malignant cancers (Cavallaro et al., 2002). For instance, loss of E-CAD-mediated cell-cell adhesion is a requirement for tumour cell invasion and metastasis formation (Birchmeier and Behrens,
Recent evidence demonstrates that N-cad is dominant over E-cad in metastatic progression and is overexpressed in a subset of cancer types in addition to the loss of E-cad (Derycke et al., 2004; Hazan et al., 2004). Nieman et al. (1999) reported that forced expression of N-cad causes E-cad to be down-regulated in breast cancer cells. The increase of N-cad expression increases the resistance to apoptotic stimuli, and a more invasive and motile cell phenotype and metastasis in nude mice (Cavallaro et al., 2002 and 2004; Jiang et al., 2007), thus demonstrating opposite effects to E-cad. It has been suggested in that a switch from epithelial to mesenchymal cadherins supports the transition from benign to an invasive, malignant tumor phenotype.

In contrast, Rosivatz et al. (2004) suggest that E-CAD transcriptional repression may not play a major role in colon cancer pathogenesis, and other studies did not always observe a correlation between reduced E-CAD immunohistochemistry and tumor progression. However, in the latter study, the same tumors had N-CAD immunoreactivity in 44% of the cases. It seems that N-cad has an invasion promoting effect, as earlier shown for other carcinomas, and that N-cad induced invasion activities can even overcome the E-CAD tumor suppressive function (Hazan et al., 1997; Nieman et al., 1999). This suggests that the “cadherin switch” can vary in a tumor-specific manner.

As discussed previously, villous cytotrophoblasts differentiating along the EVT pathway utilize similar molecular mechanisms to those employed in cancer cells (Bischof et al., 2001; Lala et al., 2002). Unlike cancer cell invasion, normal EVT invasion into the maternal endometrium and vasculature is highly regulated (Graham et al., 1993; Irving et
al., 1995). We therefore speculate that cadherins play an important role in human trophoblast invasion.

Several mechanisms are involved in the loss of E-CAD function during tumourigenesis; these include mutation or deletions of the E-cad gene itself, transcription repression of the E-cad gene, hypermethylation of CpG islands or chromatin rearrangements in the E-cad promoter region, as well as in the β-catenin gene (Hirohashi, 1998).

Several studies have highlighted transcription repression as the major mechanism leading to decreased E-cad expression (Schipper et al., 1991; Bussemakers et al., 1992; Brabant et al., 1993). E-cad transcription repressors belong to three families: i) TWIST; ii) SNAIL (SNAIL1, SNAIL2 (SLUG), SNAIL3), and ZEB1 (DeltaEF1)/ ZEB2 (SIP1), and interact with the E-cad gene promoter (Cano et al., 2000; Comjin et al., 2001; Bolos et al., 2003). For example, in many human carcinomas of the ovary, liver, colon, and gastrointestinal tract, Snail expression correlates with inhibition of E-cad expression (Blanco et al., 2002; Jiao et al., 2002). Furthermore, TWIST has been shown to transcriptionally repress E-cad in breast cancers (Yang et al., 2004; Vesuna et al., 2008).

In human gastric cancer, an increase in Snail mRNA expression is associated with a down-regulation of E-cad. An increase in N-cad mRNA levels was also detected in the same tumours, likely due to the overexpression of Twist (Rosivatz et al., 2002). Twist also induces N-cad expression in prostate carcinoma cells (Alexander et al., 2006). This suggests these EMT regulators could play different roles in gastric carcinogenesis depending on the histological subtype (Rosivatz et al., 2002). In relation to the mechanism that regulates E-cad, in vivo footprinting analysis shows that the positive
regulatory elements of the E-cad promoter (the CCAAT-box) were bound by transcription factors in cells that expressed E-cad but not in non-expressing cells (Hirohashi, 1998).

1.4.4: Classical cadherins and placentation

It is acknowledged that morphogenesis and cell differentiation depend, in part, on the regulated expression of cell surface glycoproteins and their connections to the cytoskeleton (Edelman, 1988). Some of these adhesion molecules are well-characterized including E-CAD (Damsky et al., 1984; Takeichi, 1991; Kemler et al., 1989).

In regard to embryonic development and placental morphogenesis, E-CAD has been gaining much attention (Coutifaris et al., 1991) because antibodies against E-CAD have shown to inhibit the compaction of preimplantation mouse embryos: a developmental process that involves blastomere adhesion and formation of intercellular junctions (Hyafil et al., 1980; Damsky et al., 1983; Vestweber and Kemler, 1984). In addition, E-cad mRNA and protein levels are high in freshly isolated villous cytotrophoblasts and decrease as the cells begin to undergo differentiation and fusion to form multinucleated syncytia (Coutifaris et al., 1991; Rebut-Bonneton et al., 1993). Similarly, E-CAD has been localized on the surface of cytotrophoblasts in situ, but not on the surface of the syncytiotrophoblast (Eidelman et al., 1989). Furthermore, immunoneutralization experiments using an antiserum directed against the cell adhesion domain of cadherins found inhibition of the formation of syncytia in comparison to an antiserum against the cytoplasmic tail of E-cad, which had no effect upon aggregation and fusion of these cells
A type II classical cadherin known as cadherin-11 (Cad-11) plays an important role in mediating trophoblast-endometrium interactions. Its expression increases during the formation of multinucleated syncytia in primary cultures of human cytotrophoblasts. When cad-11 was transfected into poorly invasive JEG-3 choriocarcinoma cells, this resulted in the formation of multinucleated syncytia in the transfected JEG-3 cell cultures (MacCalman et al., 1996; Getsios and MacCalman, 2003). This suggests that cad-11 contributes to the morphological and functional differentiation of the multinucleated syncytial trophoblast.

1.5: TWIST- A basic helix-loop-helix transcription factor

The Twist gene encodes a transcription factor that was originally identified in Drosophila. The human Twist gene is located at 7p21 and comprises two exons that are separated by an intron. TWIST contains a conserved basic helix-loop-helix (bHLH) domain (Bourgeois et al., 1996) (Figure 1.3). The function of bHLH transcription factors depends on the DNA-binding region and an HLH motif that mediates homodimerization or heterodimerization with other HLH proteins to form a functional dimer that can recognize and bind to a DNA motif called the E-box (Benezra et al., 1990; Massari and Murre, 2000; Castanon and Baylies, 2002).
Figure 1.3. Schematic diagram representing of the protein structure of the human Twist. The TWIST protein has 202 amino acids with a basic helix-loop-helix domain. The basic (b) is the DNA-binding region and the helix-loop-helix mediates homodimerization or heterodimerization with other HLH proteins to form a functional dimer.
Post-translational modifications like phosphorylation can alter the dimerization choices of TWIST, either promoting homodimer or heterodimer formation (Firulli et al., 2005), and different TWIST dimerization partners could have specific effects on the transcription regulatory function of TWIST. It has been suggested that TWIST as a heterodimer functions as a transcription repressor, while TWIST homodimers favour the upregulation gene expression by functioning as a transcription activator. For example, in studies of human cranial suture patterning and Drosophila mesoderm development, TWIST homodimers function as transcriptional activators (Castanon et al., 2001; Connerney et al., 2006).

1.5.1: Twist- A key player in cell differentiation and morphogenesis

Twist is expressed in mesodermal and cranial neural crest cells during embryogenesis in vertebrate and invertebrate development (Thisse et al., 1988; Fuchtbauer, 1995). Studies have shown that mutated Twist results in a twisted phenotype in Drosophila embryos, suggesting the expression pattern of Twist is associated with the formation and specification of the mesoderm (Thisse et al., 1988; Leptin, 1991). Heterozygous Twist mutant mice show a number of craniofacial defects, including a narrow palate and craniosynostosis. This is similar to patients with a skeletal dysplasia termed Saethre-Chotzen’s syndrome, in which reported mutations were found to involve the bHLH domain of the Twist gene (El Ghouzzi et al., 1997; Bourgeois et al., 1998).

Furthermore, Bialet et al. (2004) demonstrated that the molecular defect in the Saethre-Chotzen syndrome is caused by haploinsufficiency at the Twist locus. This gene
mutation which leaves TWIST’s bHLH domain intact but disrupts its TWIST box results in a serious form of the disease, with limb patterning defects (Gripp et al., 2000; Bialet et al., 2004). Bialet et al. (2004) has also shown that TWIST inhibits osteoblast differentiation by interfering with RUNX2, a member of the RUNX family of transcription factors which function through interacting with specific domains in these proteins; i.e., the TWIST box (a domain distinct from their bHLH domains) and a RUNX2 DNA binding domain.

1.5.2: Twist and cancers

Twist is linked to metastases of a wide range tumour types including those of ovary, breast and prostate tissues (Kwok et al., 2005; Puisieux et al., 2006; Hosono et al., 2007). Recently, Twist was shown to play a key role in inducing cell movement and tissue reorganization during invasion and metastasis in breast cancer. Indeed Twist clearly appears to be one of the most strongly up-regulated genes responsible for invasiveness and/or intravasation of mouse mammary tumors (Yang et al., 2004). Twist also has anti-apoptotic effects and can play a role in cell survival (Maestro et al., 1999). Yang et al. (2004) reported that suppression of Twist expression in highly metastatic mammary carcinoma cells specifically inhibits their metastasis to the lung. Furthermore, inhibition of Twist expression using small interfering RNA (siRNA) significantly impairs the metastatic ability of the most metastatic tumour cell lines (Yang et al., 2004).

EMT is characterized by the gain of mesenchymal cell markers such as N-CAD, vimentin, smooth muscle actin, and fibronectin; and the lost of epithelial markers such as
E-CAD and catenins (Thiery, 2003; Ridisky, 2005). The loss of E-CAD protein and/or transcriptional repression of E-cad mRNA are hallmarks of EMT, both in cancer progression and embryonic development (Thiery, 2002 and 2003). As mentioned previously, a major mechanism leading to decreased E-CAD levels seems to be a decrease in E-cad transcription (Bussemakers et al., 1993). TWIST is known to play a key role in E-cad repression and EMT induction (Yang et al., 2004). Inactivation of Twist reduces migration and invasion abilities of androgen-independent prostate cancer cells, and is correlated with induction of E-cad expression as well as morphologic and molecular changes linked with EMT (Kwok et al., 2005). In line with its function in EMT, TWIST represses transcription from the E-cad promoter via the E-boxes that are also targeted by SNAIL and SIP1 (Comijn et al., 2001). In addition, high TWIST levels are also linked with deep myometrial invasion of cancer cells and were concurrent with decreased E-CAD levels, a hallmark of EMT (Satoru et al., 2006).

The gain of N-cad expression, a mesenchymal marker, may increase motility and invasion of carcinoma cells as well (Cavallaro et al., 2002). The switch from E-CAD to N-CAD is mediated by a number of transcription factors, including TWIST, SIP1 and SNAIL1 (Rosivatz et al., 2004). As mentioned earlier, TWIST has been shown to be essential for the initiation of N-cad expression in Drosophilla (Oda et al., 1998) and in cancer cell invasion (Alexander et al., 2002; Rosivatz et al., 2002). The effect of TWIST on inducing N-cad is exerted by a direct interaction with an E-box cis-element located within the first intron of the N-cad gene (Alexandra et al., 2006).
Since Twist has regulatory and functional roles in both cancer differentiation and normal differentiation, we speculate that Twist may play an important role in human trophoblast differentiation.

1.6: Runt-related Gene (Runx) family

The Runx family is composed of three closely related genes; Runt-related gene 1 (Runx1), Runt-related gene 2 (Runx2), and Runt-related gene 3 (Runx3), each with tissue-specific functions and are homologous to the *Drosophila* gene runt. RUNX proteins are scaffolding transcription factors, which contain a runt homology domain that serves as the DNA-binding domain. They localize to subnuclear domains and translate cell signals through the formation of gene promoter regulatory complexes (Zaidi *et al*., 2001 and 2003). An essential feature of RUNX proteins is their C-terminal nuclear matrix targeting signal (NMTS) domain that mediates the organization of regulatory complexes (Zaidi *et al*., 2004) (Figure 1.4). They can form heterodimers with the transcriptional co-activator core binding factor β (CBF β)/ polyoma enhancer binding protein 2β (PEBP 2β) *in vitro* (Komori, 2006).

RUNX proteins control different aspects of embryonic development, and they are usually anti-proliferative in cellular differentiation in normal tissues. In addition, these transcription factors are known for their pathogenic function in different human diseases (Guo *et al*., 2002; Pratap *et al*., 2003; Wotton *et al*., 2004). RUNX proteins are known to be involved in haematopoiesis (RUNX1), osteogenesis (RUNX2), and neurogenesis (RUNX3), and are also involved in other developmental processes. For example,
Figure 1.4. Schematic diagram representing of the protein structure of the human Runx2. The RUNX2 protein consists of runt homology domain (RHD) that serves as the DNA-binding domain, the nuclear localization signal (NLS) that directs newly synthesized protein into the nucleus and the nuclear matrix targeting signal (NMTS) domain that mediates the organization of regulatory complexes.
conditional expression of Runx1 in an endothelial progenitor cell line from the aorta-gonad mesonephros region in mice, initiated Vascular Endothelial-cadherin expression and greatly enhanced the vascular network formation activity of the cells, suggesting that Runx1 plays a role in angiogenesis through Vascular Endothelial-cadherin (Iwatsuki et al., 2005). Furthermore, RUNX1 and RUNX3 have both been identified to play a role in the nervous system of mice. RUNX1 plays a role in the nociceptive development of the sensory neurons, however, RUNX3 is responsible for the proprioceptive sensory neurons. Both of these developmental processes are critical in neuronal development (Inoue and Ito, 2008).

RUNX proteins can function as cell context-dependent tumour suppressors or oncogenes (Blyth et al., 2005). Aberrant expression of Runx genes is associated with cell transformation and tumour progression (Pratap et al., 2006). For example, Runx1 mutations and chromosomal translocations have been associated with leukemia subtypes. Amplification of Runx1 is associated with poor prognosis in childhood B-cell leukemia (Osato and Ito, 2005), and loss of Runx3 predisposes mice to gastric hyperplasia (Lau et al., 2006).

Recently, the study of RUNX3 in tumour pathogenesis is gaining more attention in the field of cancer research. The RUNX3 transcription factor has been identified to be a downstream effector of the transforming growth factor-β (TGF-β) signalling pathway in controlling cell proliferation, cell invasion, cell adhesion and apoptosis. This transcription factor has also been shown to play a role as a tumour suppressor in colorectal and gastric cancers (Subramanian et al., 2009). However, RUNX3 functional
inactivation caused by mutation or epigenetic silencing has been seen in a wide range of tumour origins from early progression to malignancy (Chuang and Ito, 2010).

1.6.1: Runt-related Gene 2 (Runx2)

Runx2 expression was initially reported in T cells during thymic development and regulates the osteoblast-specific expression of osteocalcin (Ducy and Karsenty, 1995; Satake et al., 1995; Ducy et al., 1997). Loss of function mutations of Runx2 are linked to Cleidocranial dysplasia syndrome in humans (Otto et al., 2002).

Runx2 provides an important mechanistic linkage between cell fate, proliferation, growth control, and lineage commitment. Runx2 has been characterized in bone tissue and is expressed in mesenchymal lineage cells promoting the osteoblast phenotype for bone formation (Otto et al., 1997, Pratap et al., 2006). RUNX2 is the most specific molecular marker of osteoblast lineage; it is needed to induce osteoblast differentiation as well as to regulate most of the genes characteristic of the osteoblast phenotype (Ducy et al., 1997; Komori et al., 1997; Otto et al., 1997). Runx2−/− mice demonstrate a complete lack of both intramembranous and endochondral ossification due to the absence of osteoblast differentiation (Otto et al., 1997). RUNX2 can also act as a suppressor of ribosomal RNA (rRNA) synthesis (Zaidi et al., 2001; Young et al., 2007). It is also highly expressed in several other tissue types, including the testis (Ogawa et al., 2000), mammary epithelium (Inman and Shore, 2003), endothelial cells (Sun et al., 2001), and prostate and breast tumours (Yeung et al., 2002; Barnes et al., 2003).
Runx2 also promotes vascular endothelial growth factor (VEGF) expression in hypertrophic chondrocytes to mediate angiogenesis during bone synthesis. Runx2 is highly expressed in human and mouse models of angiogenesis, suggesting a possible function for RUNX2 in neovascularisation of adult tissues. Inactivation of the Runx2 gene in mice leads to an absence of vascularisation, in addition to the abnormal bone formation described above (Ducy et al., 1997; Zelzer et al., 2001).

1.6.1.1: Runx2 and cancers

The proper control of gene expression by transcriptional regulators is crucial in balancing the physiological levels of proteins necessary for normal cell function. However, the expression and activities of master transcription factors such as RUNX, TWIST and HOX can become irregular due to mutation, epigenetic changes in chromatin or chromosomal translocations, and can alter the expression of their downstream targets in cancer cells (Yang et al., 2004; Blyth et al., 2005; Grier et al., 2005). The oncogenic potential of Runx2 is suggested by high levels of endogenous RUNX2 in breast and prostate cancer cells associated with aggressive tumour growth in bone (Barnes et al., 2004; Javed et al., 2005). However, tumours do not appear in heterozygotes with haploinsufficiency of Runx2, suggesting Runx2 does not have a role in tumour suppression (Blyth et al., 2005).

In cancer cells, Runx2 can activate expression of adhesion proteins, matrix metalloproteinases and angiogenic factors that are related to the invasive properties of metastatic cancer cells (Pratap et al., 2006a), and MMPs have long been implicated in
tumour invasion and metastasis (Egeblad and Werb, 2002). RUNX2 transcription factor plays a role in regulating MMP-9 expression and promoting cell invasion in bone metastatic cancer cells (Pratap et al., 2005). This is important because one of the processes required for trophoblast invasion is the degradation and remodelling of the MMPs (Cohen et al., 2006).

1.6.1.2: Regulation and activation of Runx2

Increased transcription, epigenetic modifications in chromatin, or silencing of Runx2 repressor proteins have been linked to upregulation of Runx2 expression in breast and prostate cancer cells (Spencer and Davie, 2000; Young et al., 2005). Dysregulation of post-translational modifications (acetylation, ubiquitination, and phosphorylation) can affect the transcriptional activity of Runx2 in cancer cells (Bae and Lee, 2006; Jeon et al., 2006).

TGF-β treatment decreases Runx2 expression in osteoblasts, and repeated TGF-β treatment also decreases the amount of functional RUNX2 binding to DNA (Komori, 2006). In addition, Runx2 mediates the responses of cells to signal pathways that are often hyperactive in tumours, including those initiated by TGF-β and other growth factors. The Smads act as effectors of TGF-β to induce changes in gene expression. TGF-β binds to the TβRI/ TβRII receptor complex at the cell surface and activates SMAD 2 and SMAD 3 through phosphorylation, these then form complexes with SMAD 4 and translocate into the nucleus. These complexes link with transcription factors to regulate gene expression through DNA binding (Feng and Derynck, 2005).
1.6.1.3: Interactions between RUNX2 and TWIST

The Saethre-Chotzen (SC) syndrome is characterized by increased osteogenesis and premature fusion of cranial sutures caused by Twist mutations (Yousfi et al., 2002). Decreased Twist production causes a narrow sutural space and fusion of bone domains (Yoshida et al., 2004). Other studies have shown that RUNX2 activity is necessary for the regulation of osteoblast differentiation and in the osteogenic switch (Lian et al., 2004). Bialek et al. (2004) suggested Twist may regulate the developmental action of RUNX2 in bone formation.

The TWIST box located within the carboxyterminal 20 residues of TWIST is necessary for anti-osteogenic function in mice (Bialek et al., 2004), and it is known to bind with the runt DNA-binding domain of RUNX2 to inhibit RUNX2 transactivation activity (Lian et al., 2004). A decreased level of TWIST may promote RUNX2 function through the lack of inhibitor protein and by the enhancement of its own promoter activity (Yoshida et al., 2005).

A point mutation in the TWIST box leads to an acceleration of bone formation in heterozygous and homozygous mice (Bialek et al., 2004). Furthermore, TWIST box mutations in humans prevent the ability of TWIST to inhibit RUNX2 transactivation (Seto et al., 2007). Cell-free pull-down assays with recombinant RUNX2 and TWIST proteins have suggested a direct physical interaction between RUNX2 and TWIST.

In contrast, Komari et al. (2007) show that Runx2 gene expression was unaltered upon transient knock down of Twist in periodontal ligament (PDL) cells using short
interference RNA (siRNA), suggesting that regulatory interactions between TWIST and
RUNX2 are tissue or cell dependent.
1.7: Hypothesis and rationale:

A successful implantation depends upon mononucleate cytotrophoblasts entering one of two distinct and mutually exclusive pathways. The villous cytotrophoblastic cells will proliferate and differentiate by fusion to form the outer syncytial trophoblast, or enter the extravillous pathway to form highly invasive EVTs.

Previous studies have shown that the down-regulation of E-cad is associated with the terminal differentiation and fusion of human villous cytотrophoblasts in vitro. There is increasing evidence to suggest that this subpopulation of cytотrophoblasts develop an invasive phenotype via molecular and cellular mechanisms adopted by metastatic tumour cells. N-cad has been assigned an integral role in tumour progression and the onset of metastasis but its role in human trophoblastic cell invasion is not known. In view of these observations, the regulated and inverse expression of E-cad and N-cad is a possible mechanism that mediates terminal differentiation of human trophoblastic cells in vitro.

The functions of these classical cadherins are known to be regulated, at least in part, by transcription factors in normal development and in cancer progression. The basic helix-loop-helix transcription factor TWIST, as well as the scaffold transcription factor RUNX2, play integral roles in the onset and progression of cancer in a wide variety of tissues. This has prompted the following hypotheses:

1. That the expression of E-cad and N-cad is tightly regulated by TWIST and/or RUNX2 during the terminal differentiation of human trophoblastic cells in vitro, which was investigated as described in Chapters 3 and 4 using BeWo cells, primary EVTs and HTR-8/SVneo cells.
2. That N-cad plays a key role in regulated development of an invasive phenotype in EVT, which was investigated as described in Chapter 4 using primary EVT and HTR-8/SVneo cells.

3. That Runx2 plays a key role in regulated development of an invasive phenotype in EVT, which was investigated as described in Chapter 5 using primary EVT and HTR-8/SVneo cells.

The specific objectives of my studies were:

1. To identify a role for Twist in regulating the cadherin-mediated terminal differentiation of human trophoblastic cells (in both villous and extravillous pathways).
2. To identify a role for N-cad in regulating human trophoblastic cell invasion in vitro.
3. To identify a role for Runx2 in regulating human trophoblastic cell invasion in vitro.
CHAPTER 2: MATERIALS AND METHODS

2.1: Tissues

Samples of first trimester placental tissues were obtained from women undergoing elective termination of pregnancy (gestational ages ranging from 6-12 weeks). The use of these tissues was approved by the committee for Ethical Review of Research on the use of Human Subjects, University of British Columbia, Vancouver, BC, Canada. All women provided informed written consent.

2.2: Cells

Cultures of EVTs were propagated from first trimester placental explants as previously described (Getsios et al, 1998). Briefly, chorionic villi were washed three times in PBS. The villi were finely minced and plated in 25cm² tissue culture flasks containing Dulbecco’s Modified Eagle’s Medium (DMEM) containing 25 mM glucose, L-glutamine, antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin) and supplemented with 10% fetal bovine serum (FBS). The fragments of the chorionic villi were allowed to adhere for 2-3 days, after which any non-adherent tissue was removed. The villous explants were cultured for a further 10-14 days with the culture medium being replaced every 48 h. The EVTs were separated from the villous explants by a brief (2-3 min) trypsin digestion at 37°C and plated in 60 mm² culture dishes in DMEM supplemented with antibiotics and 10% FBS. The purity of the EVT cultures was determined by
immunostaining with a monoclonal antibody directed against human cytokeratin filaments 8 and 18 (data not shown). These cellular markers have been used to determine the purity of human EVT cultures (MacCalman et al., 1996). Only cell cultures that exhibited at least 90% immunostaining for cytokeratin were included in these studies.

HTR-8/SVneo, an EVT cell line, was obtained as a gift from Dr Charles H. Graham (Queen’s University, Kingston, ON, Canada). Culturing of HTR-8/SVneo has been described previously (Graham et al., 1993). HTR-8/SVneo cells were harvested from ongoing cultures with 0.125% (w/v) trypsin in EDTA buffer. HTR-8/SVneo cells were cultured in 100mm culture dishes (Becton Dickinson and Co, Franklin Lakes, NJ, USA) containing Dulbecco’s Modified Eagle’s Medium (DMEM) containing 25 mM glucose, L-glutamine, antibiotics (100U/ml penicillin, 100 μg/ml streptomycin) and supplemented with 10% fetal bovine serum (FBS).

BeWo and JEG-3 choriocarcinoma cell lines (American Type Culture Collection, Rockville, MD, USA) were harvested from ongoing cultures with 0.125% (w/v) trypsin in EDTA buffer. BeWo and JEG-3 cells were cultured in 100mm culture dishes (Becton Dickinson and Co, Franklin Lakes, NJ, USA) containing F12 Kaighn’s medium (F12K) containing L-glutamine, antibiotics (100U/ml penicillin, 100 μg/ml streptomycin) and supplemented with 10% fetal bovine serum (FBS).
2.3: Experimental culture conditions

BeWo cells (2.5 x 10^6 cells) were plated in 35 mm² tissue culture dishes and grown to 80% confluency. Cells were treated with or without 8-bromo-cAMP (1.5mM; Sigma-Aldrich, St Louis, MO, USA) for 0, 12, 24, 36 or 48 h. According to the manufacturer, cell-permeable 8-bromo-cAMP has greater resistance to hydrolysis by phosphodiesterases than cAMP. The dosage (1.5mM) of 8-bromo-cAMP was chosen based on previous studies from my laboratory.

EVTs (5 x 10^6 cells) (passages 4-6) were plated in 60 mm² tissue culture dishes (Becton Dickinson and Co, Franklin Lakes, NJ, USA) and grown to 80% confluency. The cells were then washed with PBS and cultured in DMEM under serum-free conditions. Twenty four hours after the removal of serum from the culture medium, the cells were again washed with PBS before cultured in the presence of TGF-β1 (0.001, 0.01, 0.1, 1 or 10 ng/ml) or IL-1β (1, 10, 100 or 1000 IU/ml) for 24 h or TGF-β1 (5 ng/ml) for 0, 6, 12, 24, or 48 h or IL-1β (100 IU/ml) for 0, 12, 24, or 48 h. EVTs cultured in the presence of vehicle (0.1% ethanol) served as controls for these studies. The treatment time and dosage for TGF-β1 and IL-1β were chosen based on previous studies from my laboratory.

To inhibit the regulatory effects of TGF-β1 and IL-1β on Runx2 mRNA and protein levels in these primary cell cultures, EVTs were cultured in the presence of either TGF-β1 (10 ng/ml) alone or in combination with a function-perturbing monoclonal antibody directed against human TGF-β1 (10 µg/ml; Sigma Aldrich) or IL-1β (100 IU/ml) alone or
in combination with a function-perturbing monoclonal antibody directed against human IL-1β (1 or 2 µg/ml; Sigma Aldrich) for 24 h.

The time points and the concentrations of cytokines and corresponding function-perturbing antibodies used in these studies were based upon previous reports (Huang et al, 1998; Chung et al, 2001). All of the EVT cell cultures were harvested for either total RNA or protein extraction.

2.4: Generation of first-strand complementary DNA (cDNA)

Total RNA was prepared from placenta tissues, cultures of EVTs and choriocarcinoma cell lines using an RNeasy Mini Kit (Qiagen, Inc, CA, USA) following a protocol recommended by the manufacturer. The total RNA extracts were then treated with deoxyribonuclease-1 to eliminate possible contamination with genomic DNA. To verify the integrity of the RNA, aliquots of the total RNA extracts were electrophoresed in a 1% (w/v) denaturing agarose gel, containing 3.7% (v/v) formaldehyde, and the 28 S and 18 S ribosomal RNA subunits visualized by ethidium bromide staining. The purity and concentration of total RNA in each of the extracts were determined by optical densitometry (260/280nm) using a Du-64 UV-spectrophotometer (Beckman Coulter, Mississauga, ON, Canada).

Aliquots (~1 µg) of the total RNA extracts prepared from placenta tissues and each of the trophoblastic cell cultures were then reverse-transcribed into cDNA using the First Strand cDNA Synthesis Kit, according to the manufacturer’s protocol (Amersham Pharmacia Biotech, Oakville, ON, Canada).
2.5: Primer design

Oligonucleotide primers for human Twist, Runx2, E-cad and N-cad were produced according to sequences deposited in GenBank (Accession No.: NM_000474, NM_004348, NM_004360 and NM_001792 respectively; National Center for Biotechnology Information, Bethesda, MD, USA). The housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was used as an internal control (Getsios et al., 1998b). Oligonucleotide primers corresponding to the nucleotide sequences for Twist, Runx2, E-cad and N-cad were synthesized at the Nucleic Acid and Protein Synthesis Unit, University of British Columbia, Vancouver, Canada. The nucleotide sequences of these primers and the expected sizes of the PCR products are listed in Table 2.1.

A second set of primers specific for Runx2, N-cad or GAPDH, were also prepared in Table 2.2. These primers were used for the real-time quantitative (q) RT-PCR.
Table 2.1. Oligonucleotide primers for Twist, Runx2, E-cad, N-cad and GAPDH mRNA amplification (Semi-quantitative PCR)

<table>
<thead>
<tr>
<th>mRNA</th>
<th>Primers (5’-3’)</th>
<th>Size (bp)</th>
<th>Position on cDNA</th>
<th>No. of cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twist</td>
<td>Upstream (5 end) AGTCCGCAGTCTTACGAGGA</td>
<td>576</td>
<td>646-665</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Downstream (5 end) GCAGAGGTGTGAGGATGGT</td>
<td></td>
<td>1222-1204</td>
<td></td>
</tr>
<tr>
<td>E-cad</td>
<td>Upstream (5 end) TGGATGTGCTGGATGTGAAT</td>
<td>560</td>
<td>1548-1567</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Downstream (5 end) ACCACCTCTAAGGCCATCT</td>
<td></td>
<td>2107-2088</td>
<td></td>
</tr>
<tr>
<td>N-cad</td>
<td>Upstream (5 end) ACAGTGCCACCTAAAGG</td>
<td>391</td>
<td>654-673</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Downstream (5 end) TGATCCCTCAGGAACGTG</td>
<td></td>
<td>1045-1026</td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>Upstream (5 end) ATGTTGTCATGGGTGTAACCA</td>
<td>378</td>
<td>449-471</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Downstream (5 end) TGGCAGGTTTTTCGACGGCAG</td>
<td></td>
<td>821-799</td>
<td></td>
</tr>
</tbody>
</table>

Table 2.2. Real-time qPCR primers for Runx2, N-cad and GAPDH mRNA

<table>
<thead>
<tr>
<th>mRNA</th>
<th>Primers (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Runx2</td>
<td></td>
</tr>
<tr>
<td>Upstream (5 end)</td>
<td>AGCCCTCGGAGAGGTACCA</td>
</tr>
<tr>
<td>Downstream (5 end)</td>
<td>TCATCGTTACCCGATGA</td>
</tr>
<tr>
<td>N-cad</td>
<td></td>
</tr>
<tr>
<td>Upstream (5 end)</td>
<td>TGGGAATCCGACGAATGG</td>
</tr>
<tr>
<td>Downstream (5 end)</td>
<td>GCAGATCGGACGGATAGT</td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
</tr>
<tr>
<td>Upstream (5 end)</td>
<td>GAGTCAACGGATTGGTCTGT</td>
</tr>
<tr>
<td>Downstream (5 end)</td>
<td>GACAAGCTTTCCGGTCAG</td>
</tr>
</tbody>
</table>
2.6: Semi-quantitative RT-PCR

Semi-quantitative RT-PCR was performed using the primer sets specific for Twist, Runx2, E-cad, N-cad or GAPDH, and template cDNA generated from the total RNA extracts prepared from BeWo, JEG-3, EVTs, HTR-8/SVneo cell cultures or placenta tissue (villi). The PCR cycles were repeated 15-40 times to determine a linear relationship between the yield of PCR products from representative samples of these cells or tissue and the number of cycles performed. The optimized numbers of cycles subsequently used to amplify Twist, Runx2, N-cad, E-cad and GAPDH are listed in Table 2.1.

All PCR reactions were performed on three separate occasions. PCR was also performed using the primer sets specific for Twist, Runx2, E-cad or N-cad and aliquots of total RNA extracts prepared from BeWo, JEG-3, EVTs, HTR-8/SVneo cell cultures or placenta tissue (villi) (i.e. non-transcribed RNA) or DEPC-treated water (negative control) under the same conditions as described above.

An aliquot (10 µl) of the Twist, Runx2, E-cad or N-cad PCR products was subjected to electrophoresis in a 1% agarose gel and visualized by ethidium bromide staining. The intensity of ethidium bromide staining of the PCR products was analysed by UV densitometry (Biometra, Whiteman Co., Frederick, MD, USA). The absorbance values obtained for Twist, Runx2, E-cad or N-cad were then normalized relative to the corresponding GAPDH absorbance value.
2.7: Real-time-quantitative (q) RT-PCR

The first-strand cDNA generated from the HTR-8/SVneo cell cultures served as a template for qRT-PCR using the ABI PRISM 7000 sequence detection system (PerkinElmer Applied Biosystems, Foster City, CA) equipped with a 96-well optical reaction plate. Real-time qPCR was performed using 12.5 µl SYBR Green PCR master mix (PerkinElmer Applied Biosystems), 7.5 µl of primer mixture (300nM), and 5 µl of cDNA template [diluted 1:7 (vol/vol)] under the following optimized conditions: 52 C for 2 min followed by 95 C for 10 min and 40 cycles of 95 C for 15 sec and 60 C for 1 min. All PCRs were performed in duplicate, with the mean being used to determine mRNA levels. A control containing DEPC-treated water instead of sample cDNA was included in each plate. Each set of primers generated a single PCR product of the appropriate size when visualized by agarose gel electrophoresis after qRT-PCR. Nucleotide sequences of the resultant PCR products were confirmed by BLAST (http://www.ncbi.nlm.nih.gov).

The amplification efficiency was determined by plotting log cDNA dilution against \( \Delta C_T \) (\( \Delta C_T = C_{T, \text{Target}} - C_{T, \text{GAPDH}} \)), the slope of which was close to zero, indicating maximal and similar efficiency of the target and reference genes (data not shown). \( C_T \) stands for Cycle threshold and is a measurement for the number of PCR cycles (in Real-time PCR) needed to get a fluorescent signal. Relative Runx2 or N-cad mRNA levels were determined using the formula \( 2^{\Delta \Delta C_T} \) where \( \Delta \Delta C_T = (C_{T, \text{Target}} - C_{T, \text{GAPDH}}) - (C_{T, \text{Target}} - C_{T, \text{GAPDH}})_0 \). In this formula, X represents siRNA transfection with control cultures being assigned a value of zero (Kenneth JL and Thomas DS, 2001). Data were analysed using SDS 2.0 software.
(PerkinElmer Applied Biosystems). This experimental approach was further validated by the observation that differences between the Cₜ for the target gene and GAPDH remained relatively constant for each amount of cDNA examined.

2.8: Western blot analysis

Cultures of EVTs or choriocarcinoma cell lines were washed three times in PBS and incubated in 100 µl of cell extraction buffer (Biosource International, Camarillo, CA, USA) supplemented with 1.0 mM phenylmethylsulphonyl fluoride and protease-inhibitor cocktail for 30 min on a rocking platform. The cell lysates were centrifuged at 10 000 x g for 10 min at 4°C and the supernatants used for Western blot analysis. The concentrations of protein in the cell lysates were determined using a BCA kit (Pierce Chemicals, Rockford, IL, USA). Aliquots (approximately 30 µg) of the cell lysates were prepared, and subjected to electrophoresis and immunoblotting, as previously described (MacCalman et al., 1996) using antibodies directed against human TWIST (Santa Cruz Inc, Santa Cruz, CA, USA), RUNX2 (Santa Cruz Inc, Santa Cruz, CA, USA), E-CAD (Transduction Laboratory, Lexington, KY, USA) or N-CAD (Upstate, Lake Placid, NY, USA). To standardize the amounts of protein loaded into each lane, the blots were reprobed with a polyclonal antibody directed against human β-actin (ACTIN) (Sigma Aldrich). The Amersham enhanced chemiluminescence system was used to detect the amount of each antibody bound to antigen with exposure to X-ray film. The absorbance values (density) obtained for TWIST, RUNX2, E-CAD or N-CAD by densitometry were then normalized relative to the corresponding ACTIN absorbance value.
2.9: siRNA transfection

siRNA (Qiagen, Valencia, CA, USA; 150 ng/ 35mm² culture dish) targeting human Twist mRNA (5’-AAGAACACCTTTAGAAATAAA-3’), Runx2 mRNA (5’-CACCTTGACCATAACGTTCT-3’) or N-cad mRNA (5’ AAGGAGTCAGCAGAAGTTGAA-3’) was transfected into BeWo or HTR-8/SVneo cells using HiPerFect Transfection Reagent (Qiagen, Valencia, CA) according to a protocol outlined by the manufacturer. BeWo or HTR-8/SVneo cells transfected with a non-silencing or scrambled siRNA (5’-AAT TCT CCG AAC GTG TCA CGT-3’), served as negative controls for these studies.

Following optimization of the HiPerFect:siRNA concentration ratio, experiments were performed using BeWo or HTR-8/SVneo cells that had been transfected with either siRNA or scrambled siRNA for 0, 12, 24, 36 or 48 h.

2.10: Expression vector

A full length human Twist cDNA (GenBank ID: BC036704) in pOTB7 vector was purchased from ATCC (Manassas, VA, USA). Twist cDNA was ligated into the BamHI/EcoRI site of pEF1α expression vector (Invitrogen, Carlsbad, CA) using standard molecular biology techniques. A clone (pEF1α-Twist) containing the Twist cDNA in the forward orientation was subsequently identified by DNA sequence analysis. Transfection reagent alone served as a control in my studies.
2.11: Generation of stably transfected BeWo cell line

Stable transfections were performed to establish BeWo cell line constitutively expressing pEF1α-Twist. pEF1α-Twist expression vectors (2.0 µg/ml) was transfected into BeWo cells using Lipofectamine™ 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Cells that were successfully transfected with pEF1α-Twist expression vectors were first selected after 24 h of culture using G418 antibiotic (400 µg/ml F12K; Invitrogen). Positives were then sub-cultured by limiting dilution and expanded into a cell line that was maintained in the selection medium.

2.12: Indirect immunofluorescence

Indirect immunofluorescence was performed using BeWo cells that had been plated on glass coverslips and fixed in methanol at -20°C for 2 min. Coverslips were incubated with primary antibodies for 45 min at 37°C. Primary antibodies were detected by using Alexa Fluor conjugated secondary antibodies (Molecular Probes, Eugene, OR, USA). BeWo cell nuclei were stained with 4’, 6-diamidino-2-phenyindole (DAPI; Sigma, St Louis, MO). The coverslips were examined by using a Leica DMR microscope/ Orca Hamamatsu system and analyzed with OpenLab software (Improvision, Lexington, MA, USA). The antibodies used for indirect immunofluorescence are similar to the antibodies used in western blotting.
2.13: Matrigel invasion assay

Cellular invasion assays were performed by using Transwells fitted with Millipore Corp. membranes coated with a thin layer of growth factor-reduced Matrigel (6.5-mm filters, 8-µm pore size; Costar, Toronto, ON, Canada) as previously described (Zhou et al, 1997; Xu et al, 2002). Briefly, 2.5 x 10⁴ cells/250 µl of DMEM supplemented with 10% FBS were plated in the upper wells of the Transwell invasion chambers. The Transwells were then immediately immersed into the lower wells of the invasion chambers which contained 1.2 ml of DMEM. Invasion assays were performed for 24 h in a humidified environment (5% CO₂) at 37°C, after which cells attached to the porous membranes were fixed in 4% paraformaldehyde, and cells from the upper surface of the Matrigel layer were completely removed by gentle swabbing. The remaining cells that had invaded into the Matrigel and appeared on the underside of the filters were fixed and stained using a Diff-Quick Stain Kit (Dade AG, Dudingen, Switzerland) according a protocol outlined by the manufacturer. The filters were then rinsed with water, excised from Transwells, and mounted upside-down onto glass slides. Invasion indices were determined by counting the number of stained cells in 10 randomly selected, non-overlapping fields at 40x magnification using a light microscope. Each cell culture was tested in triplicate wells, on three independent occasions.
2.14: Statistical analysis

The absorbance values obtained from the semi-quantitative RT-PCR, real-time RT-PCR products and the fluorograms generated by Western blotting were subjected to statistical analysis using GraphPad Prism 4 computer software (San Diego, CA, USA). Statistical differences between the absorbance values were assessed by analysis of variance (ANOVA). Differences were considered significant when \( P < 0.05 \). Significant differences between the means were determined using Dunnett’s test. The results are presented as the mean relative absorbance (± SEM) obtained from 4 different experiments.
CHAPTER 3: TWIST REGULATES CADHERIN-MEDIATED DIFFERENTIATION AND FUSION OF HUMAN TROPHOBLASTIC CELLS IN VITRO

3.1: Introduction and rationale

The human placenta plays a key role in regulating growth, development, and survival of the fetus during pregnancy (Aplin, 1991). It is the site of transfer of respiratory gasses, nutrients and waste products between the maternal and fetal systems. It serves as a barrier against blood-borne pathogens and the maternal immune system. It also fulfills an endocrine role by secreting hormones, growth factors and other bioactive substances required for the establishment and maintenance of pregnancy. Upon implantation, cytotrophoblastic cells proliferate and differentiate to form syncyntial trophoblasts, the outer cell layers of chorionic villi (Kaufman, 1985). Less recognized is that the syncytial trophoblast, a large multinucleated cell that forms the continuous outer layer of the human placenta, is responsible for the majority of biological functions assigned to this dynamic tissue (Richart, 1961; Kliman et al., 1986).

The multinucleated syncytial trophoblast is formed from the underlying layer of mitotically active, mononucleate cytotrophoblasts, involving a cellular process dependent upon a precise series of membrane-mediated events (Douglas and King, 1990). The cadherins are likely molecular players that mediate terminal differentiation and fusion of the cytotrophoblast. They belong to a gene superfamily of integral membrane glycoproteins that mediate calcium-dependent cell adhesion through homophilic
interactions. There is a marked reduction in E-cad expression during the aggregation, differentiation and fusion of human trophoblastic cells in vitro (MacCalman et al., 1996; Getsios et al., 2000). Immunoneutralization studies have shown that an antiserum directed against the extracellular domain of E-CAD inhibits the formation of syncytial trophoblast (Coutifaris et al., 1991). Taken together, these observations have led to the proposal that down-regulation of E-cad plays discrete roles in differentiation and fusion events of human trophoblastic cells in vitro. Although the molecular mechanisms underlying the down-regulation of E-cad during these cellular events remain to be elucidated, transcriptional repression mechanisms have emerged as one of the crucial processes for down-regulating E-cad expression during embryonic development (Carver et al., 2001; Castanon and Baylies, 2002; Thiery, 2003) and tumourigenesis (Bussemakers et al., 1994; Baudry et al., 2003; Yang et al., 2004). In particular, the highly conserved basic helix-loop-helix (bHLH) transcription factor known as TWIST has been shown to inhibit human E-cad gene expression (Yuen et al., 2007; Zhang et al., 2007).

Previous studies have demonstrated that down-regulation of E-cad is necessary during the terminal differentiation and fusion of human trophoblasts in vitro (Coutifaris et al., 1991; MacCalman et al., 1996; Getsios et al., 2000), but none of these studies have investigated the transcriptional factors that may down-regulate E-cad during these processes in vitro. Taken together, it is possible that Twist is involved in the mechanisms underlying the formation and organization of the human placenta through down-regulation of E-cad. In these studies, I first determined the levels of Twist and E-cad mRNA and protein during the terminal differentiation and fusion of BeWo cells cultured
in the presence of 8-bromo-cAMP by using semi-quantitative RT-PCR and Western blotting, respectively. Next, by establishing a stably transfected cell line containing Twist cDNA or utilizing a siRNA targeting Twist, I examined whether Twist is capable of promoting the terminal differentiation in these trophoblastic cells through affecting E-cad expression. Immunofluorescence staining was used in these studies to examine the morphological changes and the localization of TWIST and E-CAD in these cells.

Dr. S. Getsios helped perform the immunofluorescence staining in Figure 3.3 and Dr. H. Zhu helped perform the semi-quantitative RT-PCR, Western blot and immunofluorescence staining in Figures 3.8 and 3.9.
3.2: Results

3.2.1: 8-bromo-cAMP promotes the terminal differentiation and fusion of BeWo cells in association with altered Twist and E-cad expression

Twist mRNA was present in cultured BeWo cells, and its levels remained relatively constant over 2 days culture in the absence of 8-bromo-cAMP (Figure 3.1 A). However, a significant increase ($P < 0.05$) in Twist mRNA levels was detectable when the BeWo cells were cultured in the presence of a fixed concentration of 1.5 mM 8-bromo-cAMP for 24 h (Figure 3.1 A). Levels of Twist mRNA in these cell cultures continued to increase up to 48 h after treatment. The E-cad mRNA levels remained relatively constant in BeWo cells cultured in the absence of 8-bromo-cAMP (Figure 3.2 A). However, E-cad mRNA levels were significantly decreased in BeWo cells cultured in the presence of 1.5 mM 8-bromo-cAMP for 36 h, with levels continuing to decline up to 48 h (Figure 3.2 A).

Western blot analysis revealed the presence of a 28 kDa TWIST protein species in all BeWo cell cultures (Figure 3.1B). TWIST protein levels remained relatively constant in BeWo cells cultured in the absence of 8-bromo-cAMP (Figure 3.1 B). In agreement with the RT-PCR analysis, there was a significant increase ($P < 0.05$) in TWIST levels in BeWo cells cultured in the presence of 8-bromo-cAMP (1.5 mM) for 24 h, and these levels continued to increase up to 48 h after treatment (Figure 3.1B). E-CAD protein levels remained relatively constant in BeWo cells cultured in the absence of 8-bromo-cAMP (Figure 3.2 B), but there was significant reduction in E-CAD levels in BeWo cells...
cultured in the presence of 1.5 mM 8-bromo-cAMP for 36 h (Figure 3.2 B). Levels of E-CAD protein in these cell cultures continued to decrease up to 48 h after treatment.

By using indirect immunofluorescence, a low level of TWIST was found to be localized in the nuclei of mononucleate cytotrophoblasts (Figure 3.3 a) when the cells were cultured in the absence of 8-bromo-cAMP. In contrast, a higher level of TWIST immunoreactivity was found to be primarily localized in the nuclei of the syncytiotrophoblast (Figure 3.3 d) 36 h after treatment with 1.5 mM 8-bromo-cAMP. Immunoreactive E-CAD was localized to areas of cell-to-cell contact when the cells were cultured in the absence of 8-bromo-cAMP (Figure 3.3b). In contrast, E-CAD immunoreactivity was distributed in a diffuse manner along the surface of the multinucleated syncytium after cells were cultured for 36 h in the presence of 1.5 mM 8-bromo-cAMP (Figure 3.3 e).

3.2.2: Twist siRNA inhibits the terminal differentiation and fusion of BeWo choriocarcinoma cells in the presence of 8-bromo-cAMP

In order to repress the increase in Twist expression in BeWo cells after treatment with 1.5 mM 8-bromo-cAMP, I utilized a siRNA complementary to human Twist mRNA. Transfection of BeWo cells with this siRNA inhibited Twist mRNA and protein levels (Figures 3.4 A and B) from being up regulated after co-treatment of these cells with 1.5 mM 8-bromo-cAMP up to 48 h. In contrast, there was a significant increase in Twist mRNA and protein levels in BeWo cells transfected with a non-silencing scrambled siRNA under the same culture conditions and time frame (Figures 3.4 A and B). The
levels of E-cad mRNA and protein remained relatively constant at all time points examined in these studies when the cells were transfected with Twist siRNA (Figures 3.5 A and B). There was, however, a significant reduction in E-cad mRNA and protein levels in BeWo cells transfected with non-silencing scrambled siRNA over the same time frame (Figures 3.5 A and B).

I also assessed whether inhibiting Twist upregulation resulted in a concomitant decrease in terminal differentiation and fusion of BeWo cells in culture. When these cells were transfected with Twist siRNA in the presence of 1.5 mM 8-bromo-cAMP for 36 h, low levels of TWIST immunoreactivity were localized to the nuclei of the syncytial trophoblast (Figure 3.6 a-c). As well, E-CAD was localized to areas of cell-cell contact under the same conditions (Figure 3.6 d-f). In contrast, when BeWo cells were transfected with non-silencing, scrambled siRNA in the presence of 1.5 mM 8-bromo-cAMP for 36 h, TWIST was clearly localized to the nuclei of the syncytial trophoblast (Figure 3.7 a-c). As well, E-CAD immunostaining was reduced in the multinucleated syncytium that formed in the trophoblastic cell cultures under these conditions (Figure 3.7 d-f).

Furthermore, to determine whether BeWo cells transfected with Twist siRNA in the presence of 1.5 mM 8-bromo-cAMP remained mononucleated, I examined the distribution of desmoplakin in these cell cultures. Desmoplakin is an essential component of desmosomal junctions and has been used as a marker to determine cell boundaries in a wide variety of normal and malignant epithelial cells in vitro, including human trophoblasts (Douglas and King, 1990; Green and Gaudry, 2000; Getsios and MacCalman, 2003). Desmoplakin immunoreactivity was readily detectable at areas of
cell-cell contact (Figure 3.6 g-i) when BeWo cells were transfected with Twist siRNA in the presence of 1.5 mM 8-bromo-cAMP for 36 h. In contrast, desmoplakin immunoreactivity was distributed diffusely along the surface of the multinucleated syncytium when BeWo cells were transfected with non-silencing, scrambled siRNA in the presence of 1.5 mM 8-bromo-cAMP for 36 h (Figure 3.7 g-i).

3.2.3: pEF1α-Twist promotes the terminal differentiation and fusion of BeWo cells: correlation with E-cad mRNA and protein levels

In order to manipulate the up-regulation of Twist expression independently of cAMP, BeWo cells were stably transfected with the Twist expression vector pEF1α-Twist. Following selection of transfected cells by G418 treatment (described in Materials and Methods, section 2.11), a pool of stable transfectants was maintained and used for experiments.

The increase in Twist in BeWo cells transfected with pEF1α-Twist was concomitant with a reduction of E-cad mRNA and protein levels (Figures 3.8 A and B). In contrast, E-cad mRNA and protein were unchanged or minimally affected in mock transfected BeWo cells as compared to the untransfected parental cell line.

TWIST immunostaining was readily detectable in BeWo cells that were transfected with pEF1α-Twist (Figure 3.9 a), and E-CAD immunostaining was diffuse along the cell boundary in the multinucleated syncytium that formed in these cell cultures (Figure 3.9 b). In contrast, TWIST was barely detectable in the nuclei of the mononucleate
cytotrophoblasts of mock transfected cells (Figure 3.9 d), while E-CAD was localized to areas of cell-cell contact in the mock transfected BeWo (Figure 3.9 e).

To confirm that the mononucleate BeWo cells transfected with pEF1α-Twist underwent terminal differentiation and fusion to form multinucleated syncytium, I examined the distribution of desmoplakin in these cell cultures. In BeWo cells transfected with pEF1α-Twist, desmoplakin immunoreactivity was diffuse along the peripheral membrane of the multinucleated syncytium that formed in these cell cultures (Figure 3.9 c). In contrast, intense desmoplakin staining was readily detectable at areas of cell-cell contact in mononucleate BeWo cells after transfection with the reagent alone (Figure 3.9 f).
Figure 3.1. Effects of cAMP on Twist mRNA and protein levels in BeWo cell cultures. A) Semi-quantitative PCR analysis of Twist mRNA levels in BeWo cells cultured in the presence or absence (control) of a fixed concentration of 1.5 mM 8-bromo-cAMP (cAMP) for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively). A 100-bp ladder is shown in lane M (marker) with the size of the cDNA indicated at the right. The Twist mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. B) Representative fluorogram of a Western blot containing total protein (30 µg) extracted from BeWo cells cultured in the presence or absence (control) of 1.5 mM cAMP for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively) and probed with rabbit polyclonal antibodies against TWIST or human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for TWIST protein were normalized to the absorbance values obtained for human β-actin (ACTIN). The results from four sets of experiments were standardized to the 0 h control and are represented (mean ± S.E.M., n = 4) in the bar graphs (*, P < 0.05 compared to 0 h control).
Figure 3.1

A

M 1 2 3 4 5

576 bp (Twist)

378 bp (GAPDH)

M 1 2 3 4 5

576 bp (Twist)

378 bp (GAPDH)

Relative Amount of Twist Protein

Relative Amount of Twist mRNA

Control

cAMP (1.5 mM)

Time (h)

0 12 24 36 48

0 1 2 3 4 5

Control
cAMP

B

1 2 3 4 5

28 kDa (TWIST)

42 kDa (ACTIN)

1 2 3 4 5

28 kDa (TWIST)

42 kDa (ACTIN)

Relative Amount of TWIST Protein

Control
cAMP

Time (h)

0 12 24 36 48

0 0.5 1 1.5 2 2.5 3 3.5 4

*
Figure 3.2. Effects of cAMP on E-cad mRNA and protein levels in BeWo cell cultures.

A) Semi-quantitative PCR analysis of E-cad mRNA levels in BeWo cells cultured in the presence or absence (control) of 1.5 mM 8-bromo-cAMP (cAMP) for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively). A 100-bp ladder is shown in lane M (marker) with the size of the cDNA indicated at the right. Values for E-cad mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from BeWo cells cultured in the presence or absence (control) of 1.5 mM cAMP for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively) and probed with a mouse monoclonal antibody directed against E-CAD. The blots were then re-probed with a polyclonal antibody specific for human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values for E-cad were normalized to the corresponding absorbance values for human β-actin (ACTIN). The results derived from both these analyses and from three other sets of experiments were standardized to the 0 h control and are represented (mean ± S.E.M., n = 4) in the bar graphs (*, P < 0.05 compared to 0 h control).
Figure 3.2

A

M 1 2 3 4 5

Control

- 560 bp (E-cad)
- 378 bp (GAPDH)

CAMP (1.5 mM)

- 560 bp (E-cad)
- 378 bp (GAPDH)

Bar graph: Relative Amount of E-cad mRNA

Control

- 1 2 3 4 5

CAMP

Bar graph: Relative Amount of E-CAD Protein

B

M 1 2 3 4 5

Control

- 120 kDa (E-CAD)
- 42 kDa (ACTIN)

CAMP (1.5 mM)

- 120 kDa (E-CAD)
- 42 kDa (ACTIN)

Bar graph: Relative Amount of E-CAD Protein

Control

- 1 2 3 4 5

CAMP
Figure 3.3. Immunolocalization of TWIST and E-CAD in BeWo cells cultured in the presence or absence (control) of 1.5 mM 8-bromo-cAMP (cAMP). Double-label immunofluorescence was carried out for BeWo cells cultured in the absence (a, b and c) or presence of 1.5 mM cAMP for 48 h (d, e and f). The cells were fixed and immunostained with a rabbit polyclonal antibody directed against TWIST (a and d) and a mouse monoclonal antibody directed against E-CAD (b and e). DAPI was used to detect the nuclei in these BeWo cell cultures (c and f). The experiment was repeated on three independent occasions. Scale bar represents 50 µm.
Figure 3.3

TWIST

E-CAD

DAPI

Control

a

b

c

1.5 mM cAMP

d

e

f
Figure 3.4. Effects of Twist siRNA on Twist mRNA and protein levels in BeWo cells cultured in the presence of 1.5 mM 8-bromo-cAMP (cAMP). A) Semi-quantitative PCR analysis of Twist mRNA levels in BeWo cells transfected with siRNA specific for Twist or a scrambled control siRNA and cultured in the presence of 1.5 mM cAMP for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively). A 100-bp ladder is shown in lane M (marker) with the size of the cDNA indicated at the right. The Twist mRNA levels in each sample were normalized against the corresponding GAPDH mRNA levels. B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from BeWo cells cultured after transfection with siRNA specific for Twist or a scrambled control siRNA in the presence of a 1.5 mM cAMP for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively), and probed with rabbit polyclonal antibodies directed against TWIST or human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values for TWIST were normalized to the absorbance values for human β-actin (ACTIN) in the corresponding samples. The results from these analyses and from three other sets of experiments were standardized to the 0 h control and are represented (mean ± S.E.M., n = 4) in the bar graphs (*, P < 0.05 compared to 0 h control).
Figure 3.4

A

**cAMP and Control siRNA**

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- 576 bp (Twist)
- 378 bp (GAPDH)

**cAMP and Twist siRNA**

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- 576 bp (Twist)
- 378 bp (GAPDH)

**Relative Amount of Twist mRNA**

- cAMP and Control siRNA
- cAMP and Twist siRNA

B

**cAMP and Control siRNA**

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
</table>

- 28 kDa (TWIST)
- 42 kDa (ACTIN)

**cAMP and Twist siRNA**

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
</table>

- 28 kDa (TWIST)
- 42 kDa (ACTIN)

**Relative Amount of TWIST Protein**

- cAMP and Control siRNA
- cAMP and Twist siRNA

- 0 12 24 36 48

- Time (h)
Figure 3.5. Effects of Twist siRNA on E-cad mRNA and protein levels in BeWo cells cultured in the presence of 1.5 mM 8-bromo-cAMP (cAMP). A) Semi-quantitative PCR analysis of E-cad mRNA levels in BeWo cells transfected with siRNA specific for Twist or a scrambled control siRNA and cultured in the presence of 1.5 mM cAMP for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively). A 100-bp ladder is shown in lane M (marker) with the size of the cDNA indicated to the right. The E-cad mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from BeWo cells cultured after transfection with siRNA specific for Twist or a scrambled control siRNA in the presence of a fixed concentration of cAMP (1.5 mM) for 0, 12, 24, 36, or 48 h (lanes 1-5, respectively), and probed with mouse monoclonal antibody directed against E-CAD or polyclonal antibody against human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for E-CAD were normalized to the absorbance values obtained for human β-actin (ACTIN) in corresponding samples. The results from these analyses and from three other sets of experiments were standardized to the 0 h control, and are represented (mean ± S.E.M., n = 4) in the bar graphs (*, P < 0.05 compared to 0 h control).
Figure 3.5

A

**cAMP and Control siRNA**

<table>
<thead>
<tr>
<th>M</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>560 bp (E-cad)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>378 bp (GAPDH)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**cAMP and Twist siRNA**

<table>
<thead>
<tr>
<th>M</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>560 bp (E-cad)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>378 bp (GAPDH)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Relative Amount of E-cad mRNA

![Graph showing relative amount of E-cad mRNA.]

0               12              24              36              48

**cAMP and Control siRNA**

0               12              24              36              48

**cAMP and Twist siRNA**

B

**cAMP and Control siRNA**

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>120 kDa (E-CAD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42 kDa (ACTIN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**cAMP and Twist siRNA**

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>120 kDa (E-CAD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42 kDa (ACTIN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Relative Amount of E-CAD Protein

![Graph showing relative amount of E-CAD protein.]

0               12              24              36              48
Figure 3.6. Immunolocalization of TWIST, E-CAD and desmoplakin (DESMOPLAKIN) in BeWo cells transfected with siRNA specific for Twist in the presence of 1.5 mM 8-bromo-cAMP (cAMP). Photomicrographs of immunoreactive TWIST (a), E-CAD (d) and desmoplakin (g) expression in BeWo cells transfected with siRNA specific for Twist and cultured in the presence of 1.5 mM cAMP for 36 h. The cells were fixed and immunostained with either a rabbit polyclonal antibody against TWIST or a monoclonal antibody against E-CAD. A rabbit polyclonal antibody against desmoplakin was used as a marker for cell-cell borders. DAPI was used to detect the nuclei of these BeWo cells (b, e and h). Merged signals are shown on the right (c, f and i). The experiment was repeated on three independent occasions. Scale bar represents 50 µm.
Figure 3.6

cAMP and Twist siRNA (36 h)
cAMP and Twist siRNA (36 h)  cAMP and Twist siRNA (36 h)

E-CAD
cAMP and Twist siRNA (36 h)

DESMOPLAKIN
cAMP and Twist siRNA (36 h)
Figure 3.7. Immunolocalization of TWIST, E-CAD and desmoplakin (DESMOPLAKIN) in BeWo cells transfected with a scrambled control siRNA in the presence of 1.5 mM 8-bromo-cAMP (cAMP). Photomicrographs of immunoreactive TWIST (a), E-CAD (d) and desmoplakin (g) in BeWo cells transfected with a scrambled control siRNA and cultured in the presence of 1.5 mM cAMP for 36 h. The cells were fixed and immunostained with either a rabbit polyclonal antibody against TWIST, a monoclonal antibody against E-CAD, or a rabbit polyclonal antibody against desmoplakin. DAPI was used to detect the nuclei of these BeWo cells (b, e and h). Merged signals are shown on the right (c, f and i). The experiment was repeated on three independent occasions. Scale bar represents 50 µm.
Figure 3.7

cAMP and scrambled siRNA (36 h)

TWIST

DAPI

MERGED

E-CAD

DAPI

MERGED

DESMOPLAKIN

DAPI

MERGED
Figure 3.8. Twist and E-cad mRNA and protein levels in BeWo choriocarcinoma cells stably transfected with pEF1α-Twist.  A) Semi-quantitative PCR analysis of Twist or E-cad mRNA levels in untransfected BeWo cells (Wild), mock transfected BeWo cells (Reagent), or BeWo cells transfected with pEF1α-Twist (pEF1α-Twist).  Values for Twist or E-cad mRNA levels in each sample were normalized to their corresponding GAPDH mRNA levels.  B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from untransfected BeWo cells (Wild), mock transfected BeWo cells (Reagent), or BeWo cells transfected with pEF1α-Twist (pEF1α-Twist) and probed with specific antibodies directed against TWIST or E-CAD.  The blots were then re-probed with a polyclonal antibody specific for human β-actin.  The Amersham ECL system was used to detect antibody bound to antigen.  The resultant fluorograms were scanned and the absorbance values obtained for TWIST or E-CAD were normalized to the absorbance values obtained for human β-actin (ACTIN) in corresponding samples.  The results from these analyses and from three other sets of experiments were standardized to the values of the transfection reagent control and are represented (mean ± S.E.M., n = 4) in the bar graphs (*, $P < 0.05$ compared to control).
Figure 3.8

A

<table>
<thead>
<tr>
<th></th>
<th>M</th>
<th>Wild</th>
<th>Reagent</th>
<th>pEF 1α-Twist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-cad</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>Wild</th>
<th>Reagent</th>
<th>pEF 1α-Twist</th>
</tr>
</thead>
<tbody>
<tr>
<td>TWIST</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-CAD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTIN</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Relative Amount of Twist mRNA**

- Wild: 1.0
- Reagent: 2.0
- pEF 1α-Twist: 1.5

**Relative Amount of Twist Protein**

- Wild: 1.0
- Reagent: 0.8
- pEF 1α-Twist: 1.2

**Relative Amount of E-cad mRNA**

- Wild: 1.0
- Reagent: 0.8
- pEF 1α-Twist: 1.2

**Relative Amount of E-CAD Protein**

- Wild: 1.0
- Reagent: 0.8
- pEF 1α-Twist: 1.2
Figure 3.9. Immunolocalization of TWIST, E-CAD and desmoplakin (DESMOPLAKIN) in BeWo cells stably transfected with pEF1α-Twist (pEF1α-Twist) or in mock transfected BeWo cells (Reagent). The Twist overexpressing cells (a-c) or the mock transfected cell (d-f) were fixed and immunostained with either a rabbit polyclonal antibody against TWIST (a and d), a mouse monoclonal antibody against E-CAD (b and e), or a rabbit polyclonal antibody against desmoplakin (c and f). DAPI was used to detect the nuclei in these BeWo cell cultures. The experiment was repeated on three independent occasions. Scale bar represents 50 μm.
Figure 3.9

(a) TWIST expression with pEF1α-Twist reagent
(b) E-CAD expression with pEF1α-Twist reagent
(c) DESMOPLAKIN expression with pEF1α-Twist reagent

(d) TWIST expression with Reagent
(e) E-CAD expression with Reagent
(f) DESMOPLAKIN expression with Reagent
3.3: Discussion and summary

Twist was first identified in *Drosophila melanogaster* as one of the zygotic genes required for dorsoventral patterning and mesoderm differentiation during embryogenesis (Thisse *et al.*, 1987; Gitelman, 1997). This transcription factor is recognized as an organizer of epithelial-mesenchymal transition (EMT) during gastrulation and regulator of mesoderm differentiation (Thisse *et al.*, 1987; Leptin *et al.*, 1990). Twist has also been found to play an important role in cancer metastasis and was first reported in a breast cancer model, which suggested that Twist induced EMT and resulted in the promotion of tumour invasion (Yang *et al.*, 2004). Similarly, disruption of E-CAD-mediated cell adhesion seems to be crucial in the EMT from non-invasive to invasive tumour cells (Comijn *et al.*, 2001; Yang *et al.*, 2004; Lee *et al.*, 2006). Also, disruption of E-CAD-mediated cell adhesion has been related to a more infiltrative growth pattern in different types of cancers (Sakuragi *et al.*, 1994; Cheng *et al.*, 1996; Bremnes *et al.*, 2000). In agreement, high Twist expression was seen to be correlated with deep myometrial invasion by endometrial cancer cells and is concurrent with decreased E-cad expression (Kyo *et al.*, 2006).

In my own studies, I observed a differential expression of Twist and E-cad during the terminal differentiation and fusion of a human trophoblastic cell line *in vitro*. These results suggest that TWIST controls the expression of E-cad, and that together they play an important role in human placental development. Importantly, the finding that Twist is up-regulated and E-cad is down-regulated when BeWo cells undergo differentiation and
fusion to become syncytia, suggests that TWIST may serve as a transcription repressor of E-cad during this highly regulated series of membrane-mediated processes.

My observation of E-cad down-regulation during Twist-regulated differentiation and fusion of human trophoblastic cell line in vitro is consistent with other reports that loss of E-cad expression is a critical process during human trophoblast differentiation (Coutifaris et al., 1991; Getsios et al., 2003). For example, E-CAD has been shown to be present on the surface of cytotrophoblasts in situ, but not on the surface of the encompassing syncytiotrophoblast (Eidelman et al., 1989). Furthermore, the loss of E-CAD function by function-perturbing antibodies against E-CAD disrupted the aggregation of mononucleate cytotrophoblasts isolated from the human term placenta, which in turn inhibited the formation of multinucleated syncytiain cell cultures (Coutifaris et al., 1991).

Primary trophoblast cultures were not used in my studies mainly because these samples contain heterogeneous populations of isolated cyto- and syncytial trophoblasts (Nasiry et al., 2006). To circumvent this problem, I used the fusigenic BeWo choriocarcinoma cell line, which has long been known to respond to increased intracellular cAMP by differentiating into a multinucleated syncytial trophoblast (Pattillo and Gey, 1968; Wice et al., 1990).

Here, I also demonstrate that siRNA directed against Twist disrupts the formation of a multinucleated syncytium in BeWo cells undergoing terminal differentiation and fusion. My gain-of-function studies showed that heterologous Twist overexpression promotes the formation of multinucleated syncytia in these cell cultures. Collectively, and since E-cad expression was inversely altered in response to enhanced or reduced Twist expression, both these studies provide further evidence that E-CAD-mediated differentiation and
fusion of human trophoblastic cells are regulated by Twist. My results have also shown that terminal differentiation and fusion of human trophoblastic cells are accurately reproduced in culture at both the morphological and molecular levels.

Suppression of Twist expression in highly metastatic mammary carcinomas or prostate cancer cells inhibits their ability to invade or metastasize (Hoek et al., 2004; Yang et al., 2004; Kwok et al., 2005; Hosono et al., 2007). On the other hand, elevated levels of Twist mRNA are associated with malignant transformation of melanoma cells, increase the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients, and induce mesenchymal components and facilitate cell motility of various tumour cells (Kang and Massague, 2004; Yang et al., 2006; Hosono et al., 2007). The major functions of E-CAD are to mediate cell-cell adhesion and to play a pivotal role in the formation and maintenance of many epithelial tissues (Suzuki et al., 1996). Changes in cellular adhesion molecules like E-CAD are important for the invasive and metastatic capacity of human cancers (Takeichi M, 1993; Wijnhoven et al., 2000). For instance, decreased membranous immunoreactivity of E-CAD has also been shown to predict lymph node metastasis in atypical carcinoids (Pelosi et al., 2005). In contrast, increased cytoplasmic immunoreactivity of E-CAD has been suggested to result in loss of cell polarity and differentiation in pancreatic intraepithelial neoplasia (Al-Aynati et al., 2004).

Several studies have strongly suggested that transcription repression is a major mechanism leading to decreased E-cad expression (Schipper et al., 1991; Bussemakers et al., 1992; Brabant et al., 1993; Dorudi et al., 1993). This commonly involves silencing of E-cad transcription through E-boxes in its promoter region. In transient reporter assays, over-expression of Twist in human mammary epithelial cells inhibited E-cad
promoter activity (Yang et al., 2004). TWIST represses transcription from the E-cad promoter through the E-box sequence, 5’-CANNTG-3’, which is also targeted by SNAIL and SIP1 (Lee et al., 2006).

Other ways of silencing E-cad gene expression have been recognized, including gene truncation mutations and loss of heterozygosity (LOH) (Yoshiura et al., 1995, Berx et al., 1996; Huiping et al., 1999; Droufakou et al., 2001). However, these mechanisms appear to be utilized in only a subset of E-cad-negative invasive lobular carcinomas, therefore suggesting that a transcriptional repression mechanism of the E-cad promoter by TWIST plays a major role in the pathogenesis of these tumours (Yang et al., 2004). Although several studies have shown that promoter methylation can influence E-cad expression (Yoshiura et al., 1995; Xue et al., 2003; Lombaerts et al., 2006), this has not always been found (Tamura et al., 2000), and the mechanisms responsible for down-regulation of E-cad may be cell type-specific.

The function of bHLH transcription factors like TWIST relies on the basic DNA-binding region and the HLH structure that allows monomers to form functional dimers that can identify and bind to the E-box DNA motif (Massari and Murre, 2000). The basic domain mediates the interaction with DNA (Elleberger et al., 1994; Ma et al., 1994) and bHLH proteins bind as dimers to the consensus hexanucleotide sequence E-box, (Ephrussi et al., 1985). TWIST forms both homodimers (T/T) and heterodimers with E2A E proteins (T/E) (Connerney et al., 2006). It has been suggested that TWIST heterodimers function as a transcription repressor, and that TWIST homodimers up-regulate expression of the target gene by functioning as a transcription activator (Castanon et al., 2001; Connerney et al., 2006). However, it remains to be determined if
the interaction of TWIST with these E-boxes occurs directly, via interactions with E2A proteins or via indirect mechanisms (Lee et al., 2006). In Drosophila, Twist can increase the expression of Snail, a known repressor of E-cad transcription (Ip et al., 1992). However, Twist expression fails to induce Snail in human mammary epithelial cells that had undergone EMT (Yang et al., 2004). This agrees with the observation that TWIST and SNAIL function independently in mice (Carver et al., 2001; Soo et al., 2002).

In summary, I have determined that Twist is capable of regulating E-CAD-mediated differentiation and fusion of human trophoblastic cells in vitro, and these results have contributed to a new understanding of TWIST’s function as a transcriptional repressor during terminal differentiation and fusion of human trophoblasts (Figure 3.10). Furthermore, my studies suggest that TWIST and E-CAD may serve as novel molecular markers for early detection of potential pregnancy disorders such as pre-eclampsia, intrauterine growth restriction (IUGR) and miscarriage.
Figure 3.10. A schematic diagram of a proposed role of Twist in regulating E-cad-mediated terminal differentiation and fusion of human trophoblastic cells. cAMP upregulates TWIST levels. TWIST down-regulates E-cad expression to mediate the formation of multinucleated syncytial trophoblast from mononucleate cytotrophoblasts.
CHAPTER 4: TWIST REGULATES CADHERIN-MEDIATED INVASION OF HUMAN TROPHOBLASTIC CELLS IN VITRO

4.1: Introduction and rationale

Successful implantation depends on the differentiation of mononucleate cytotrophoblasts via two distinct and mutually exclusive pathways. The villous cytotrophoblastic cells will proliferate and differentiate by fusion to form the outer syncytiotrophoblastic cells; or enter the extravillous pathway to form highly invasive extravillous cytotrophoblasts (EVTs) (Bischof and Campana, 2000). In the extravillous pathway, these cells invade deeply into the underlying maternal tissues (Pijnenborg et al., 1980). EVTls invade the uterine stroma and superficial myometrium as individual mononucleate cells, penetrate the basal lamina, and replace the endothelia of uterine vasculature. This allows an increase in blood supply to the placenta and ensures an adequate supply of oxygen and nutrients to the developing fetus, a critical step in human pregnancy (Aplin., 1991; Pijnenborg et al., 1983 and 1994). Failure of this process is associated with clinical pathological conditions such as miscarriage, intrauterine growth retardation, or preeclampsia (King and Loke, 1994). The process of human trophoblast invasion utilizes similar molecular mechanisms as those of tumour cell invasion, albeit trophoblast invasion is more tightly regulated (Lala et al., 2002).

The precise control of trophoblastic cell differentiation along the extravillous pathway has been demonstrated to occur through regulated changes in cell-cell and cell-matrix interactions, and the modification of distinct extracellular matrix (ECM) components...
through proteolytic degradation and/or activation (Lala and Hamilton, 1996; MacCalman et al., 1998; Chakraborty et al., 2002).

To date, the molecular mechanisms that regulate trophoblast differentiation and invasion during formation and organization of the human placenta remain to be elucidated. TWIST, a highly conserved basic helix-loop-helix (bHLH) transcription factor, is known to play a key role in promoting tumour metastasis and is associated with potent invasiveness and poor prognosis of epithelial cancer (Thiery, 2002; Kang and Massague, 2004; Vernon et al., 2004; Yang et al., 2004; Kwok et al., 2005; Lee et al., 2006). In addition, Twist mRNA levels were found to be up-regulated in the highest grade of gliomas (Elias et al., 2005). TWIST has also been shown to be a key regulator of N-cad expression in different types of cancer cell lines (Alexander et al., 2006; Rosivatz et al., 2002). TWIST is essential for the initiation of N-cad expression in Drosophila (Oda et al., 1998).

N-CAD is a member of the superfamily of integral membrane glycoproteins that mediate calcium-dependent cell adhesion (Takeichi, 1995; Suzuki, 1996). During cancer progression, there is an increase in expression of N-cad (Tomita et al., 2000; Derycke et al., 2004; Hazan et al., 2004). Other studies have shown a functional role for N-CAD in promoting an invasive phenotype. For example, exogenous expression of N-cad in breast epithelial cells and squamous epithelial cells results in a more invasive phenotype (Islam et al., 1996; Nieman et al., 2000). To date, N-cad has received significant attention in cancer studies (Hazan et al., 2000).

Based on these observations, I hypothesize that Twist plays a key role in trophoblastic cell invasion through regulation of N-cad expression during human pregnancy. In my
studies, I first determined the expression levels of Twist and N-cad in the villi of first trimester human placentas, in cultures of highly invasive EVTs, and in two choriocarcinoma cell lines (JEG-3 and BeWo) by using semi-quantitative RT-PCR and Western blotting. Next, by using a Matrigel invasion assays, I determined the ability of interleukin (IL)-1β and transforming growth factor (TGF)-β1, two cytokines that are spatiotemporally expressed at the maternal-fetal interface (Graham et al., 1991 and 1993), to regulate trophoblastic cell invasion and Twist expression in these cells. Loss-of-function studies using siRNA for Twist were employed to determine the role of Twist or N-cad in trophoblastic cell invasion. Finally, by using a function-perturbing antibody directed against N-CAD, the role of N-cad in regulating the invasive phenotype of these cells was assessed.
4.2: Results

4.2.1: Determining the levels of Twist and N-cad mRNA and protein levels in the human placenta, highly invasive EVTs, and poorly invasive trophoblastic cell lines.

Semi-quantitative RT-PCR and Western blot analysis show that Twist was expressed in the first trimester human placenta and highly expressed in EVTs propagated from first trimester human placenta (refer to Section 2.2 in Materials and Methods for preparation details) and HTR-8/SVneo, a human EVT cell line. In contrast, Twist mRNA and proteins levels were significantly lower in poorly invasive JEG-3 and BeWo trophoblastic cell lines (Figure 4.1A and B).

I then determined the expression of N-cad in human placental tissue, EVTs, and trophoblastic cell lines. N-cad expression was absent in the first trimester human placenta. It was barely detectable at the mRNA level and absent at the protein level in poorly invasive JEG-3 and BeWo trophoblastic cell lines. In contrast, N-cad mRNA and protein levels were higher significantly in EVTs and HTR-8/SVneo cells (Figure 4.2A and B).

4.2.2: IL-1β and TGF-β1 respectively promote and restrain the invasive ability of EVT primary cultures.

Previous studies have shown that IL-1β and TGF-β1 play major regulatory roles in the establishment of pregnancy (Graham and Lala, 1991; Chakraborty et al., 2002). In view
of these observations, I examined the ability of these two cytokines to regulate the invasive ability of EVT primary cultures.

My results show that the addition of a vehicle (ethanol) to the culture medium of EVTs had no significant effect on the invasiveness of these cells, but a significant increase in EVT invasion was observed when these cells were treated with IL-1β (Figure 4.3A). In contrast, TGF-β1 significantly reduced the invasive ability of these cells (Figure 4.3B).

I also examined the effect of TGF-β1 on HTR-8/SVneo cell invasion, but found that these cells did not respond at all to TGF-β1 treatment (data not shown).

4.2.3: Time-dependent effects of IL-1β and TGF-β1 on Twist mRNA and protein levels in EVTs

Significant increases in Twist mRNA and protein levels \( (P < 0.05) \) were detected in primary EVTs cultured in the presence of 100 IU IL-1β for 24 h that were maintained or even slightly elevated after 48 h culture (Figure 4.4A and B). In contrast, the addition of TGF-β1 to the culture medium of these primary cells caused a significant decrease in Twist mRNA and protein levels after 24 h. Levels of Twist mRNA and protein expression continued to decrease until 48 h after treatment with this cytokine (Figure 4.5A and B).
4.2.4: Concentration-dependent effects of IL-1β and TGF-β1 on Twist mRNA and protein levels in EVTs

A significant increase \((P < 0.05)\) in Twist mRNA and protein levels was detected in primary EVTs cultured for 24 h in the presence of 100 and 1000 IU IL-1β, with 1000 IU of IL-1β having the greatest effect (Figure 4.6A and B).

Twist mRNA and protein expression levels were significantly decreased in EVTs cultured in the presence of TGF-β1 (5 and 10 ng/ml) for 24 h, but not at lower concentrations of this cytokine utilized with these primary cell cultures (Figure 4.7A and B).

4.2.5: Decreased Twist down-regulates N-cad expression and reduces the invasive capacity of HTR-8/SVneo cells

I utilized siRNA complementary to human Twist mRNA to decrease Twist expression in cultures of the HTR-8/SVneo EVT cell line. As a control, HTR-8/SVneo cells were transfected with a non-silencing (NS) scrambled siRNA. Transfection of HTR-8/SVneo cells with Twist siRNA significantly decreased Twist (Figure 4.8A and B) and N-cad (Figure 4.9A and B) mRNA and protein levels in these cell cultures after 36 h when compared to the control treatments.

I next determined whether a reduction in Twist expression in HTR-8/SVneo resulted in a concomitant decrease in their invasive capacity. I performed invasion assays using Matrigel-coated Transwell chambers. My results show that the numbers of cells that penetrated the Matrigel barrier and appeared on the underside of the Millipore filter were
significantly lower in cultures of HTR-8/SVneo transfected with Twist siRNA than in cultures transfected with scrambled control siRNA (Figure 4.10).

4.2.6: Loss of N-cad reduces the invasive capacity of HTR-8/SVneo cells

In order to directly reduce the N-cad mRNA and protein levels in HTR-8/SVneo cells, these cells were transfected with siRNA specific for N-cad. To assess siRNA efficacy, real-time RT-PCR and Western blot analysis were performed. The results demonstrated a significant reduction in N-cad mRNA and protein levels (Figure 4.11A and B) compared to HTR-8/SVneo cells transfected with a non-silencing scrambled siRNA.

I examined whether a reduction in N-cad levels in HTR-8/SVneo cells resulted in a concomitant decrease in their invasive capacity. The number of cells that penetrated the Matrigel and reached the underlying side of the filter of the Transwell invasion chambers was significantly lower in cultures of HTR-8/SVneo cells transfected with N-cad siRNA versus cell cultures that were transfected with non-silencing scrambled siRNA (Figure 4.12).

To determine whether the reduction in the invasive capacity of HTR-8/SVneo cells transfected with N-cad siRNA was potentially caused by a loss of N-CAD cell-cell adhesion function, HTR-8/SVneo cells were cultured in the presence of a N-CAD function-perturbing antibody that binds to the N-CAD extracellular domain. The invasive ability of the antibody-treated cells was then assayed as previously described. A pan-cadherin antibody that binds to the N-CAD intracellular domain was used as the control. My results showed that an N-CAD extracellular domain-specific antibody-mediated perturbation of endogenous N-CAD function led to a significantly less invasive
phenotype in HTR-8/SVneo cells, when compared to cells cultured with the control pan-cadherin antibody (Figure 4.13).
Figure 4.1. Twist mRNA and protein levels in human placenta, highly invasive EVTs, and poorly invasive trophoblastic cell lines. A) Semi-quantitative RT-PCR analysis of Twist mRNA levels in first trimester placenta, EVTs, HTR-8/SVneo cells, JEG-3 or BeWo cells (lanes 1-5 respectively). A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. The photomicrographs were scanned using a laser densitometer. The absorbance values for Twist mRNA were then standardized to the absorbance value obtained for GAPDH mRNA levels. The experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to EVT control). B) Representative fluorogram of a Western blot containing 30 µg of total protein extract prepared from a first trimester placenta, EVTs, HTR-8/SVneo cells, JEG-3 cells or BeWo cells (lanes 1-5 respectively). Western blot analysis was performed using a polyclonal antibody against TWIST. The resultant fluorograms were scanned and the absorbance values obtained for TWIST protein levels were normalized to the absorbance values obtained for human β-actin (ACTIN) in the corresponding samples. The experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to EVT control).
Figure 4.1

A

![Relative Amount of TWIST Protein](image)

<table>
<thead>
<tr>
<th></th>
<th>M</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placenta (Villi)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVTs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTR-8/ SVneo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JEG3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BeWo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

576 bp (Twist)
378 bp (GAPDH)

B

![Relative Amount of Twist mRNA](image)

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placenta (Villi)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVTs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTR-8/ SVneo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JEG3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BeWo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

28 kDa (TWIST)
42 kDa (ACTIN)

![Relative Amount of TWIST Protein](image)

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placenta (Villi)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVTs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTR-8/ SVneo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JEG3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BeWo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

28 kDa (TWIST)
42 kDa (ACTIN)
Figure 4.2. N-cad mRNA and protein levels in human placenta, highly invasive EVTs, and poorly invasive trophoblastic cell lines. A) Semi-quantitative RT-PCR analysis of N-cad mRNA levels in first trimester placenta, EVTs, HTR-8/SVneo cells, JEG-3 or BeWo cells (lanes 1-5 respectively). A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. The photomicrographs were scanned using a laser densitometer. The absorbance values for N-cad mRNA were then standardized to the absorbance value obtained for GAPDH mRNA levels. The experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to EVT control). B) Representative fluorogram of a Western blot containing 30 µg of total protein extracts prepared from first trimester placenta, EVTs, HTR-8/SVneo cells, JEG-3 cells or BeWo cells (lanes 1-5 respectively). Western blot analysis was performed using a monoclonal antibody against N-CAD. The resultant fluorograms were scanned and the absorbance values for N-CAD were normalized to the absorbance values obtained for human β-actin (ACTIN) in the corresponding samples. The experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to EVT control).
Figure 4.2

A

B
Figure 4.3. Regulatory effects of IL-1β and TGF-β1 on EVT invasion. EVTs were either treated with IL-1β (A) or TGF-β1 (B) for 24 h. The cells were then placed in the upper well of Transwell invasion chambers. After a further 24 h of incubation, the porous membranes from the bottom of the Transwell were removed and fixed, stained, and mounted upside-down on a glass microscope slide. Invasion was determined by counting the number of cells that had invaded through the thin pre-coated layer of Matrigel on the top of the porous (8 µm) membrane and migrated through the pores to the underside of the membrane. Cells were visualized using a light microscope, and counted in three randomly selected fields of each membrane. Each cell line was plated in triplicate wells, and the experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to control).
Figure 4.3

A

![Graph A: IL-1β (IU/ml) vs. Invasion Index](image)

B

![Graph B: TGF-β1 (ng/ml) vs. Invasion Index](image)
Figure 4.4. Time-dependent effects of IL-1β on Twist mRNA and protein levels in EVTs.

A) Semi-quantitative RT-PCR analysis of Twist mRNA levels in EVTs cultured in the presence of 100IU/ml IL-1β for 0, 12, 24, or 48 h (lanes 1-4, respectively). A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. A representative photomicrograph of the ethidium bromide-stained gels is presented. Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 h control).

B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from corresponding EVTs cultures treated with 100IU/ml IL-1β for 0, 12, 24, or 48 h (lanes 1-4, respectively) and probed with a rabbit polyclonal antibody against TWIST or human β-actin. The Amersham enhanced chemiluminescence (ECL) system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for TWIST were normalized to the absorbance values obtained for human β-actin (ACTIN) in the samples. The results derived from this analysis and from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 h control).
Figure 4.4

A

**Relative Amount of Twist Protein**

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Control</th>
<th>IL-1β 100 IU/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td><img src="image1" alt="Control" /></td>
<td><img src="image2" alt="IL-1β 100 IU/ml" /></td>
</tr>
<tr>
<td>12</td>
<td><img src="image1" alt="Control" /></td>
<td><img src="image2" alt="IL-1β 100 IU/ml" /></td>
</tr>
<tr>
<td>24</td>
<td><img src="image1" alt="Control" /></td>
<td><img src="image2" alt="IL-1β 100 IU/ml" /></td>
</tr>
<tr>
<td>48</td>
<td><img src="image1" alt="Control" /></td>
<td><img src="image2" alt="IL-1β 100 IU/ml" /></td>
</tr>
</tbody>
</table>

**Relative Amount of Twist mRNA**

![Graph showing relative amount of Twist mRNA](image3)

B

**Relative Amount of TWIST Protein**

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Control</th>
<th>IL-1β 100 IU/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td><img src="image4" alt="Control" /></td>
<td><img src="image5" alt="IL-1β 100 IU/ml" /></td>
</tr>
<tr>
<td>12</td>
<td><img src="image4" alt="Control" /></td>
<td><img src="image5" alt="IL-1β 100 IU/ml" /></td>
</tr>
<tr>
<td>24</td>
<td><img src="image4" alt="Control" /></td>
<td><img src="image5" alt="IL-1β 100 IU/ml" /></td>
</tr>
<tr>
<td>48</td>
<td><img src="image4" alt="Control" /></td>
<td><img src="image5" alt="IL-1β 100 IU/ml" /></td>
</tr>
</tbody>
</table>

**Graph showing relative amount of TWIST protein**

*Significant difference compared to control.*
Figure 4.5. Time-dependent effects of TGF-β1 on Twist mRNA and protein levels in EVTs. A) Semi-quantitative RT-PCR analysis of Twist mRNA levels in EVTs cultured in the presence of 5 ng/ml TGF-β1 for 0, 6, 12, 24, or 48 h (lanes 1-5, respectively). A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. A representative photomicrograph of the ethidium bromide-stained gels is presented. Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to 0 h control). B) Representative fluorogram of a Western blot containing 30 μg of total protein extracted from corresponding EVTs cultures treated with 5 ng/ml TGF-β1 for 0, 6, 12, 24, or 48 h (lanes 1-5, respectively) and probed with a rabbit polyclonal antibody against TWIST or human β-actin. The Amersham enhanced chemiluminescence (ECL) system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for TWIST were normalized to the absorbance values obtained for human β-actin (ACTIN) in the corresponding samples. The results derived from this analysis and from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to 0 h control).
Figure 4.5

A

Relative Amount of TWIST Protein

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Control</th>
<th>TGF-β1</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>6</td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>12</td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td>24</td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
<tr>
<td>48</td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
</tr>
</tbody>
</table>

* 28 kDa (TWIST)
* 42 kDa (ACTIN)

B

Relative Amount of Twist mRNA

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Control</th>
<th>TGF-β1</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
</tr>
<tr>
<td>6</td>
<td><img src="image13.png" alt="Image" /></td>
<td><img src="image14.png" alt="Image" /></td>
</tr>
<tr>
<td>12</td>
<td><img src="image15.png" alt="Image" /></td>
<td><img src="image16.png" alt="Image" /></td>
</tr>
<tr>
<td>24</td>
<td><img src="image17.png" alt="Image" /></td>
<td><img src="image18.png" alt="Image" /></td>
</tr>
<tr>
<td>48</td>
<td><img src="image19.png" alt="Image" /></td>
<td><img src="image20.png" alt="Image" /></td>
</tr>
</tbody>
</table>

* 576 bp (Twist)
* 378 bp (GAPDH)
Figure 4.6. Concentration-dependent effects of IL-1β on Twist mRNA and protein levels in EVTs. A) Semi-quantitative RT-PCR analysis of Twist mRNA in EVTs cultured in the presence of IL-1β (0, 1, 10, 100 or 1000 IU/ml; lanes 1-5, respectively) for 24 h. A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. Representative photomicrographs of the resultant ethidium bromide-stained gels are presented. Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 IU/ml control). B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from corresponding EVTs cultures treated with IL-1β (0, 1, 10, 100 or 1000 IU/ml; lanes 1-5, respectively) for 24 h and probed with rabbit polyclonal antibodies against TWIST or human β-actin. The Amersham enhanced chemiluminescence (ECL) system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for TWIST were normalized to the absorbance values obtained for human β-actin (ACTIN) in the corresponding samples. The results derived from this analysis and from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 IU/ml control).
Figure 4.6

A

![Image of gel electrophoresis showing bands at 576 bp (Twist) and 378 bp (GAPDH).]

B

![Image of Western blot showing bands at 28 kDa (TWIST) and 42 kDa (ACTIN).]

![Graph showing relative amount of Twist mRNA and protein with IL-1β concentrations.](112)
Figure 4.7. Concentration-dependent effects of TGF-β1 on Twist mRNA and protein expression levels in EVTs. A) Semi-quantitative RT-PCR analysis of Twist mRNA in EVTs cultured in the presence of TGF-β1 (0, 0.01, 0.1, 1, 5 or 10 ng/ml; lanes 1-6, respectively) for 24 h. A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. Representative photomicrographs of the resultant ethidium bromide-stained gels are presented. Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 ng/ml control) in the graph. B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from corresponding EVTs cultures treated with TGF-β1 (0, 0.01, 0.1, 1, 5 or 10 ng/ml; lanes 1-6, respectively) for 24 h and probed with rabbit polyclonal antibodies against TWIST or human β-actin. The Amersham enhanced chemiluminescence (ECL) system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for TWIST were normalized to the absorbance values obtained for human β-actin (ACTIN) in the corresponding samples. The results derived from this analysis and from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 ng/ml control).
Figure 4.7

A

Relative Amount of TWIST Protein

0
0.2
0.4
0.6
0.8
1
1.2

378 bp (GAPDH)

0          0.01         0.1          1             5           10

TGF-β1 (ng/ml)

576 bp (Twist)

B

Relative Amount of Twist mRNA

0
0.2
0.4
0.6
0.8
1
1.2

0            0.01         0.1           1              5            10

TGF-β1 (ng/ml)

29945101233689615384981581345062912x444804983

42 kDa (ACTIN)

28 kDa (TWIST)

10186036962008160310142999898095616x728377975

29913920660498500533146715414331392x469806780

A

M     1     2     3     4     5     6

1             2            3             4             5            6

1             2            3             4             5            6

13662418308973448848365510664912896x660782504 to 27497632913150534894848139094654976x683699763
Figure 4.8. Effects of Twist siRNA on Twist mRNA and protein levels in HTR-8/SVneo cell cultures. A) Semi-quantitative RT-PCR analysis of Twist mRNA levels in cells transfected with a scrambled control siRNA (lane 1) or siRNA specific for Twist (lane 2) for 36 h. A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. Values for Twist mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to scrambled control siRNA). B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from HTR-8/SVneo cells cultured with a scrambled control siRNA (lane 1) or siRNA specific for Twist (lane 2) for 36 h and probed with rabbit polyclonal antibodies against TWIST or human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for TWIST protein levels were normalized to the absorbance values obtained for human β-actin (ACTIN) in the corresponding samples. The results derived from this analysis and from three other studies were standardized to the scrambled control siRNA and are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to scrambled control siRNA).
Figure 4.8

A

- Relative Amount of TWIST Protein
- Relative Amount of Twist mRNA
- Control siRNA Twist siRNA

B

- 576 bp (Twist)
- 378 bp (GAPDH)
- 576 bp (Twist)
- 378 bp (GAPDH)

- Control siRNA Twist siRNA
- Control siRNA Twist siRNA
Figure 4.9. Effects of Twist siRNA on N-cad mRNA and protein levels in HTR-8/SVneo cell cultures.  A) Semi-quantitative RT-PCR analysis of N-cad mRNA levels in cells transfected with a scrambled control siRNA (lane 1) or siRNA specific for Twist (lane 2) for 36 h. A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. Values for N-cad mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to scrambled control siRNA). B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from HTR-8/SVneo cells transfected with a scrambled control siRNA (lane 1) or siRNA specific for TWIST (lane 2) for 36 h and probed with mouse monoclonal antibody against N-CAD or rabbit polyclonal antibody against human \( \beta \)-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for N-CAD protein levels were normalized to the absorbance values obtained for human \( \beta \)-actin (ACTIN) in the corresponding samples. The results derived from this analysis and from three other studies were standardized to the scrambled control siRNA and are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to scrambled control siRNA).
Figure 4.9

A

![Relative Amount of N-cad mRNA](image)

B

![Relative Amount of N-CAD Protein](image)
Figure 4.10. Reduced Twist expression decreases the invasive capacity of HTR-8/SVneo cells. HTR-8/SVneo cells were transfected with a scrambled control siRNA (lane 1) or siRNA specific for Twist (lane 2) for 24 h. The cells were then placed in the upper wells of Transwell invasion chambers. After a further 24 h of culture, the porous membranes from the bottom of the Transwells were removed and fixed, stained and mounted upside-down on a glass microscope slide. Invasion was determined by counting the number of cells that had invaded through the thin pre-coated layer of Matrigel on the top of the porous (8 µm) membrane and migrated through the pores to the underside of the membrane. Cells were visualized using a light microscope, and counted in three randomly selected fields of each membrane. Each cell line was plated in triplicate wells, and with the experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to HTR-8/SVneo scrambled control siRNA).
Figure 4.10

Invasion Index

Control (1)  Twist siRNA (2)

*
Figure 4.11. Effects of N-cad siRNA on N-cad mRNA and protein levels in HTR-8/SVneo cell cultures. A) Real-time PCR analysis of N-cad mRNA levels transfected with a scrambled control siRNA (lane 1) or siRNA specific for N-cad (lane 2) for 36 h. Values for the levels of the N-cad mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to scrambled control siRNA). B) Representative fluorogram of a Western blot containing total protein extracted from HTR-8/SVneo cells transfected with a scrambled control siRNA (lane 1) or siRNA specific for N-cad (lane 2) for 36 h and probed with mouse monoclonal antibody directed against N-CAD or rabbit polyclonal antibody against human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for N-CAD protein levels were normalized to the absorbance values obtained for human β-actin (ACTIN) in the corresponding samples. The results derived from both these analyses and from three other sets of experiments were standardized to the scrambled control siRNA and are represented (mean ± SEM., n = 4) in the bar graphs (*, P < 0.05 compared to scrambled control siRNA).
Figure 4.11

A.

![Bar graph showing relative amount of N-cad mRNA expression with Control siRNA and N-cad siRNA](image)

B.

![Western blot images showing 140 kDa (N-CAD) and 42 kDa (ACTIN) bands](image)

![Bar graph showing relative amount of N-CAD protein expression with Control siRNA and N-cad siRNA](image)
Figure 4.12. Reduced N-cad levels decrease the invasive capacity of HTR-8/SVneo cells. HTR-8/SVneo cells were transfected with a scrambled control siRNA (lane 1) or siRNA specific for N-cad (lane 2) for 24 h. The cells were then placed in the upper wells of Transwell invasion chambers. After a further 24 h of incubation, the porous membranes from the bottom of the Transwells were removed and fixed, stained and mounted upside-down on a glass microscope slide. Invasion was determined by counting the number of cells that had invaded through the thin pre-coated layer of Matrigel on the top of the porous (8 µm) membrane and migrated through the pores to the underside of the membrane. Cells were visualized using a light microscope, and were counted in three randomly selected fields of each membrane. Each cell line was plated in triplicate wells, and the experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to scrambled control siRNA).
Figure 4.12

![Graph showing Invasion Index comparison between Control siRNA (1) and N-cad siRNA (2). The graph indicates a significant difference marked by an asterisk (*) between the two groups.]
Figure 4.13. Disruption of N-CAD function decreases the invasive ability of HTR-8/SVneo cells. HTR-8/SVneo cells were treated with a control pan-cadherin antibody (lane 1) or an N-CAD function-perturbing antibody (lane 2) for 24 h. The cells were then placed in the upper wells of Transwell invasion chambers. After a further 24 h of incubation, the porous membranes from the bottom of the Transwells were removed and fixed, stained, and mounted upside-down on a glass microscope slide. Invasion was determined by counting the number of cells that had invaded through the thin pre-coated layer of Matrigel on the top of the porous (8 µm) membrane and migrated through the pores to the underside of the membrane. Cells were visualized using a light microscope, and were counted in three randomly selected fields of each membrane. Each cell line was plated in triplicate wells, and the experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to control pan-cadherin (PAN-CAD) antibody).
Figure 4.13
4.3: Discussion and summary

My studies demonstrate that Twist and N-cad are highly expressed in highly invasive EVTs propagated from first trimester human placenta and the HTR-8 EVT cell line but are not readily detectable in the poorly invasive JEG-3 and BeWo cell lines. In addition, IL-1β and TGF-β1 were found to have differential effects on Twist mRNA and protein levels in primary cultures of EVTs, and this suggests that these molecules play important roles in human trophoblastic cell invasion.

Extravillous trophoblasts (EVTs) can be divided into two populations: 1) interstitial cytotrophoblasts that will invade into the decidual stroma and superficial myometrium; and 2) endovascular cytotrophoblasts which will invade into the lumen of the spiral arteries (Pijnenborg et al., 1981; Pijnenborg 1983; Roberston et al., 1986). In order for the human placenta to properly form, the trophoblast must invade into the uterus, which involves attachment of these cells to the extracellular matrix (ECM), degradation of the matrix, and migration. The spiral arteries of the placental bed also have to undergo a certain degree of alteration. The interaction between the invasive cytotrophoblast and the spiral artery vessel wall is the major step in achieving these physiological modifications (Lyall, 2006). Trophoblast invasion is controlled by cell adhesion molecules including cadherins, which are expressed on the surface of cytotrophoblasts that interact with the ECM of the decidua (Kreis et al., 1993; Alberts et al., 1994).

The cadherin N-CAD has been shown to have the ability to mediate homotypic cell aggregation as well as the ability to form heterotypic adhesions in various cell types including stromal fibroblasts, vascular endothelial cells, smooth muscle cells, and
myofibroblasts (Hazan et al., 1997; Tran et al., 1999; Li et al., 2001; De Wever et al., 2003). For instance, by increasing the interaction with the surrounding stroma, N-CAD is able to promote invasion and metastasis (Hazan et al., 1997). In addition, the transcription factor Twist has been reported to increase vascular volume and vascular permeability by increasing vascular endothelial growth factor (VEGF) synthesis, and inducing *in vivo* angiogenesis (Mironchik et al., 2005).

In my studies, when I used a siRNA strategy targeting Twist in human trophoblastic cells, the invasive ability of these cells was significantly reduced. Others have also reported that inactivation of Twist suppressed the migration and invasion abilities of androgen-independent prostate cancer cells (Kwok et al., 2005). In my studies, when the invasive ability of trophoblastic cells was reduced in the presence of Twist siRNA, I also observed decreased N-cad mRNA and protein levels in these cells. This suggests that Twist regulates human trophoblast invasion *via* N-cad. Furthermore, my results show that by directly limiting N-cad expression in a Twist-independent manner (i.e. with N-cad-directed siRNA) in human trophoblastic cells, the invasive ability of these cells was significantly reduced.

My loss-of-function studies in which either Twist or N-cad was targeted have clearly shown a concomitant reduction in the invasive ability of human trophoblastic cells. Furthermore, by blocking the extracellular domain of N-CAD with a function-perturbing antibody, the invasive ability of these trophoblastic cells was reduced. This novel finding further strengthens the growing consensus that trophoblast invasion utilizes similar molecular mechanisms to those of tumour cell invasion.
As previously mentioned, decreased Twist expression, which is involved in cancer metastasis, was found to be associated with down-regulation of N-cad in a variety of cancer tumours such as osteosarcomas (Guo et al., 2007). However, in my study, I could not determine whether TWIST interacts with N-cad directly or indirectly. In a prostate cell line, TWIST did not show an increase in promoter-binding activity, but was found to regulate N-cad expression through its direct interaction with an E-box regulatory element located within the first intron of the N-cad gene (Alexander et al., 2006).

Rosivatz et al. (2004) suggest that E-cad transcriptional repressors may not play a major role in colon cancer pathogenesis, and other studies have not always found a correlation between reduced E-CAD immunohistochemistry and tumour progression. It seems that N-cad induced invasion activities can even overcome the E-cad tumour suppressive function (Hazan et al., 1997; Nieman et al., 1999). In my preliminary data, I observed that when I silenced Twist expression in human trophoblastic cells, E-cad expression levels remain unchanged (data not shown). This requires further validation, but indicates that the “cadherin switch” varies in a tumour or tissue-specific manner.

Collectively, my results have clearly identified TWIST and its associated protein, N-CAD, to be key molecules in human EVT invasion (Figure 3.14). To my knowledge, this is the first study to demonstrate the regulation of trophoblast invasion by Twist through its role in the induction of N-cad gene expression. TWIST and N-CAD may serve as useful diagnostic and prognostic tools or novel therapeutic targets for human trophoblastic diseases such as miscarriage, intrauterine growth restriction (IUGR), or preeclampsia.
Figure 4.14. A schematic diagram of a proposed role of Twist in regulating N-cad-mediated differentiation of human trophoblastic cells. Silencing Twist expressing by siRNA strategy reduces N-cad expression level and reduces the invasion ability of human trophoblastic cells.
CHAPTER 5: A KEY ROLE FOR RUNX2 IN HUMAN TROPHOBLAST INVASION.

5.1: Introduction and rationale

The trophoblastic cells form the outer layer of the blastocyst and play an essential role in implantation and placentation during human pregnancy. The cytotrophoblast stem cells are specialized epithelial cells of the placenta which can undergo two differentiation pathways (Zhou et al., 1997). In one pathway, the cytotrophoblast cells fuse to form multinucleated syncytial trophoblast cells, which are involved in maternal-fetal exchanges and placental endocrine functions. In the other pathway, the cytotrophoblasts differentiate into the invasive extravillous cytotrophoblast (EVT) cells. These EVT cells invade the maternal uterine wall and its blood vessels to establish the flow of oxygenated blood to the placenta (Aplin et al., 1991). Proper trophoblast invasion is critical for a healthy pregnancy, and insufficient invasion is associated with preeclampsia, intrauterine growth restriction and recurrent miscarriage (Goldman-Wohl and Yagel, 2002).

Cells at the maternal-fetal interface are exposed to numerous cytokines, growth factors and hormones that play critical roles in mediating the processes required for cell invasion (Chakraborty et al., 2002). The processes required for trophoblast invasion include degradation and remodelling of the extracellular matrix (ECM) components, and regulated changes in cell-cell and cell-matrix interactions (MacCalman et al., 1998, Chakraborty et al., 2002; Cohen et al., 2006).

The RUNX proteins (runt-related transcription factor) are a family of transcription factors that contain a DNA-binding runt domain (Ito, 1999). The Runx2 gene (also
known as PEBP2α/AML3/CBFA1) is essential for osteoblast development and proper bone formation (Otto et al., 1997). In cancer cells, Runx2 is capable of activating the expression of adhesion proteins, matrix metalloproteinases (MMPs) and angiogenic factors known to be associated with invasive properties of metastatic cancer cells (Pratap et al., 2006).

Interleukin-1β (IL-1β) is a cytokine that plays a major regulatory role in the establishment of pregnancy (Salamonsen et al., 2000, 2003; Fazleabas et al., 2004). In particular, IL-1β has been shown to increase the invasiveness of primary cultures of trophoblastic cells (Librach et al., 1994; Simon et al., 1994; Karmakar and Das, 2002). Conversely, another cytokine, transforming growth factor-β1 (TGF-β1) is highly expressed in both fetal and maternal cellular compartments of the term human placenta and reduces trophoblastic cell invasion (Lala and Graham, 1990; Graham and Lala, 1991, 1992; Godkin and Dore, 1998), TGF-β1 also plays a key regulatory role in placenta development and function (Graham and Lala, 1991). Nevertheless, the precise mechanisms that regulate trophoblast invasion are not fully understood.

Cadherins play an important role in embryogenesis. The neural cell adhesion molecule, N-cadherin (N-CAD), serves as a key molecule during gastrulation and neural crest development. In previous studies, I have identified that N-cad plays a role in human trophoblastic cell invasion. Furthermore, in cancer, the expression of N-cad in epithelial cells alters cell morphology to a fibroblastic phenotype, enhancing their motility and invasive potential (Deryckke and Bracke, 2004). Studies have shown that N-cad plays critical roles in the invasive properties of various cancer cell types, such as those of the
colon, breast and pancreas (Nieman et al., 1999; Nakajima et al., 2003; Rieger-Christ et al., 2004).

In view of the above observations, I hypothesized that Runx2 expression plays a key role in regulating human trophoblastic cell invasion by modulating N-cad expression. In this study, by using semi-quantitative RT-PCR and Western blotting, I have examined Runx2 mRNA and protein levels in human placental tissues and cells. Furthermore, I have examined the ability of IL-1β and TGF-β1 to regulate Runx2 mRNA and protein expression levels in primary cultures of EVTs. By using the Matrigel invasion assay, I have also identified a role for Runx2 in human trophoblastic cell invasion through silencing Runx2 expression using a siRNA strategy. Finally, I determined whether N-cad can be regulated by Runx-2 in human trophoblastic cell invasion.
5.2: Results

5.2.1: Runx2 is expressed in human placenta, highly invasive EVTs, and poorly invasive trophoblastic cell lines.

Prior to these studies, nothing was known about the expression of Runx2 in the human placenta. Semi-quantitative RT-PCR and Western blot experiments revealed the presence of Runx2 mRNA and protein in first trimester human placenta. Runx2 mRNA and protein were most abundant in primary EVTs and HTR-8/SVneo EVT cells but were present in very low amounts in JEG-3 and BeWo cells (Figure 5.1A and B).

5.2.2: Time-dependent effects of IL-1β on Runx2 mRNA and protein levels in human EVTs

IL-1β (100 IU/ml) treatment resulted in a significant increase in Runx2 mRNA levels in primary EVTs after 24 h of culture, with maximum levels being detected in cells cultured in the presence of this cytokine for 48 h (Figure 5.2A). Treatment with 100 IU/ml IL-1β for 24 h induced an approximately 1.4-fold increase in Runx2 mRNA, while the same treatment for 48 h induced approximately a 1.5-fold increase. In correspondence with the fold-increases in mRNA, RUNX2 protein levels in EVT cultures increased approximately 1.6-fold by treatment with 100 IU/ml IL-1β for 24 h, and increased approximately 1.8-fold upon treatment for 48 h (Figure 5.2B).
5.2.3: Time-dependent effects of TGF-β1 on Runx2 mRNA and protein levels in human EVTs

A significant decrease in Runx2 mRNA levels was detected in EVTs cultured in the presence of 5 ng/ml TGF-β1 for 24 h and 48 h (Figure 5.3A). Treatment with 5 ng/ml TGF-β1 for 24 h induced approximately a 30% decrease in Runx2 mRNA, while the same treatment for 48 h induced an approximately 35% decrease in these primary cell cultures. In agreement with the results obtained using semi-quantitative RT-PCR, RUNX2 protein levels decreased approximately 30% upon treatment with 5 ng/ml TGF-β1 for 24 h, and approximately 35% after the same treatment for 48 h (Figure 5.3B).

5.2.4: Concentration-dependent effects of IL-1β on Runx2 mRNA and protein levels in human EVTs

Increasing concentrations of IL-1β increased the Runx2 mRNA levels present in primary cultures of human EVTs in a concentration-dependent manner (Figure 5.4A). However, significant increases in Runx2 mRNA levels were only observed in EVTs treated with higher concentrations of IL-1β (10, 100 or 1000 IU/ml) in these studies. IL-1β at 10 IU/ml induced approximately a 1.3-fold increase in Runx2 mRNA levels, while 100 and 1000 IU/ml induced approximately 1.5 and 1.7-fold increases, respectively.

In agreement with the results obtained using semi-quantitative RT-PCR, IL-1β increased RUNX2 protein levels in EVT cultures in a concentration-dependent manner (Figure 5.4B). In correspondence with the fold-increases in mRNA, RUNX2 protein
levels were increased 1.4-fold by 10 IU/ml of IL-1β, 1.6-fold by 100 IU/ml of IL-1β and 1.8-fold by 1000 IU/ml of IL-1β.

**5.2.5: Concentration-dependent effects of TGF-β1 on Runx2 mRNA and protein levels in human EVTs**

TGF-β1 decreased Runx2 mRNA levels in primary EVTs in a concentration-dependent manner. A significant decrease in Runx2 mRNA was observed only in EVTs treated with the highest concentrations of TGF-β1 (1 or 10 ng/ml) (Figure 5.5A). TGF-β1 at 1 ng/ml induced a 20% decrease in Runx2 mRNA, while treatment with 10 ng/ml TGF-β1 resulted in a 30% decrease in Runx2 mRNA. TGF-β1 treatment also reduced RUNX2 protein levels in primary cultures of EVTs in a concentration-dependent manner (Figure 5.5B). In accordance with the fold-decreases in mRNA, RUNX2 protein levels were decreased 25% by 5 or 10 ng/ml of TGF-β1.

**5.2.6: Attenuation of cytokine-modulated Runx2 mRNA and protein levels in EVTs using neutralizing antibodies directed against IL-1β or TGF-β1**

Function-perturbing monoclonal antibodies directed against either IL-1β or TGF-β1 had no significant effect on Runx2 mRNA and protein levels in my primary EVTs after 24 h of culture (data not shown). However, IL-1β-mediated increases in the Runx2 mRNA and protein levels in these primary cell cultures were inhibited by the addition of an anti-IL-1β neutralizing antibody to the culture medium for 24 h. IL-1β at 100 IU/ml together with anti-IL-1β antibody at 1 µg/ml induced approximately a 26% decrease in
Runx2 mRNA compared to the control treatment (IL-1β at 100IU/ml), while IL-1β at 100 IU/ml together with anti-IL-1β antibody at 2 µg/ml induced approximately a 35% decrease in Runx2 mRNA compared to the control treatment (IL-1β at 100IU/ml) (Figure 5.6A). In accordance with these fold-decreases in mRNA, RUNX2 protein expression was decreased 30% by 100 IU/ml of IL-1β together with anti-IL-1β antibody at 1 µg/ml, and 35% by 100 IU/ml of IL-1β together with anti-IL-1β antibody at 2 µg/ml (Figure 5.6B). Similarly, the monoclonal antibody against TGF-β1 abolished the decrease in Runx2 mRNA and protein levels observed in EVTs cultured in the presence of this cytokine. TGF-β1 at 10 ng/ml together with anti-TGF-β1 antibody at 10 µg/ml induced approximately a 1.3-fold increase in Runx2 mRNA compared to control (TGF-β1 at 10 ng/ml) (Figure 5.7A). A similar fold-increase (1.4-fold) in RUNX2 protein expression was observed under these conditions (Figure 5.7B).

5.2.7: Inhibition of Runx2 expression down-regulates N-cad mRNA and protein levels and reduces the invasive capacity of HTR-8/SVneo cells

In order to repress Runx2 expression in cultures of HTR-8/SVneo cells, I utilized siRNA complementary to human Runx2 mRNA. Transfection of HTR-8/SVneo cells with this siRNA significantly decreased Runx2 mRNA and protein levels in these cell cultures after 36 h compared to cells transfected with a non-silencing, scrambled siRNA (Figure 5.8A and B). The N-cad mRNA and protein levels were significantly decreased after 36 h of siRNA targeting Runx2, compared to HTR-8/SVneo cells transfected with non-silencing, scrambled siRNA in these studies (Figure 5.9A and B).
I also examined whether a reduction in Runx2 expression in HTR-8/SVneo cells results in a concomitant decrease in their invasive capacity using Matrigel coated Transwell chambers. The number of cells that penetrated the Matrigel and reached the underside of the membrane in the Transwell invasion chambers was significantly lower in cultures of HTR-8/SVneo cells which had been transfected with Runx2 siRNA compared to cell cultures that had been transfected with non-silencing, scrambled siRNA (Figure 5.10).
Figure 5.1. Runx2 mRNA and protein expression levels in human placenta, highly invasive EVTs and poorly invasive trophoblastic cell lines. A) Semi-quantitative PCR analysis of Runx2 mRNA levels in first trimester placenta, primary EVT cell cultures, HTR-8/SVneo cells, JEG-3 or BeWo cells (lanes 1-5, respectively). A 100 bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. The photomicrographs were scanned using a laser densitometer. The absorbance values obtained for Runx2 were then standardized to the absorbance value obtained for GAPDH mRNA levels. The experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to EVTs control). B) Representative fluorogram of a Western blot containing 30 µg of total protein extract prepared from first trimester placenta, primary EVT cell cultures, HTR-8/SVneo cells, JEG-3 cells or BeWo cells. Western blot analysis was performed using a polyclonal antibody against RUNX2. The resultant fluorograms were scanned and the absorbance values obtained for RUNX2 protein levels were normalized to the absorbance values obtained for β-actin (ACTIN) in the corresponding samples. The experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to EVT control).
Figure 5.1

A

![Relative Amount of RUNX2 Protein and mRNA](image)

B

![Relative Amount of RUNX2 Protein](image)
Figure 5.2. Time-dependent effects of IL-1β on Runx2 mRNA and protein levels in EVTs. A) Semi-quantitative RT-PCR analysis of Runx2 mRNA levels in EVTs cultured in the presence of 100 IU/ml IL-1β for 0, 12, 24, or 48h (lanes 1-4, respectively). A 100bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right. A representative photomicrograph of the ethidium-stained gels is presented. Gels generated from three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to 0h control). B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from corresponding EVTs cultures treated with 100 IU/ml IL-1β for 0, 12, 24, or 48h (lanes 1-4, respectively) and probed with a rabbit polyclonal antibody against RUNX2 or human β-actin. The Amersham enhanced chemiluminescence (ECL) system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for RUNX2 were normalized to the absorbance values obtained for human β-actin (ACTIN) in the samples. The results derived from this analysis and from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to 0h control).
Figure 5.2

A

Control

IL-1β

Relative Amount of Runx2 mRNA

Relative Amount of RUNX2 protein

B

Control

IL-1β

Relative Amount of RUNX2 protein

Control

IL-1β

100IU/ml
Figure 5.3. Time-dependent effects of transforming growth factor-β1 (TGF-β1) on Runx2 mRNA and protein levels in EVTs.  A) RT-PCR analysis of Runx2 mRNA levels in EVTs cultured in the presence of 5 ng/ml TGF-β1 for 0, 6, 12, 24 or 48h (lanes 1-5, respectively).  A 100-bp ladder is shown in lane M (marker) with the size of the target cDNA indicated at the right.  A representative photomicrograph of the resultant ethidium bromide-stained gels is presented.  Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis.  The data are presented as (mean absorbance ± S.E.M., n = 4) in the bar graph (*, $P < 0.05$ compared to 0 h control).  B) Representative fluorogram of a Western blot containing 30 µl of total protein extracted from corresponding EVT cultures treated with 5 ng/ml TGF-β1 for 0, 6, 12, 24 or 48h (lanes 1-5, respectively) and probed with a rabbit polyclonal antibody against RUNX2 or human β-actin.  The Amersham enhanced chemiluminescence system was used to detect antibody bound to antigen.  The resultant fluorograms were scanned and the absorbance values obtained for RUNX2 were normalized to the absorbance values obtained for human β-actin (ACTIN) in the samples.  The results derived from this analysis as well as those from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, $P < 0.05$ compared to 0h control).
Figure 5.3

A

<table>
<thead>
<tr>
<th>Control</th>
<th>TGF-β1</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

- 161 bp (Runx2)
- 378 bp (GAPDH)

B

<table>
<thead>
<tr>
<th>Control</th>
<th>TGF-β1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

- 55kDa (RUNX2)
- 42kDa (ACTIN)
Figure 5.4. Concentration-dependent effects of IL-1β on Runx2 mRNA and protein levels in EVTs. A) Semi-quantitative RT-PCR analysis of Runx2 mRNA in EVTs cultured in the presence of vehicle alone (lane 1) or increasing concentrations of IL-1β (1, 10, 100 or 1000 IU; lanes 2-5, respectively). A 100-bp ladder is shown in lane M with the size of the target cDNA indicated at the right. Representative photomicrographs of the resultant ethidium bromide-stained gels are presented. Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 IU/ml control). B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from corresponding EVT cultures treated with vehicle alone (lane 1) or increasing concentrations of IL-1β (1, 10, 100 or 1000 IU; lanes 2-5, respectively) and probed with rabbit polyclonal antibodies against RUNX2 or human β-actin. The Amersham enhanced chemiluminescence (ECL) system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for RUNX2 were normalized to the absorbance values obtained for human β-actin (ACTIN) in the samples. The results derived from this analysis as well as those from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to 0 IU/ml control).
Figure 5.4

A.

[Image: Gel showing bands for 161 bp (RUNX2) and 378 bp (GAPDH).]

B.

[Image: Gel showing bands for 55 kDa (RUNX2) and 42 kDa (ACTIN).]
Figure 5.5. Concentration-dependent effects of TGF-β1 on Runx2 mRNA and protein levels in EVTs.  A) Semi-quantitative RT-PCR analysis of Runx2 mRNA in EVTs cultured in the presence of vehicle alone (lane 1) or increasing concentrations of TGF-β1 (0.001, 0.01, 0.1, 1 or 10 ng/ml; lanes 2-6, respectively).  A 100-bp ladder is shown in lane M with the size of the target cDNA indicated at the right.  Representative photomicrographs of the resultant ethidium bromide-stained gels are presented.  Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis.  The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to 0 ng/ml control) in the graph.

B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from corresponding EVTs cultures treated with vehicle alone (lane 1) or increasing concentrations of TGF-β1 (0.001, 0.01, 0.1, 1 or 10 ng/ml; lanes 2-6, respectively) and probed with rabbit polyclonal antibodies against RUNX2 or human β-actin. The Amersham enhanced chemiluminescence (ECL) system was used to detect antibody bound to antigen.  The resultant fluorograms were scanned and the absorbance values obtained for RUNX2 were normalized to the absorbance values obtained for human β-actin (ACTIN) in the samples. The results derived from this analysis as well as those from three other studies were standardized to the untreated control and are represented (mean ± S.E.M., n = 4) in the bar graph (*, \( P < 0.05 \) compared to 0 ng/ml control).
Figure 5.5

A

![Figure A: Gel Electrophoresis and qPCR Analysis](image)

1. **Gel Electrophoresis**
   - Lane M: Molecular Weight Marker
   - Lanes 1 to 6: Experimental Samples
   - 161 bp (Runx2)
   - 378 bp (GAPDH)

2. **qPCR Analysis**
   - Relative Amount of Runx2 mRNA
   - TGF-β1 (ng/ml): 0, 0.001, 0.01, 0.1, 1, 10
   - M: Control
   - 161 bp (GAPDH)
   - 378 bp (GAPDH)

B

![Figure B: Western Blot Analysis](image)

1. **Western Blot Analysis**
   - 55kDa (RUNX2)
   - 42kDa (ACTIN)

2. **Western Blot Analysis**
   - Relative Amount of RUNX2 Protein
   - TGF-β1 (ng/ml): 0, 0.001, 0.01, 0.1, 1, 10
   - M: Control
   - 55kDa (RUNX2)
   - 42kDa (ACTIN)
Figure 5.6. Attenuation of IL-1β-mediated increase in Runx2 mRNA and protein levels in EVTs. A) Semi-quantitative RT-PCR analysis of Runx2 mRNA levels in EVT cultures cultured with vehicle alone (lane 1), IL-1β alone (100 IU/ml; lane 2), IL-1β (100 IU/ml) plus 1 ug/ml of an anti-IL-1β antibody (lane 3) or IL-1β (100 IU/ml) plus 2 ug/ml of an anti-IL-1β antibody (lane 4) for 24 h. A 100 bp ladder is shown in lane M with the size of the target cDNA indicated at the right. A representative photomicrograph of the resultant ethidium bromide-stained gels is presented. Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are presented as (mean ± S.E.M., n = 4) in the bar graph (a, \( P < 0.05 \) compared to untreated control; b, \( P < 0.05 \) compared to cytokine alone). B) Representative fluorogram of a Western blot containing 30 ug of total protein extracted from corresponding EVT cultures treated with cultured with vehicle alone (lane 1), IL-1β alone (100 IU/ml; lane 2), IL-1β (100 IU/ml) plus 1 ug/ml of an anti-IL-1β antibody (lane 3) or IL-1β (100 IU/ml) plus 2 ug/ml of an anti-IL-1β antibody (lane 4). The blots were probed for RUNX2 and human β-actin (ACTIN). The data are presented as (mean ± S.E.M., n = 4) in the bar graph (a, \( P < 0.05 \) compared to untreated control; b, \( P < 0.05 \) compared to cytokine alone).
Figure 5.6

A

![Image of gel electrophoresis with bands at 161 and 378 bp, labeled as Runx2 and GAPDH respectively.]

Bar graph showing relative amount of Runx2 mRNA with IL-1β (0, 100, 100, 100 IU/ml) and Anti IL-1β (0, 0, 1, 2 ug/ml).

B

![Image of Western blot with bands at 55 and 42 kDa, labeled as Runx2 and ACTIN respectively.]

Bar graph showing relative amount of Runx2 protein with IL-1β (0, 100, 100, 100 IU/ml) and Anti IL-1β (0, 0, 1, 2 ug/ml).
Figure 5.7. Attenuation of TGF-β1-mediated decreases in Runx2 mRNA and protein levels in EVTs. A) Semi-quantitative RT-PCR analysis of Runx2 mRNA levels in EVTs cultured with vehicle alone (lane 1), TGF-β1 alone (10 ng/ml; lane 2) or TGF-β1 (10 ng/ml) plus anti-TGF-β1 antibody (10 ug/ml; lane 3). A 100 bp ladder is shown in lane M with the size of the target cDNA indicated at the right. A representative photomicrograph of the resultant ethidium bromide-stained gels is presented. Gels generated from this and three other independent experiments were analysed by densitometry and subjected to statistical analysis. The data are presented in the bar graph as (mean ± S.E.M., n = 4; a, P < 0.05 compared to untreated control; b, P < 0.05 compared to cytokine alone). B) Representative fluorogram of a Western blot containing 30 ug of total protein extracted from corresponding EVT cultures treated vehicle alone (lane 1), TGF-β1 alone (10 ng/ml; lane 2) or TGF-β1 (10 ng/ml) plus anti-TGF-β1 antibody (10 ug/ml; lane 3). The blots were probed for RUNX2 and human β-actin (ACTIN). The data are presented in the bar graph as (mean ± S.E.M., n = 4; a, P < 0.05 compared to untreated control; b, P < 0.05 compared to cytokine alone).
Figure 5.7

A

<table>
<thead>
<tr>
<th>TGF-β1 (ng/ml)</th>
<th>Anti-TGF-β1 antibody (ug/ml)</th>
<th>Relative Amount of Runx2 mRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>a</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>b</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>TGF-β1 (ng/ml)</th>
<th>Anti-TGF-β1 antibody (ug/ml)</th>
<th>Relative Amount of RUNX2 protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>a</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>b</td>
</tr>
</tbody>
</table>
Figure 5.8. Effects of Runx2 siRNA on Runx2 mRNA and protein levels in HTR-8/SVneo cell cultures. A) Real-time RT-PCR analysis of Runx2 mRNA levels in cells transfected with a scrambled control siRNA (lane 1) or siRNA specific for Runx2 (lane 2) for 36 h. Values for Runx2 mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to scrambled control siRNA). B) Representative fluorogram of a Western blot containing 30 µg of total protein extracted from HTR-8/SVneo cells cultured with a scrambled control siRNA (lane 1) or siRNA specific for Runx2 (lane 2) for 36 h and probed with rabbit polyclonal antibodies against RUNX2 or human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for RUNX2 protein levels were normalized to the absorbance values obtained for β-actin (ACTIN) in the samples. The results derived from this analysis and from three other studies were standardized to the scrambled control siRNA and are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to scrambled control siRNA).
Figure 5.8

A

B

- 55 kDa (RUNX2)
- 42 kDa (ACTIN)
Figure 5.9. Effects of Runx2 siRNA on N-cad mRNA and protein levels in HTR-8/SVneo cell cultures. A) Real-time RT-PCR analysis of N-cad mRNA levels transfected with a scrambled control siRNA (lane 1) or siRNA specific for Runx2 (lane 2) for 36 h. Values for N-cad mRNA levels in each sample were normalized to the corresponding GAPDH mRNA levels. The data are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to scrambled control siRNA). B) Representative fluorogram of Western blot containing 30 µg of total protein extracted from HTR-8/SVneo cells cultured with a scrambled control siRNA (lane 1) or siRNA specific for Runx2 (lane 2) for 36 h and probed with mouse monoclonal antibody against N-CAD or rabbit polyclonal antibody against human β-actin. The Amersham ECL system was used to detect antibody bound to antigen. The resultant fluorograms were scanned and the absorbance values obtained for N-CAD protein levels were normalized to the absorbance values obtained for human β-actin (ACTIN) in the samples. The results derived from this analysis and from three other studies were standardized to the scrambled control siRNA and are represented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05 compared to scrambled control siRNA).
Figure 5.9

A

![Graph showing relative amount of N-cad mRNA and protein with control and Runx2 siRNA treatments]

B

![Image showing Western blots for N-CAD and ACTIN with control and Runx2 siRNA treatments]

Legend:
- 140 kDa (N-CAD)
- 42 kDa (ACTIN)

Control siRNA Runx2 siRNA

Relative Amount of N-cad mRNA

Control siRNA Runx2 siRNA

Relative Amount of N-CAD protein
Figure 5.10. Reduced Runx2 levels decrease the invasive capacity of HTR-8/SVneo cells. HTR-8/SVneo cells were transfected with a scrambled control siRNA (lane 1) or siRNA specific for Runx2 (lane 2) for 24 h. The cells were then placed in the upper wells of Transwell invasion chambers. After a further 24 h of incubation, the porous membranes from the bottom of the Transwells were removed and fixed, stained and mounted upside-down on a glass microscope slide. Invasion was determined by counting the number of cells that invaded through the thin pre-coated layer of Matrigel on the top of the porous (8 μm) membrane. Cells were visualized using a light microscope, and counted in three randomly selected fields of each membrane. Each cell line was plated in triplicate wells, and the experiment was repeated on three independent occasions. The results are presented (mean ± S.E.M., n = 4) in the bar graph (*, P < 0.05, compared to HTR-8/SVneo scrambled control siRNA).
Figure 5.10

[Graph showing Invasion Index with bars for Control siRNA (1) and Runx2 siRNA (2)]
5.3: Discussion and summary

Runx2 expression has been mostly characterized in bone tissue (Otto et al., 1997), but it has also been found to be highly expressed in several other tissue types, including the testes (Ogawa et al., 2000), mammary epithelium (Inman and Shore, 2003), endothelial cells (Sun et al., 2001), and in prostate and breast tumours (Yeung et al., 2002; Barnes et al., 2003). In this study I have examined the expression of Runx2 in first-trimester human placenta tissue and in four human trophoblastic cell types: highly invasive primary EVTs, the immortalized EVT cell line HTR-8 cells/SVneo, and the poorly invasive JEG-3 and BeWo choriocarcinoma cell lines. Runx2 was expressed in placental tissue, and the high levels of Runx2 expression in highly invasive EVT cells suggest that Runx2 plays a role in trophoblast invasion. Furthermore, the two choriocarcinoma cell lines, which are considered much less invasive, display significantly lower Runx2 expression.

It is known that IL-1β promotes human trophoblast invasion (Karmakar and Das, 2002) and in my studies it increased the expression of Runx2 in EVTs. It has also been shown that IL-1β increases the invasiveness of trophoblast cells, at least in part through the up-regulation of MMP-2 and MMP-9 (Karmakar and Das, 2002), which are key molecules in human trophoblast invasion (Staun-Ram et al., 2004). While my results showed that IL-1β induces the expression of Runx2, I also demonstrated that TGF-β1 suppresses Runx2 expression in EVTs and this is important because TGF-β1 reduces the invasiveness of trophoblasts (Graham and Lala, 1991). TGF-β1 has been previously shown to decrease the functional activity of Runx2 by promoting an interaction between
SMAD3 and the Runx2 proteins in osteoblast cells (Alliston et al., 2001). RUNX2 forms co-regulatory complexes with Smads and other co-activator and co-repressor proteins that are organized in subnuclear domains to regulate gene transcription. In addition, Runx2 can also mediate the responses of cells to hyperactive signalling pathways in tumours in response to TGF-β and other growth factor signals. These observations strongly suggest that RUNX2 is a key molecule in regulating human trophoblastic cell invasion (Pratap et al., 2006).

A siRNA knockdown of Runx2 in metastatic breast cancer cell lines reduced their invasive properties. In contrast, forced expression of Runx2 in non-metastatic breast cancer lines induced a three-fold increase in cellular invasion (Pratap et al., 2005). In my loss-of-function study, I was able to demonstrate that a decrease in Runx2 expression is concomitant with a reduction in human trophoblast invasion.

Studies by Pratap et al. (2005) have provided experimental evidence that Runx2 can regulate the expression of MMP-9 and cellular invasion in breast cancer cell lines. They have demonstrated through chromatin immunoprecipitation that RUNX2 is recruited to the MMP-9 promoter. In other studies, Hazan et al. (2000) demonstrated that increased MMP-9 production in N-cad–expressing breast cancer cells occurred in response to fibroblast growth factor-2 and that this provided the cells with a greater ability to penetrate matrix protein barriers.

In my previous studies, I have demonstrated that N-CAD is a significant player in a molecular mechanism underlying the invasive capacity of EVTs in vitro. In addition, it has been prevailously reported that N-cad is a potential target of RUNX2 in embryonic bone tissue (Chua et al., 2009). In this study, I have identified a role for Runx2 in
regulating N-cad in human trophoblastic cells. In support of this, when HTR-8/SVneo cells were transfected with siRNA against Runx2, N-cad expression was significantly reduced along with a reduction in the invasive ability of the cells.

In summary, my results provide evidence that RUNX2 is a key molecule in mediating human trophoblast invasion through regulating N-cad (Figure 5.11). However, further studies will be necessary to address the molecular interaction between RUNX2 and N-cad.
Figure 5.11. A schematic diagram of a proposed role of Runx2 in regulating N-cad-mediated differentiation of human trophoblastic cells. Silencing Runx2 expressing by siRNA strategy reduces N-cad expression level and reduces the invasion ability of human trophoblastic cells.
CHAPTER 6: GENERAL DISCUSSION

6.1: Discussion

In my studies, I have investigated the roles of the transcription factors TWIST and RUNX2, and the cell adhesion molecules E-CAD and N-CAD, in the villous (non-invasive) and extravillous (invasive) pathways in human trophoblastic cells.

When studying the terminal differentiation of human cytotrophoblasts in vitro, I used both primary cultures of human trophoblasts and human trophoblastic cell lines. There are both advantages and disadvantages when using these cell cultures. The advantage of using primary cell cultures is their close biological and morphological proximity to the human placenta. However, there is a number of limitations to these primary cell cultures. Due to limited access to term placental tissues, I switched to using the BeWo trophoblastic cell line in order to study the cellular and molecular mechanisms in the villous pathway. As previously mentioned, BeWo cells have been widely used to study syncytialization in human trophoblasts in the presence of 8-bromo cAMP (Seamon et al., 1981; Wice et al., 1990). Furthermore, the advantages of using a cell line include their immortal and consistent characteristics, cell purity, and commercial availability. To investigate the extravillous pathway, I used primary EVTs for regulatory studies with cytokines such as TGF-β1 and IL-1β, because HTR-8/SVneo cells do not respond to TGF-β1 treatment in my experiments and as reported by another group (Graham et al., 1993). As for the functional studies, I chose to use HTR-8/SVneo cells because these cells are easier to transfect and their characteristics are more uniform, as mentioned earlier.
My studies have provided a greater understanding of the cellular and molecular mechanisms that mediate the formation and organization of the human placenta, and demonstrate that Twist can regulate and promote cellular fusion (Figure 6.1). In addition, my studies have suggested a role for Twist, Runx2 and N-cad in regulating EVT invasion (Figure 6.2).

In the first part of my studies, I examined the expression of Twist and E-cad during the terminal differentiation and fusion of BeWo cells, a human trophoblastic cell line. I observed Twist was up-regulated and E-cad was down-regulated during the differentiation and fusion processes in human trophoblastic cells. In gain- or loss-of-function studies, I have shown that increasing Twist expression promotes terminal differentiation and fusion of human trophoblastic cells through down-regulation of E-cad expression.

In the second part of my studies, I investigated whether Twist and N-cad may play important roles in human trophoblast cell invasion. I first examined the expression of Twist and N-cad in highly invasive EVTs and the poorly invasive JEG-3 and BeWo human trophoblastic cell lines. My results have revealed that Twist and N-cad are highly expressed in highly invasive EVTs but the expression of both is significantly lower in the poorly invasive human trophoblastic cell lines.

Next, I determined the regulatory effects of IL-1β and TGF-β1, two cytokines known to control trophoblast invasion (Graham and Lala, 1991; Karmakar and Das, 2002), on primary cultures of EVTs. I found a differential regulation of Twist expression. Twist expression increases after IL-1β treatment in a time- and concentration-dependent manner.
Figure 6.1. A schematic diagram of a proposed role of Twist in regulating terminal differentiation and fusion of human trophoblastic cells. (a) cAMP up-regulates TWIST levels and down-regulates E-cad expression to promote the formation of syncytial trophoblast. (b) Silencing Twist expression inhibited TWIST levels from up-regulated and E-cad expression from down-regulated in cAMP-induced BeWo cells. These cells remain as mononucleate cytotrophoblasts. (c) Stable transfection with Twist expression vectors in BeWo cells reduces E-cad expression and promotes the formation of syncytial trophoblast.
Figure 6.2. A schematic diagram of the proposed roles of Twist, Runx2 and N-cad in regulating the invasive ability of human trophoblastic cells. TGF-β1 down-regulates Twist and Runx2 expression and reduces the invasion ability of EVTs. IL-1β up-regulates Twist and Runx2 expression and increases the invasion ability of EVTs. Silencing Twist or Runx2 expression reduces N-cad expression and reduces the invasion ability of HTR-8/SVneo cells. Silencing N-cad expression reduces the invasion ability of HTR-8/SVneo cells.
In contrast, Twist expression with TGF-β1 treatment decreases in a time and concentration-dependent manner. However, IL-1β and TGF-β1 have no effects upon N-cad expression, suggesting that other growth factors may be involved in regulating N-cad expression in human EVTs.

I continued to determine a role for Twist in human trophoblast invasion by performing a gain-of-function study using JEG-3 cell line. Although Twist mRNA level increased, the protein level remains unchanged. Therefore, I could not determine a role for Twist in trophoblast invasion in these cell models.

I then took an opposite approach by using a loss-of-function study to silence Twist expression. This demonstrated that down-regulation of Twist reduced the invasive capacity of the EVT cell line and the expression of N-cad, suggesting that Twist promotes trophoblast invasion via N-cad.

Next, I performed a loss-of-function study by utilizing a siRNA strategy to silence N-cad expression to investigate a role for this CAM in human trophoblastic cell invasion. My results show that by silencing N-cad expression the trophoblastic cells became significantly less invasive. I continued to determine a functional role for N-CAD in these trophoblastic cells by using a function-perturbing antibody against the extracellular binding domain of N-CAD. This antibody effected a significant reduction in trophoblastic cell invasion, thus confirming a functional role of N-CAD in human trophoblastic cells in vitro.

I continued to investigate whether Runx2 plays important roles in human trophoblast cell invasion. First, I demonstrated that Runx2 is highly expressed in highly invasive EVTs, but it is present at significantly lower levels in poorly invasive JEG-3 and BeWo
trophoblastic cell lines. Next, I investigated whether IL-1β and TGF-β1 were able to respectively promote and repress Runx2 mRNA and protein levels in EVTs. I found that IL-1β significantly increases Runx2 expression, while TGF-β1 significantly reduces Runx2 expression. Taken together, these observations support my hypothesis that Runx2 plays an important role in human trophoblast invasion. In my loss-of-function study, silencing Runx2 expression results in significant reduction of N-cad expression and reduces the invasive ability of HTR-8/SVneo cell.

Membrane fusion plays a critical role in development. For example, it mediates the fertilization of the egg and sperm (Wilson and Snell, 1998), and the formation of myotubes from the mononucleate myoblasts in the embryo (Nadal-Ginard, 1987). In addition, during human placentation, it mediates the formation of the syncytial trophoblast from the mononucleate cytotrophoblasts (Kliman et al., 1986). Cell fusion not only brings about morphological changes in these trophoblastic cells, but also influences the physiology of the cells. For instance, the formation of the syncytial trophoblast plays a critical role in the onset of placental hormone production (Hoshina et al., 1982; Cronier et al., 1994).

Fox (1964) demonstrated a decrease in the thickness of the syncytial trophoblast layer and an increase in the number of villous cytotrophoblasts in human placental specimens from pregnancies complicated by intrauterine hypoxia. A reduction in the formation of syncytial trophoblast structures in cultures of villous cytotrophoblasts isolated from the term placenta was observed in patients suffering from preeclampsia, a condition in pregnancy characterized by a sharp rise in blood pressure together with large amounts of protein in the urine (Pijnenborg et al., 1996).
It has been well documented that cell differentiation and morphogenesis depend partly on the regulated expression of cell adhesion molecules. The commonly known cell adhesion molecules that play a role in terminal differentiation and fusion of human cytotrophoblasts include CAD-11 (MacCalman et al., 1997) and E-CAD (Coutifaris et al., 1991). High levels of E-CAD were immunolocalized to the surface of BeWo cells before they undergo terminal differentiation and fusion, and E-CAD is needed for the cells to undergo cell aggregation prior to cell fusion (Coutifaris et al., 1991). Down-regulation of E-cad expression has been shown to be necessary to promote the formation of syncytial trophoblast (Coutifaris et al., 1991; Getsios et al., 2003). In a similar manner, E-cad expression was also down-regulated during the formation of multinucleated osteoclasts from bone marrow mononucleate cells in mice (Suda et al., 1992).

Several studies have identified the ability of growth factors to regulate the terminal differentiation and fusion of villous cytотrophoblasts. One example would be epidermal growth factor (EGF) that is produced by both decidual cells and trophoblastic cells at the maternal-fetal interface (Hofmann et al., 1992; Morrish et al., 1998; Leach et al., 1999). Blocking EGF receptor function using an anti-EGF-receptor monoclonal antibody increases E-cad expression in primary cultures of human trophoblastic cells (Rebut-Bonneton et al., 1993; Al Moustafa et al., 1999). This suggests that EGF can down-regulate E-cad expression in human trophoblastic cells. EGF treatment of A431 cells, an epidermoid cancer cell line, has been shown to increase cAMP accumulation induced by forskolin (Ball et al., 1990). In addition, cAMP analog has shown to increase MAPK-1/3
and cAMP response element-binding protein (CREB) phosphorylation in BeWo cells (Maymo et al., 2010).

TWIST, a helix-loop-helix transcription factor that has long been implicated in embryonic morphogenesis, also promotes epithelial-mesenchymal transition (EMT) through the down-regulation of E-cad in a wide range of cancer cells (Yang et al., 2004, Kwok et al., 2005, Yuen et al., 2007). Yang et al. (2004) demonstrated that Twist transcriptionally represses E-cad in human breast cancer cells through direct interaction with an E-Box present in the promoter region of E-cad. As mentioned before, I did not determine the actual mechanism by which up-regulated Twist expression effects down-regulated E-cad expression in these trophoblastic cells. However, it is possible that TWIST represses E-cad through direct contact with the E-box present in the promoter region of E-cad during the terminal differentiation and fusion of human villous cytotrophoblasts in vitro. In order to examine whether the repression of E-cad by TWIST in my studies is determined by the E-box located within the promoter region, luciferase reporter gene assays will have to be carried out to assess the transcription efficiency of the E-cad promoter with an E-box mutation. My studies are the first to investigate a role for the Twist gene in terminal differentiation of human cytotrophoblasts in vitro. Collectively, the observations from my studies suggest that Twist and E-cad, which mediate EMT processes in cancer cells, can also influence the terminal differentiation and fusion of human trophoblasts. Additional studies will be needed to identify the underlying mechanisms that increase Twist expression in the human trophoblast differentiation.
Increased expression of N-cad promotes the motility and invasion of carcinoma cells (Nienam et al., 1999; Cavallaro et al., 2002; Hazan et al., 2000). Studies have suggested that N-cad-expression in cancer cells may promote homophilic interactions with N-cad expressing tissues such as endothelia and stroma (Hazan et al., 2000). For example, N-CAD mediates the transmigration of melanomas through the vascular endothelium (Sandig et al., 1997). Although it is tempting to speculate that N-cad expression in EVTs may facilitate adhesion with the endometrial stroma or the maternal endovascular cells to facilitate the remodelling of the endothelial lining, my single cell model could not confirm this.

Besides facilitating homophilic cell adhesion between cancer cells and normal cells, N-cad is also believed to promote cell invasion through cell signalling events (Hazan et al., 2004). It has been reported that in breast cancer cell invasion, there is an interaction between N-CAD and fibroblast growth factor receptor 1 (FGFR1) at the cell surfaces to form an extracellular complex. This complex is formed by the interaction between the extracellular domain of N-CAD and immunoglobulin domains 1 and 2 of FGFR-1, which eventually stabilizes FGFR-1 and leads to prolonged mitogen-activated protein kinase (MAPK) activation (Kim et al., 2000; Suyama et al., 2002).

Hazan et al. (2004) proposed that while N-cad promotes homophilic cell-adhesive mechanisms, E-cad controls tumour progression. Previous studies have reported that down-regulation of E-cad is necessary for cancer cells to become invasive (Onder et al., 2008). However, preliminary data from our laboratory (Alex Beristain, unpublished data) show that the exogenous expression of N-cad in JEG-3 cells leads to increased invasion without altering the expression of E-cad. Similarly, Nieman et al. (1999) have reported
that N-cad plays a dominant role over the high expression of E-cad in promoting breast cancer cell invasion. In contrast, exogenous expression of E-cad resulted in decreased invasiveness and reduction of N-cad expression in tumour cells expressing endogenous N-cad (Yanagisawa and Anastasiadis, 2006). Indeed, the molecular mechanisms in which N-cad and E-cad regulate invasion remain unclear, probably due to the differences in cell types.

TWIST is able to increase N-cad expression in a variety of cancer cells (Alexander et al., 2002; Rosivatz et al., 2002). Although the precise mechanism by which Twist regulates N-cad in human trophoblastic cells is unknown, others have found that the effect of TWIST on the induction of N-cad mRNA requires an E-box located within the first intron of the N-cad gene (Alexandra et al., 2006).

RUNX2 is a scaffolding transcription factor, which has been well documented to play a role in osteoblast differentiation (Otto et al., 1997). Runx2-null mutations in mice result in severe bone deficiency as well as hypothyroidism, a disease caused by insufficient production of thyroid hormones (Harada and Roden, 2003; Endo and Kobayashi, 2010). Runx2 is phosphorylated and can be activated by the MAPK pathway (Xiao et al., 2000). Runx2 is known to play key roles in angiogenesis (Zelzer et al., 2001), and vascular invasion of bone and is highly expressed in endothelial cells (Mundlos, 1999; Enomoto et al., 2000). Runx2 has been termed an oncogene and it is highly expressed in different types of cancer cells, including breast and prostate cancer cells (Barnes et al., 2004; Javed et al., 2005, Pratap et al., 2006b). These studies have provided additional support that Runx2 play an important role in regulating human trophoblast invasion. My results are also the first to show a regulatory linkage between
Runx2 and N-cad. However, further studies will be necessary to identify the molecular mechanisms on how Runx2 regulates N-cad expression.

Transforming growth factor-β1 (TGF-β1) is a secreted protein that controls cell growth, cell proliferation, cell differentiation and apoptosis (Ghadami et al., 2000; Vaughn et al., 2000). TGF-β1 has been assigned major regulatory roles in placental development and in decidualization of the endometrial stroma (Godkin and Dore, 1998; Karmakar and Das, 2002). This growth factor binds to a type II receptor dimer, which recruits and phosphorylates a type I receptor dimer to form a hetero-tetrameric complex (Wrana et al., 1992). The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) to form R-SMAD/coSMAD (e.g. SMAD4) complexes in the nucleus to regulate targeted gene expression (Souchelnytskyi et al., 2001; Feng and Derynck, 2005). TGF-β is able to differentially regulate Twist expression in a variety of cell types (Leu et al., 2008; Mori et al., 2009; Murakami et al., 2010) and to decrease RUNX2 binding to DNA (Komori, 2006).

Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that plays a key regulatory role in the establishment of pregnancy (Salamonsen et al., 2000, 2003; Fazleabas et al., 2004). IL-1β can bind to type 1 IL-1 receptor protein, IL-1 binding activates IL-1 receptor associated kinase-1 and -2 (IRAK-1 and -2), IRAK-1 then recruits TNF receptor associated factor 6 (TRAF6) to the IL-1 receptor complex and activates two pathways, one leading to the map-erk kinase (MEK)/c-Jun N-terminal kinases (JNK) signalling system and the other leading to nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation (Muzio et al., 1997; Allan and Rothwell, 2001; Wang et al., 2001). Several NF-kB targets include Twist, snail1, zeb1 (Min et al., 2008).
6.2: Summary and Conclusions

My studies are the first to find that Twist is up-regulated and E-cad is down-regulated during the terminal differentiation and fusion of human trophoblastic cells. By using gain- and loss-of-function studies, I was able to demonstrate that Twist is a key regulator of E-cad in these trophoblastic cells. My results also show that Twist regulates cadherin-mediated morphological and functional differentiation of human trophoblastic cells. The second part of my thesis describes studies that identify a role for Twist in extravillous cytotrophoblasts. These demonstrated that Twist promotes human trophoblastic cell invasion through down-regulating N-cad expression. In a loss-of-function study in which N-cad expression was silenced, there was a significant reduction of trophoblastic cell invasion. Finally, I was able to demonstrate that Runx2, which is known to regulate cancer invasion, also regulates human trophoblastic cell invasion. In addition, silencing Runx2 expression caused a significant down-regulation of N-cad expression.

Although the molecular mechanisms involved in the terminal differentiation of human trophoblast are rather complex, my findings help in furthering the understanding of many diseases that are linked to human placentation.
6.3: Future directions

A successful human pregnancy depends upon mononucleate cytotrophoblasts entering one of two distinct and mutually exclusive pathways. Villous cytotrophoblastic cells proliferate and differentiate by fusion to form the outer syncytial trophoblast, or enter the extravillous pathway to form highly invasive extravillous cytotrophoblasts. However, the molecular mechanisms involved in determining which pathway the mononucleate cytotrophoblasts will enter remain to be elucidated. Studies have shown that the interaction between TWIST and RUNX2 involves unique domains in these proteins, the twist box and the RUNX2 DNA binding domain (Lian et al., 2004), and it will be necessary to determine if the fate of mononucleate cytotrophoblast is differentially or co-ordinately regulated by Twist and Runx2 expression.

6.3.1: Investigate the regulation and function of Runx2 in human trophoblast cell fusion

First, it will be necessary to examine Runx2 mRNA and protein expression levels in BeWo choriocarcinoma cells undergoing terminal differentiation and fusion in response to the secondary intracellular signalling molecule 8-bromo-cAMP, by using semi-quantitative RT-PCR and Western blotting, respectively. Subsequently, gain- or loss-of-function studies could be carried out using these cells and either a mammalian expression vector containing a cDNA encoding Runx2 or siRNA specific for this transcription factor, respectively. In addition to examining subsequent Runx2 and E-cad mRNA and protein expression levels in these cell cultures, the presence or absence of multinucleated syncytia
will be confirmed by indirect immunofluorescence using antibodies directed against RUNX2, E-CAD or DESMOPLAKIN, a cellular marker of mononucleate cytotrophoblasts.

**6.3.2: Investigate whether the inter-related expression of Runx2 and Twist determines the differentiation pathway of mononucleate cytotrophoblasts**

My preliminary findings demonstrate that Twist expression levels correlate with Runx2 expression levels in human trophoblastic cell invasion. Further investigation is needed into the regulatory effects between Twist and Runx2 in the formation of the multinucleated syncytial trophoblast of the human placenta. The co-coordinated or differentially regulated expression of Twist and Runx2 in human trophoblastic cells could be the determining factor for whether the mononucleate cytotrophoblasts enter either the villous or invasive pathway.

In future studies, I would investigate the relationship(s) between Runx2 and Twist in terminal differentiation of human trophoblastic cells, either by transfecting a siRNA for Runx2 or Twist into BeWo cells that can undergo terminal differentiation and fusion in response to the secondary intracellular signalling molecule 8-bromo-cAMP. Semi-quantitative RT-PCR and Western blotting can be used to examine Runx2 and Twist mRNA and protein levels in these trophoblastic cells.
6.3.3: Immunolocalization of TWIST and RUNX2 at the human maternal-fetal interface during pregnancy

If TWIST and RUNX2 in fact play critical role in formation, maintenance, and/or function of the maternal-fetal interface then it would be important to confirm that these proteins are indeed localized here during one or more stages of pregnancy. Tissue sections will be prepared from archived permanent paraffin blocks containing maternal-fetal tissues (n=3) obtained during the first trimester of pregnancy. These tissue sections will be immunostained using a commercially available polyclonal antibody directed against human TWIST or RUNX2. A nonspecific isotype-matched antibody would served as an appropriate negative control for these experiments.
BIBLIOGRAPHY


Chung HW, Wen Y, Ahn JJ, Moon HS and Polan ML (2001) Interleukin-1β regulates urokinase plasminogen activator (uPA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells. *J Clin Endocrinol Metab* **86**:1332-1340.


Damsky CH, Fitzgerald ML, Fischer SJ (1992) Distribution of extracellular matrix components and adhesion receptors are intricately modulated during first trimester


**Khoo NKS, Bechberger JF, Sheperd T, Bond SL, McCrae, Hamilton GS, Lala PK** (1998) SV-40 Tag transformation of the normal invasion trophoblast results in a


related to epithelial-to-mesenchymal transition in breast cancer cell lines. *British J Cancer* **94**:661-671.


Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S (1989) Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with medium follow-up of 18 years. J ClinOncol 7:1239-1251.


Vestweber D (1992) Selectin: cell surface lectins which mediate the binding of leukocytes to endothelial cells. *Semin Cell Biol* **3:**211-220.


Whiteside EJ, Kan M, Jackson MM, Thompson JG, McNaughton C, Herington AC, Harvey MB (1996) Urokinase-type plasminogen activator (uPA) and matrix


**ETHICS CERTIFICATE OF FULL BOARD APPROVAL: RENEWAL**

<table>
<thead>
<tr>
<th>PRINCIPAL INVESTIGATOR:</th>
<th>DEPARTMENT:</th>
<th>UBC CREB NUMBER:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin D. MacCalman</td>
<td>UBC/Medicine, Faculty of/Obstetrics &amp; Gynaecology</td>
<td>H06-70260</td>
</tr>
</tbody>
</table>

**INSTITUTION(S) WHERE RESEARCH WILL BE CARRIED OUT:**

<table>
<thead>
<tr>
<th>Institution</th>
<th>Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**OTHER LOCATIONS WHERE THE RESEARCH WILL BE CONDUCTED:**

**N/A**

**CO-INVESTIGATOR(S):**

- Hua Zhu
- York HUNT Ng
- Fatemeh K. Khatibi

**SPONSORING AGENCIES:**

- Canadian Institutes of Health Research (CIHR) - "Structure, Function and Regulation of the Cadherin-11 Complex in the Human Placenta"
- Canadian Institutes of Health Research (CIHR) - "Structure, function and regulation of the cadherin-11 complex in the human placenta"

**PROJECT TITLE:**

Structure, Function and Regulation of the Cadherin-11 Complex in the Human Placenta

**THE CURRENT UBC CREB APPROVAL FOR THIS STUDY EXPIRES:** January 27, 2010

The UBC Clinical Research Ethics Board Chair or Associate Chair, has reviewed the above described research project, including associated documentation noted below, and finds the research project acceptable on ethical grounds for research involving human subjects and hereby grants approval.

**DOCUMENTS INCLUDED IN THIS APPROVAL:**

- N/A

**APPROVAL DATE:** February 17, 2009

**CERTIFICATION:**

In respect of clinical trials:

1. The membership of this Research Ethics Board complies with the membership requirements for Research Ethics Boards defined in Division 5 of the Food and Drug Regulations.
2. The Research Ethics Board carries out its functions in a manner consistent with Good Clinical Practices.
3. This Research Ethics Board has reviewed and approved the clinical trial protocol and informed
The UBC Clinical Research Ethics Board has reviewed the documentation for the above named project. The research study, as presented in the documentation, was found to be acceptable on ethical grounds for research involving human subjects and was approved for renewal by the UBC Clinical Research Ethics Board.

Approval of the Clinical Research Ethics Board by:

Dr. Gail Bellward, Chair